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4Abstract
The inner surfaces of blood vessels are covered with heterogeneous population of endothelial cells. Phenotypes
of these cells vary between different organs, between different parts of the vasculature in a given organ and
even within neighboring endothelial cells of the same organ and the same type of blood vessel. Every single
endothelial cell of the body is subjected to an infinite amount of signals leading to diverse phenotypes,
including soluble factors, such as growth factors and chemokines, cell-cell and cell-basement membrane
interactions and other variables, such as pH, pO2, sheer stress from blood flow, stretch and temperature, to name
a few. All these variables in the endothelial cell microenvironment will influence the phenotype--thus function--
of the cell, to the extent that its predetermined genetic makeup allows. All these phenotypic and functional
differences in endothelial cells lead to vascular heterogeneity, i.e. the organ-, tissue-, and vessel specific
differences.
Structural and functional heterogeneity of the endothelium has been a subject for studies for decades, but only
more recently has the focus of studies in endothelial cell biology shifted to the molecular heterogeneity of the
endothelium. The exploration of the molecular diversity of blood vessels is a rapidly expanding research area
that is driven by the vast potential of the discoveries in molecular heterogeneity to contribute to the
development of targeted diagnostics and therapeutics. It is now recognized that a complex system of ligand-
receptor pairs exists within tissues. The expression levels and activation states of these addresses are modulated
in blood vessels during tumor progression, and can also be altered in the context of other pathological
conditions involving abnormal blood vessel development and function, such as retinopathies, inflammation and
atherosclerosis.
Our studies have demonstrated new roles for two aminopeptidases, CD13/ aminopeptidase N (CD13/APN) and
aminopeptidase A (APA), in pathological angiogenesis. We show that these membrane-associated proteases are
upregulated in angiogenic vasculature of murine and human tumors. By using genetic elimination and
biochemical inhibition of CD13/APN and APA our results demonstrate an unrecognized mechanistic role for
CD13/APN and APA in pathological angiogenesis. Thus, specific CD13/APN and APA inhibitors--such as
chemical inhibitors, peptidomimetics or inhibitory anti-CD13/APN and anti-APA antibodies--may prove useful
for translational applications targeting tumor vasculature. We also studied the regulation of CD13/APN gene
expression by factors contributing to angiogenic progression and showed that CD13/APN functions in the
control of endothelial cell morphogenesis and that endogenous CD13/APN levels in primary cells and cell lines
are upregulated in response to hypoxia, angiogenic growth factors, and signals regulating capillary tube
formation during angiogenesis. In addition, we showed that the proximal promoter of CD13/APN contains the
essential elements for the angiogenic induction of CD13/APN expression in vitro and in vivo.
We also demonstrate that the angiogenic response in the retina can be altered by the reduction of the number of
photoreceptor cells in the retina. Both mouse and human data indicate that reactive retinal neovascularization
either fails to develop or regresses when the number of photoreceptor cells is markedly reduced. Our findings
support the hypothesis that a functional mechanism underlying this anti-angiogenic state is failure of the
predicted upregulation of vascular endothelial growth factor (VEGF), although other growth factors may also
be involved in this complex biological phenomenon. These findings lead us to a hypothesis that reducing the
metabolic rate of rod cells at critical time windows may improve the incidence of retinopathy of prematurity or
perhaps slow the progression of diabetic retinopathy in adults.
Finally, we developed new methodology for the identification, validation, and prioritization of functional
molecular targets on endothelial cells and human blood vessels. Biopanning and rapid analysis of selective
interactive ligands (termed BRASIL) is based on single-step organic phase separation and it is faster, more
sensitive and more specific than current methods. BRASIL may prove itself as a superior method for probing
target cell surfaces with a broad range of potential applications. We also took the first steps towards the
assembly of ligand-receptor based molecular map of the blood vessels in the human body; the vascular map, by
performing an in vivo screening of a peptide library in a patient. A survey of 47,160 motifs that localized to
different organs indicates that the tissue distribution of circulating peptides is nonrandom. High-throughput
analysis of the motifs revealed similarities to ligands for differentially expressed cell-surface proteins, and a
candidate ligand–receptor pair was validated.
Identification of vascular bed specific ligand-receptor pairs and knowledge about their cellular distribution and
accessibility will be requisite for the development of endothelium-targeted therapies. In addition, many
changes in the expression patterns of cell surface molecules during pathological blood vessel formation reflect
the various activities of those molecules that are required during the formation of new blood vessels.
Modulating the activities of these molecules may lead to inhibition or even regression of new blood vessel
formation offering an important therapeutic opportunity for pathological conditions involving angiogenesis.
5Review of the literature
1. Components of the vasculature
1.1. Endothelial cells
The endothelium, which lines the blood vessels, is
a truly pervasive cell layer composed of 1-6 x 1013
cells covering a 1-7 m2 surface area in human.
The endothelium is highly active, participating in
several physiological processes. Endothelial cells
are elongated and thin cells lining the inner lumen
of the blood vessel walls. They do not only
provide a functional barrier between the
circulation and surrounding tissue, but they also
secrete mediators that affect vascular
hemodynamics. Endothelial cells secrete
vasodilators such as nitric oxide and prostacyclin
and vasoconstrictors such as endothelin and
platelet-activating factor regulating blood pressure
and blood flow. Endothelium also facilitates the
blood flow by creating an antithrombotic surface
inhibiting platelet aggregation and blood clotting,
but after vascular damage the endothelium
changes to a prothrombic surface facilitating
fibrin clot formation. Endothelial cells express
surface molecules that control the trafficking of
circulating cells (reviewed in Cines et al., 1998).
Finally, endothelial cells have an important role in
angiogenesis, the formation of new blood vessels
from existing ones, which accompany many
pathological conditions including inflammation,
diabetic retinopathy and cancer (reviewed in
Carmeliet, 2003).
In the embryo, endothelial cells originate from
hemangioblasts (Choi et al., 1998) present in
various organs (Jiang et al., 2002) and in the
adult, from endothelial progenitor cells,
mesoangioblasts, multipotent adult progenitor
cells or side population cells in the bone marrow
(Reyes et al., 2002). Endothelial cells can
originate also by the migration and proliferation
of endothelial cells of existing vessels
(angiogenesis; reviewed in Carmeliet, 2003).
Endothelial cells have half-lives of several years,
but when stimulated, they are capable of rapid
proliferation and migration, and sending out
sprouts in a coordinated manner.
One of the important determinants of endothelial
cell differentiation is the local microenvironment
where they reside, and especially the interactions
with surrounding cells. Endothelial cells
communicate between surrounding endothelial
cells, periendothelial cells/mural cells (such as
smooth muscle cells and pericytes) and cells
inside the vessel lumen, and dynamically interact
with these cells and their surrounding extracellular
matrix.
There are several useful markers for the
identification of endothelial cells. Vascular
endothelial cadherin (VE-cadherin; Lampugnani
et al., 1992) and vascular endothelial growth
factor (VEGF) receptors (Peters et al., 1993) are
more specific to vascular endothelial cells,
whereas angiotensin converting enzyme (ACE:
Belloni and Tressler, 1990) von Willebrad factor
(vWF; Yamamoto et al., 1998), platelet-
endothelial cell adhesion molecule PECAM
(CD31; Vecchi et al., 1994), P-selectin (Johnston
et al., 1989) and CD34 (Fina et al., 1990) are also
present in other (predominantly hematopoietic)
cell types. Uptake of acetylated low density
lipoprotein has been widely used as a marker of
endothelial cells (Voyta et al., 1984). Inducible
expression of cell adhesion molecules vascular
cell adhesion molecule 1 (VCAM-1) and E-
selectin by inflammatory cytokines can be used as
a marker to identify endothelial cells, particularly
postcapillary venule-derived endothelial cells
(Bevilacqua, 1993). There are many more
endothelial cell markers than mentioned here, and
I will refer the reader to Aird (2003), for a more
complete list of markers.
Endothelial cells are plastic with respect to their
proliferative capacity and differentiation potential.
Endothelial cells can differentiate into either
arterial or venous endothelial cells during
embryonic development, neonatal retina and even
in the heart of an adult (Stalmans et al., 2002;
Visconti et al., 2002). Growth factor induced
endothelial cells have the inherent ability to form
a network of capillaries in vitro (Flamme and
Risau, 1992). A vast number of growth factors
and growth inhibitors influence the phenotype and
functions of endothelial cell through the signaling
of their receptors on endothelial cells including
vascular endothelial cell growth factors (VEGFs),
angiopoietins 1 and 2 (ang-1 and ang-2)
transforming growth factor β (TGF-β) and Ephrin
B2 to name a few (these growth factors and their
receptors will be reviewed and referenced
throughout this review of the literature).
Endothelial cells communicate with other
endothelial cells and periendothelial cells/mural
cells through adherens and gap junctions and
through tight junctions in brain and retinal
capillaries. VE-cadherin mediates the adherens
type endothelial-endothelial cell junctions in
blood vessels (Lampugnani et al., 1992) and
controls an endothelial cell survival pathway
through its intracellular interactions with β-
catenin (Carmeliet et al., 1999). Adherens type
endothelial-mural cell junctions are mediated by
VE-cadherin and N-cadherin. The α 5
connexin/connexin 40 and α4 connexin/connexin
37 are expressed in endothelial cells and form the
gap junctions between endothelial cells and
between endothelial cells and mural cells. Tight
junctions in brain and retinal vasculature
regulating interactions between endothelial cells
and mural cells are formed by occludins, zona
occludins and claudins (reviewed in Darland and
D’Amore, 2001). Cell surface adhesion molecules
integrins govern interactions and communication
between endothelial cells (as well as mural cells)
and the matrix surrounding these cells. Of the
more than 20 known integrins, α1β1, α2β1, α3β1,
α5β1, α 6β1, α 6β4, α vβ3 and αvβ5 are known to be
expressed on endothelial cells and α1β1, α2β1,
α3β1, α4β1, α5β1, α6β1, α7β1, α8β1, α9β1, αvβ1, α6β4,
αvβ3 and αvβ5 on mural cells (the role of integrins
6in vascular control is reviewed in Martinez-Lemus
et al., 2003).
1.2. Periendothelial cells/mural cells
In addition to endothelial cells, periendothelial
cells or mural cells (pericytes in capillaries and
postcapillary venules and smooth muscle cells in
larger vessels) are also required for the formation
of functional blood vessels.
Pericytes are adventitial cells lying within the
basement membrane of capillaries and
postcapillary venules at the interface between the
endothelium and the surrounding tissue. They are
functionally codependent on endothelial cells,
each cell type influencing each other’s phenotypic
expression and function. Initially, pericytes were
recognized by their morphology and their location
adjacent to endothelial cells within the same
basement membrane (reviewed in Allt and
Lawrenson, 2001). Nowadays the more common
way to identify pericytes is by the expression
patterns of several molecular markers. Such
markers include α-smooth muscle actin (α-SMA),
non muscle myosin, tropomyosin, desmin, nestin,
platelet-derived growth factor receptor β
( P D G F R - β ) and high-molecular weight
melanoma-associa ted  ant igen  (NG2) .
Identification of pericytes is not straightforward
since the marker expression varies between
different organs and vessel types (Morikawa et
al., 2002).
Periendothelial cells originate from multiple
sources during embryonic development, including
the local and distal mesenchyme (reviewed in
Hungerford and Little, 1999 and in Sartore et al.,
2001). Some evidence for transdifferentiation of
embryonic endothelial cells to smooth muscle
cells has been reported in vivo. Endothelial cells
from the dorsal aorta can also transdifferentiate
into periendothelial cells (DeRuiter et al., 1997).
Both hemangioblasts and angioblasts may have
some potential to also generate smooth muscle
cells (Ema and Rossant, 2003). VEGF receptor
(VEGFR)-2 positive cells derived from embryonic
stem cells can differentiate into both endothelial
cells and mural cells (pericytes and vascular
smooth muscle cells) and can reproduce the
vascular organization process. With VEGF
treatment, VEGFR-2 positive embryonic stem
cells form endothelial cells sheets whereas in the
absence of VEGF, expression of VEGFR-2 is lost,
and cells differentiate into mural cells through
mainly platelet-derived growth factor-B (PDGF-
B) signaling (Yamashita et al., 2000). In adult,
putative smooth muscle progenitor cells have been
isolated from human peripheral blood and further
differentiated to smooth muscle outgrowth cells in
vitro (Simper et al., 2002) and to smooth muscle
cells in vivo (Yeh et al., 2003). Fibroblasts can
also differentiate into myofibroblasts, which in
turn differentiate into vascular smooth muscle
cells in response to biochemical or mechanical
cues (Tomasek et al., 2002; Chambers et al.,
2003).
Figure 1. Morphology of mural cells on normal and tumor
blood vessels. Tissue sections from normal and tumor
tissues were stained for CD31 (green) and α-SMA or
desmin (red) in order to identify endothelial cells and
mural cells, respectively. Upper panel: Smooth muscle
cells are circumferentially oriented and closely spaced on
a larger arteriole (left) and venule (right) in normal tissue
(pancreas). Middle panel: Arrow is pointing to a pericyte
positioned along the vessel axis on normal capillary.
Most of the pericyte processes are oriented
longitudinally. Lower panel: Unlike normal pericytes
some pericytes in tumor blood vessels project away from
the endothelium and into the tumor parenchyma and
some pericytes in overlap other pericytes. Adapted with
permission, from Morikawa et al., 2002.
7Pericytes significantly determine the development
of blood vessels. They may act in a paracrine
manner and through cell-cell dependent contacts
with endothelial cells. During the development of
blood vessels, endothelial cells direct the
migration of undifferentiated mesenchymal cells
and induce their differentiation toward a smooth
muscle cell/pericyte lineage. Modulation of the
proliferation and differentiation of mesenchymal
cells occurs during the recruitment of these cells
by endothelial cells. Heterotypic cell-cell contacts
and soluble factors play a role in growth control
during vessel assembly (Hirschi et al., 1999).
Pericytes stabilize nascent blood vessels by
inhibiting proliferation and migration of
endothelial cells, and they induce endothelial cell
differentiation, quiescence and survival.
Periendothelial cells also influence endothelial
permeability. Periendothelial cells secrete
extracellular matrix proteins and elastin fibers
thus playing a role in establishing the structural
integrity of the vessel wall as well as in
vasomotion and viscoelasticity. They control
vessel remodeling and plasticity, since smooth
muscle cell covered blood vessels are more
resistant to regression (reviewed in Allt and
Lawrenson, 2001; Hellstrom et al., 2001).
Endothelial cells produce chemotactic, growth and
survival factors for mural cells, recruit the mural
cells to the newly formed vessel and induce their
differentiation. Most studied growth factors
influencing mural cells are PDGF-B, TGF-β and
angiopoietins (these growth factors and their
receptors will be reviewed and referenced
throughout this review of the literature). PDGF-B-
PDGF receptor-β (PDGFR-β) ligand-receptor pair
has a major influence on the pericyte phenotype in
vivo. Endothelial cells secrete PDGF-B which
induces the differentiation of PDGFR-β positive
cells to mural cells (Hellstrom et al., 1999); this
ligand-receptor interaction is crucial for the
establishment of the blood vessel wall. TGF-β
induces differentiation of mesenchymal cells to
myofibroblasts and smooth muscle cells
(Chambers et al., 2003). The endothelial TGF-β
binding protein, endoglin, and its downstream
signaling molecule Smad-5 also have essential
role in vascular smooth muscle cell differentiation
and their recruitment to blood vessel wall (Li et
al., 1999; Yang et al., 1999). Ang-1 through the
interactions with its receptor Tie2 stabilizes blood
vessels by facilitating communication between
endothelial cell and mural cells (Suri et al., 1996).
I n  vitro Ang-1 enhances endothelial cell
stimulated smooth muscle cell migration by a
mechanism involving up-regulation of heparin
binding EGF-like growth factor (HB-EGF)
expression in endothelial cells and subsequent
signaling via ErbB1 and ErbB2 in smooth muscle
cells and pericytes (Iivanainen et al., 2003).
Rather low density of pericyte coverage is
required for basal microvascular function, since
up to 90% reduction of pericyte coverage is still
tolerated during embryonic development and
postnatal survival, while loss of 95% of the
pericyte coverage is lethal (Lindahl et al., 1997;
Enge et al., 2002). Current anti-angiogenic
approaches have been focusing mainly on
endothelial cells, but recent studies suggest that
combinatorial strategies targeting both the
endothelial and perivascular cell compartments
are likely to provide improved efficacy for anti-
angiogenic therapies in multiple stages of
tumorigenesis (Bergers et al., 2003).
Although several growth factors and chemotactic
factors have already been described for the
proliferation and recruitment of vascular smooth
muscle cells around capillaries, only a few
repressors of vascular smooth muscle cell
migration is known thus far. Endothelial cells
produce an inhibitory protein of mural cell
migration, called vascular endothelial-statin (VE-
statin; Soncin et al., 2003). Secreted VE-statin
inhibits PDGF-BB -induced smooth muscle cell
migration, but not proliferation, without affecting
endothelial cell migration. Unlike many other
endothelial cell markers, VE-statin is expressed
by endothelial cells regardless of their origin (vein
or artery) or vessel size (Soncin et al., 2003). The
receptor and intracellular signaling pathways of
VE-statin in vascular smooth muscle cells
remains to be identified.
1.3. Basement membrane
Cells in tissues are surrounded by the extracellular
matrix (ECM), which is composed of long and
filamentous protein fibers providing tensile
strength and channels for communication and
movement of cells within the tissue. The main
proteinaceous components of the ECM are the
structural proteins, collagens, produced by a
variety of stromal cells, mainly fibroblasts. ECM
contains also proteoglycans such as lecticans and
heparan sulphate proteoglycans (including
perlecan), latent and active growth factors as well
as matricellular proteins, such as SPARC,
thrombospondins-1 and -2 (TSP-1 and TSP-2),
osteopontin, tenascins-C and -X and hevin/SC1
(reviewed in Bosman and Stamenkovic, 2003).
The basement membrane is a specialized form of
ECM that separates epithelium from the stroma of
the tissue. The basement membrane is also an
important component of blood vessels; it forms
the scaffold for the endothelial cells and pericytes,
the inner lining of this cylinder being lined by the
endothelial cells and pericytes covering the outer
part of the cylinder. The cells producing and
secreting the proteins of the basement membrane
are the very same cells, endothelial cells and
pericytes, which it envelops. The main
constituents of the basement membrane include
type IV collagen, laminin, heparan sulphate
proteoglycans and nidogen. The basic structure of
the basement membrane is formed by the collagen
network/scaffold, but another scaffold, the
laminin scaffold, forms independently interacting
with the collagen scaffold through nidogen
(Aumailley et al., 1989; Timpl and Brown, 1996).
Other adhesive glycoproteins, like tenascin, as
well as proteoglycans adhere to the scaffold and
interact with cells in or adjacent to the matrix.
8Matricellular proteins have an important role in
modulating cell-matrix interactions. Several
different isoforms of type IV collagen, laminin,
proteoglycans and nidogen have been described
providing specificity to the basement membrane
associated with different tissue types. Tissue
specific functions are the consequence of the
different compositions of the basement membrane
resulting in the regulation of the tissue specific
behavior of endothelial cells (reviewed in Kalluri,
2003).
Basement membranes and other ECMs undergo
constant dynamic changes in response to a vast
number of cellular stimuli, and the remodeling of
the vascular basement membrane is a vital aspect
of angiogenesis. When endothelial cells and mural
cells migrate to form new blood vessels, the ECM
network is not only degraded, but its composition
is also altered and new cryptic epitopes of the
ECM proteins are exposed that facilitate the
migration of endothelial and mural cells. Growth
factor stimulation leads to the secretion of ECM
digesting enzymes from endothelial cells, and in
some cases from the surrounding stromal cells and
tumor cells (reviewed in Kalluri, 2003).
Besides providing structural framework upon
which cells grow, migrate and differentiate to
form blood vessels, the basement membrane is an
important source of angiogenic growth factors,
such as basic fibroblast growth factor (bFGF),
VEGF, PDGF-B and TGF-β  as well as
angiogenesis inhibitors, such as TSP-1, canstatin,
tumstatin, platelet factor-4 and endostatin. Cell
produced proteinases are required for the
liberation of these factors from the matrix
(reviewed in Egeblad and Werb, 2002, and
Kalluri, 2003). ECM-bound VEGF can also
promote endothelial cell adhesion, migration, and
survival through integrin ligation. A new VEGF
receptor-independent role for immobilized VEGF
in supporting cell adhesion and survival has been
discovered to act through interactions with
integrins. Immobilized VEGF almost totally
abolishes endothelial cell apoptosis through
interactions with integrins (Hutchings et al.,
2003).
Degradation and remodeling of the ECM must
occur in a balanced manner, thus, it is a highly
regulated process. Insufficient breakdown of the
ECM will prevent endothelial and mural cells
from leaving their original position, but on the
other hand, excessive breakdown of the ECM
removes critical support and guidance cues for
migrating endothelial and mural cells inhibiting
the formation of new blood vessels. Studies with
matrix metalloproteinase (MMP) inhibitor RECK
elegantly demonstrates the importance of the
ECM degradation and regeneration for normal
angiogenesis. In the absence or RECK expression,
excess MMP activity results in increased
degradation of the ECM, causing reduced
structural integrity of blood vessels and
surrounding tissue. Consequently, the maturation
of the early vascular network gets stalled. In the
presence of excessive RECK expression, MMP
activity is inhibited to the point where ECM
remodeling is compromised and the pre-existing
blood vessels are not able to send out capillary
sprouts. Consequently, the formation of new
blood vessels is inhibited (Oh et al., 2001).
2. Development of the vasculature
Cardiovascular system is the first functional organ
system to develop during embryogenesis. The
failure of the cardiovascular system to develop
will unavoidably lead to embryonic lethality.
During vasculogenesis, the primary capillary
plexus is formed by proliferating endothelial
precursor cells, angioblasts, coalescing into a
primitive vascular network (Risau and Flamme,
1995). This endothelial cell network further serves
as a scaffold for angiogenesis, the sprouting,
bridging and intussusceptive growth of existing
blood vessels (Risau, 1997). The immature
vascular network must mature at the level of the
blood vessel wall as well as at the level of overall
vascular system, forming a highly organized
network of blood vessels providing all the
parenchymal cells of the body the required
nutrients and oxygen (see Jain, 2003, for an
excellent review). VEGFs are probably the most
critical drivers of vascular formation both during
development and postnatal life regulating
differentiation of angioblasts to endothelial cells,
endothelial cell proliferation and fusion into tubes
with lumina and organization into primitive
plexus as well as in endothelial cell sprouting.
VEGFs and their receptors will be discussed in
more detail in section 3.3.
2.1. Formation of immature vasculature
The first step in the development of a functional
vascular network is the formation of immature
vasculature. The formation of the primary
capillary plexus starts from blood islands, which
are aggregations of mesodermal cells that colonize
the yolk sac and where the earliest hematopoietic
cells and endothelial cells appear. Peripheral cells,
angioblasts, surrounding primitive erythrocytes
differentiate into endothelial cells, whereas central
cells differentiate into hematopoietic cells (Risau
and Flamme, 1995). The first hematopoietic and
endothelial progenitors are derived from a
common embryonic precursor termed
hemangioblast (Choi et al., 1998). The faith of
hemangioblasts are determined by co-expression
of lineage-specific transcription factors. Recently,
a homeoprotein HEX has been indicated as a
regulator of hemangioblast differentiation into
hematopoietic and endothelial cell lineages (Guo
et al., 2003), and the transcription factor
Tal1/SCL has been shown to regulate the choice
of cell fate into hematopoietic, smooth muscle and
endothelial cell lineages (Ema et al., 2003).
The endothelial cells lining the blood vessels
differentiate from mesodermal CD31, CD34,
VEGFR-2 positive precursor cells, angioblasts, to
form a primitive vascular network in a process
called vasculogenesis giving rise to the dorsal
aorta, the cardinal vein and the embryonic stems
9of yolk sac arteries and veins. Blood vessel
formation is dependent on the action of VEGF on
its receptor tyrosine kinases, VEGFR-1/Flt-1 and
VEGFR-2/Flk-1, expressed in endothelial cells
(Fong et al., 1995; Shalaby et al., 1995; Carmeliet
et al., 1996; Ferrara et al., 1996). Deletion of flk-1
causes an arrest in vasculogenesis during the
angioblast differentiation state (Shalaby et al.,
1995), while deletion of flt-1 causes embryonic
lethality from edema following initial formation
of definitive blood vessels (Fong et al., 1995).
Current models for the genetic programming of
vasculogenesis suggests that a multifactorial
combinations of transcription factors in a tightly
synchronized expression pattern are required for
vasculogenesis (Oettgen, 2001).
Hypoxia is an important stimulus for the
expansion of the vascular bed. Initially, cells in
the developing embryo are oxygenated by
diffusion of oxygen. Sprouting angiogenesis is
probably triggered by hypoxia when the tissues
grow beyond the limit of oxygen diffusion.
Hypoxia is signaled through hypoxia-inducible
transcription factors (HIFs) that induce the
expression of number of genes involved in blood
vessel formation and maturation, including
VEGF, nitric oxide synthetase and Ang-2
(Semenza, 2003a). Blood vessels become leaky,
and the plasma proteins leaked from these nascent
vessels serve as a provisional matrix. The
basement membrane is degraded by the activated
proteases, such as MMPs (Egeblad and Werb,
2002). Differential expression of cell adhesion
molecules like vascular cadherins (Lampugnani et
al., 1992) and integrins (Friedlander et al., 1995)
is also essential for the formation of nascent blood
vessels, where growth factors and morphogens
differentially regulate the expression of these
molecules. Endothelial cells migrate through
interactions between integrins and the ECM, and
proliferate in response to endothelial cell mitogens
such as VEGF.
2.2. Stabilization of immature vasculature
The signaling of Angiopoietins (ang 1-4) through
their receptor tyrosine kinase system (Tie1 and
Tie2), play an important role in the formation of
the vascular loops and networks in the immature
vasculature and the further stabilization of this
immature vasculature. Tie1 and Tie2 are
expressed in embryonic angioblasts, vascular
endothelium and endocardium, whereas in adult,
Tie1 is expressed in endocardium and lung
capillaries and Tie2 is expressed in endocardium
and vascular endothelium (Dumont et al., 1994;
Korhonen et al., 1994). Genetic studies implicate
a major role for the Tie receptor system in
angiogenesis and vascular remodeling. In Tie1
deficient mice, blood vessels are established, but
the vascular integrity is compromised leading to
embryonic or perinatal lethality, suggesting a role
for Tie1 in the integrity and survival of
endothelial cells in angiogenesis. Tie2 is required
for sprouting and branching of blood vessels
during angiogenesis; Tie2 deficient mice have
reduced number of endothelial cells and abnormal
vascular network formation lacking the normal
sprouting, branching and remodeling of blood
vessels. Consequently, Tie2 deficiency is
embryonically lethal (Dumont et al., 1994; Sato et
al., 1995). Tie2 receptor ligand Ang-1 is critical
for vascular development in stabilizing the
forming blood vessels making them impermeable
by facilitating the endothelial cell-mural cell
communication. Ang-1 deficient mice have a
similar phenotype as Tie2 deficient mice,
including embryonic lethality (Suri et al., 1996).
Ang-1 is expressed in embryonic heart
myocardium (Suri et al., 1996) and later during
development within the mesenchyme surrounding
developing blood vessels. In adult, the main
sources of Ang-1 are the mural cells; vascular
smooth muscle cells and pericytes (Davis et al.,
1996). Ang-1 has a role in pericyte recruitment to
developing blood vessels by stimulating
endothelial cells to produce growth factors that in
turn stimulate the differentiation of the
surrounding mesenchyme into pericytes or smooth
muscle cells. In Ang-1 deficient mice, endothelial
cells are poorly associated in the underlining
basement membrane, and they do not recruit
pericytes properly leading to more rounded
endothelial cell phenotype (Suri et al., 1996). In
contrast, mice over expressing Ang-1 show
increased vascularization (Suri et al., 1998), and
in the absence of mural cells, exogenous Ang-1
can restore the hierarchal order of functionality of
larger blood vessels in developing retinal
vasculature in mice (Uemura et al., 2002). Ang-1
is involved in regulating endothelial cell survival,
endothelial cell sprouting and blood vessel
branching in vitro and in vivo as well as in
regulating endothelial cell-basement membrane
interactions by serving as a substrate for cell
adhesion through integrins and Tie2 (Carlson et
al., 2001). In addition of being secreted, Ang-1 is
incorporated in the ECM of tumor cells.
Endothelial cell adhesion causes a release of ECM
associated Ang-1 and subsequent Tie2 receptor
activation (Xu and Yu, 2001). Ang-1 and Tie1 in
combination are critical in establishing vascular
polarity during angiogenesis since mice deficient
for both Ang-1 and Tie1 showed a specific
disruption of the right system of the sinus venosus
(Loughna and Sato, 2001).
Ang-2 plays a dynamic role in vascular
remodeling and angiogenesis in conjunction with
VEGF and Ang1. In the absence of VEGF, Ang-2
acts as an antagonist of Ang-1 and destabilizes
blood vessels, leading to vessel regression
whereas in the presence of VEGF, Ang-2
facilitates vascular sprouting and branching by
blocking the constitutive stabilizing Ang-1 signal
(Maisonpierre et al., 1997). Ang-1 and TGF-β,
both important in maturation and stabilization of
developing blood vessels, downregulate Ang-2
expression, whereas for instance hypoxia and
VEGF up-regulate the Ang-2 expression
(Mandriota and Pepper, 1998). Angiotensin II
(AngII) induces Ang-2 expression without
affecting Ang-1 or Tie2 expression. Furthermore,
angiotensin receptors 1 and 2 (AT1 and AT2)
regulate Ang-2 and VEGF expression
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differentially. AT1 stimulates the ECM bound
EGF by metalloproteinases, which transactivates
EGF-receptor to induce angiogenesis via the
combined effects of Ang-2 and VEGF. On the
other hand, AT2 attenuates these affects by
blocking EGF-receptor phosphorylation
(Fujiyama et al., 2001).
TGF-β and its signaling pathways play a role both
in the formation and stabilization of the
vasculature. TGF-β induces differentiation of
endothelial cells after their recruitment to
endothelial walls (Hirschi et al., 1998) and
through endoglin signaling, functions in the
recruitment of mesenchymal cells to blood vessels
and their differentiation to mural cells (Li et al.
1999).
Paracrine signaling via PDGF-B expressed in
endothelial cells and its receptor PDGFR-β
expressed on mural cells plays an important role
in mural cell recruitment to blood vessels and the
following stabilization of the vessel. PDGF-B and
PDGFR-β deficient mice lack pericytes and
develop microaneurysms and die late in gestation
(Lindahl et al., 1997). Pericyte deficiency leads to
a variety of microvascular abnormalities including
endothelial cell hyperplasia and abnormalities in
shape and ultrastucture, vessel tortuosity and
leakiness leading to widespread microaneurysms
(Hellstrom et al., 1999; Hellstrom et al., 2001).
This reduced coverage of dilated and tortuous
microvessels by pericytes leads to embryonic
lethality due to fatal hemorrhages in both PDGF-
B knockout mice (Leveen et al., 1994; Lindahl et
al., 1997) and PDGFR-β knockout mice (Soriano,
1994; Lindahl et al., 1997).
Sphingosine-1-phosphate (S1P)- sphingosine-1-
phosphate receptor (S1P1/Edg1) interaction is also
essential for blood vessel maturation (Liu et al.,
2000). S1P1 is a widely distributed G-protein
coupled receptor for S1P, a bioactive platelet-
derived lipid (Zhang et al., 1991). Disruption of
the edg-1 gene results in massive embryonic
hemorrhage and embryonic lethality caused by an
incomplete vascular maturation due to a failure in
vascular smooth muscle cell/pericyte recruitment
to immature blood vessels (Liu et al., 2000). This
recruitment of vascular smooth muscle
cells/pericytes is directed by the activity of the
S1P1 receptor in endothelial cells even though
both endothelial cells and vascular smooth muscle
cells/pericytes express S1P1 receptor (Allende et
a l . , 2003). Loss of S1P1/Edg1 results in
dysfunctional migration of diverse cell types
(including aortic smooth muscle cells) toward
PDGF (Hobson et al., 2001), linking the
phenotype of edg-1 knockout mice (Liu et al.,
2000) to the phenotypes of PDGF-BB and
P D G F R -β  phenotypes. This highlights the
importance of cross-communication between
PDGFR and S1P1/Edg1 in which activation of the
G-protein coupled receptor, S1P1/Edg1, by a
receptor tyrosine kinase, PDGFR-β, is critical for
cell motility playing an essential role in the
maturation of the vasculature (Hobson et al.,
2001).
The currently favored view states that the initial
endothelial tubes form without pericyte contact,
ant that subsequent acquisition of pericyte
coverage leads to vessel remodeling, maturation
and stabilization. Improved means of identifying
and visualizing pericytes now challenge this view
and show that high number of pericytes invest an
actively sprouting and remodeling vessels
(Morikawa et al., 2002).
2.3. Branching, remodeling and pruning of
vasculature
The growth, branching, remodeling and pruning
of the different segments of the developing
vascular network determine the hierarchy of the
vascular network with an optimal pattern for a
given tissue. There are several mechanisms that
can result in the branching of blood vessels. New
vessel branches can sprout towards a cluster of
cells in the surrounding mesenchyme that
produces the angiogenic stimulus. Existing vessels
can split into individual daughter vessels by the
formation of transendothelial cell bridges or the
vessels can branch via intussusception, based
upon insertion of interstitial tissue columns into
the lumen of pre-existing vessels (Djonov et al.,
2000). The subsequent growth of these columns
and their stabilization results in partitioning of the
vessel lumen and remodeling of the vascular
network.
The spatial distribution of secreted VEGF-A is
critical for the balance between capillary
branching and growth in vessel size since mice
lacking heparin-binding VEGF-A isoforms and
therefore ECM interaction domains, exhibited a
specific decrease in capillary branch formation
and impairment of the direct extension of
endothelial cell filopodia (Ruhrberg et al., 2002).
The patterning of retinal blood vessels has also
been shown to depend on the balance between two
different qualities of the extracellular VEGF-A;
the gradient and the concentration. Properly
shaped extracellular pattern of VEGF-A
distribution is necessary for the correct guidance
of filopodial extension from specialized
endothelial cells at the tips of the vascular sprouts,
and endothelial cell proliferation occurs in the
sprout stalks in response to VEGF-A
concentration. Both of these effects are mediated
via VEGFR-2 (Gerhardt et al., 2003). VEGFR-1
has recently been suggested also to play a role in
vascular sprout formation and morphogenesis.
VEGFR-1 was shown to positively affect sprout
formation by negatively controlling the amount of
VEGF-A signal that is sensed by endothelial cells,
using soluble VEGFR-1 as the primary mediator
of the effect (Kearney et al., 2004). Kearney et al.
also suggests a critical role for VEGF-A and/or
VEGFR-1 gradient formation in modulating
vascular sprout formation. Thus, the local
availability of VEGF-A signal is critical to proper
vascular morphogenesis and sprouting (Gerhardt
et al., 2003; Kearney et al., 2004). In addition to
signaling through VEGFRs, VEGF also signals
through neuropilin receptors (reviewed in Neufeld
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et al., 2002). VE-cadherin is essential for normal
vascular integrity and the expansion and
remodeling of the primitive vascular network, but
it is not required for the initial assembly of the
vascular endothelium (Carmeliet et al., 1999).
VE-cadherin controls an endothelial cell survival
pathway through its intracellular interactions with
β-catenin (Carmeliet et al., 1999). VE-cadherin
deficient endothelial cells are unable to respond to
VEGF-A dependent cell survival signals through
f o r m a t i o n  o f  a  V E - c a d h e r i n /β-
ca t en in /phospha t idy l inos i t o l  3 -k inase
(PI3K)/VEGFR-2 complex. In mice, genetic
ablation of VE-cadherin or VE-cadherin-β-catenin
interaction impair expansion, remodeling and
maturation of vascular network and reduced
endothelial cell survival causing embryonic
lethality (Carmeliet et al., 1999). Neuropilin-1 and
–2 (NRP-1 and NRP-2) belong to the class-3
semaphorin subfamily and function as receptors
for the axon guidance factors during embryonic
development. During blood vessel formation,
neuropilins regulate VEGFR-1 and -2 signal
transduction by forming complexes with these
receptors. Besides disorganization of nerve fibers,
NRP-1 deficient mice showed defects in neural
vascularization, transposition of blood vessels and
development of vascular network of the yolk sac
leading to embryonic lethality (reviewed in
Neufeld et al., 2002). Recently, semaphorin-3, a
NRP-2 receptor ligand was shown to inhibit tumor
angiogenesis (Kessler et al., 2004).
Nerves often run along larger blood vessels in
adult tissues. The intimate association of nerves
and blood vessels and their functional
interactions, like the control of vasoconstriction
and vasodilation, has been the reason to speculate
that the branching patterns of these two systems
might be ontogenetically or mechanistically
related. Arteries are preferentially aligned with
nerves following their branching pattern, whereas
veins are not. Arteries fail to develop properly in
mouse embryos that lack sensory nerves, while
their branching is altered to follow the nerve in
mouse embryos containing disorganized nerves.
Peripheral nerves seem to provide a template
determining the organotypic pattern of blood
vessel branching and arterial differentiation, at
least in the mouse skin, through local secretion of
VEGF from sensory nerve fibers, Schwann cells
surrounding them, or from both cell types
(Mukouyama et al., 2002).
Components of the basement membrane and ECM
provides cues for the growth and remodeling of
the vasculature by regulating the proliferation,
migration, survival and differentiation of
endothelial cells, pericytes and smooth muscle
cells. Degradation of the ECM involves an array
of proteinases, which not only provide space for
the migrating endothelial cells of the growing
vessel, but also results in the release of matrix
sequestered growth factors and proenzymes. In
addition, degradation of the ECM can result in the
exposure of cryptic adhesion sites hidden in non-
proteolyzed matrix (reviewed in Kalluri, 2003).
Endothelial cell movement through ECM is a
tightly regulated process that requires the
polarization of the molecular machinery for
matrix degradation to the advancing edge of the
moving cell, integrin mediated cell-matrix
adhesion complex formation and subsequent
disassembly involving reversible integrin/matrix
binding, assembly and disassembly of cell
cytoskeleton. In this process, integrins do not just
mediate cell-cell and cell-matrix adhesion, but
they also act as a link between the extracellular
and intracellular environments allowing inside-out
and outside-in signal transduction modulating
endothelial cell functions (reviewed in Martinez-
Lemus et al., 2003). Cells express a combination
of integrins on their cell surface, and this
combination is constantly changing during
vascular development, suggesting that specific
combination of integrins are required as
development of the vasculature proceeds.
2.4. Specialization of blood vessels
The specialization of the tissue- and organ-
specific structure of the blood vessel network and
the molecular specialization of the endothelial
cells lining the vessel walls are the least
understood processes of the blood vessel
development.
Arterio-venous specialization of blood vessels is
genetically determined by the Notch-Gridlock
signaling pathway (Lawson et al., 2001; Zhong et
al., 2001). Bidirectional ephrin-ephrin receptor
signaling during the formation of the capillary
plexus repels the arterial and venous sides guiding
vascular branching (Wang et al., 1998).
Cell-cell adhesion in developing blood vessels is
mediated through adherens junctions that are
formed by transmembrane adhesive protein VE-
cadherin in endothelial cell-endothelial cell
junctions and N-cadhering in endothelial cell-
mural cell junctions. VE-cadherins are organized
in clusters at cell-cell contacts and connect
through their cytoplasmic domain with a complex
network of cytoskeletal proteins. As the vessel
matures, more classical cell-cell junctions
including tight junctions and gap junctions start
forming, depending on the function of the
particular vascular bed (reviewed in Dejana,
1996). The factors determining the organ-specific
nature of the cell-cell junction formation remain
unknown.
Development of the retinal vasculature provides
some interesting examples of the specialization of
the blood vessels. In the retina, the fovea is
specialized for high-resolution vision. Within the
central fovea, cone photoreceptors reach their
highest numerical density, yet the fovea is
avascular. During the development of the retinal
vasculature, the slow growth of blood vessels
towards the central fovea and the low levels of
endothelial cell proliferation suggest a presence of
anti-proliferative and/or anti-angiogenic factor(s)
within the foveal region. The requirement for
nutrients and oxygen by photoreceptor cells,
which are metabolically extremely active, must be
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met by the specialization of the extra-retinal
choroidal circulation; in the vicinity of the fovea,
the density of the choroidal arcades is increased
(reviewed in Provis, 2001).
Minority of blood vessels that forms during
embryonic development persists until adulthood.
After the onset of circulation, the primary
capillary plexus is remodeled many times until the
mature vascular network is formed. For example,
all capillaries in the prechondrogenic area regress
to allow the differentiation of the cartilage tissue
(Hallmann et al. 1987). Hyaloid vascular system
of the developing eye regresses to allow the
development of a translucent vitreous body
compatible with vision (Latker and Kuwabara,
1981).
Specialization of the developing vasculature leads
ultimately to a vast structural and molecular
heterogeneity of the vasculature, which will be the
topic of the section 4 of this review of the
literature.
2.5. Development of lymphatic vessels
Lymphatic vessels collect extravasated immune
cells as well as fluid and proteins leaked from
blood vessels and return them back to the
circulation after passing through a series of lymph
nodes. Lymphatic vessels develop from
specialized endothelial cells in pre-existing blood
vessels. The homeobox gene Prox1 was identified
to be required for the induction of lymphatic
vascular development from preexisting embryonic
veins (Wigle and Oliver, 1999) and has an
essential role in the developmental program
specifying lymphatic endothelial cell fate (Hong
et al., 2002).
Expression of Prox1 is sufficient to induce a
lymphatic phenotype in blood vessel endothelial
cells. Ectopic expression of Prox1 downregulates
blood vessel-associated genes and also
upregulates some of the known lymphatic
endothelial cell markers suggesting that the blood
vascular phenotype represents the default in the
endothelial cell differentiation and they identify
an essential role of Prox1 in the program
specifying lymphatic endothelial cell fate (Hong
et al., 2002). Lymphatic endothelial cells might
also be derived from mesenchymal precursor
cells, lymphangioblasts (Papoutsi et al., 2001).
VEGF-C has been shown to be the paracrine
factor essential for lymphangiogenesis
(Karkkainen et al., 2004). Pericytes have been
though to play a lesser role in the lymphatic
vascular bed, but lymphatic endothelium has been
shown to recruit pericytes/smooth muscle cells in
vivo, collecting lymphatic vessels being covered
by smooth muscle cells in contrast to lymphatic
capillaries, which are negative for α - S M A
positive cells (Veikkola et al., 2003).
Figure 2. Formation of a vascular network. Endothelial progenitors differentiate to arterious and venous endothelial cells,
which assemble in a primitive capillary plexus. Vessels then sprout and become stabilized by smooth muscle cells and
pericytes, differentiating from their progenitors. Hematopoietic stem cells contribute to angiogenesis directly and indirectly, by
differentiating to leukocytes or platelets. Shh, Sonic hedgehog; Grdl, gridlock, AML, acute myeloid leukemia; Scl, stem cell
leukemia. Adapted from Carmeliet, 2003.
.
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3. Angiogenesis
3.1. Formation of angiogenic vasculature
Angiogenesis occurs during embryonic
development and it is an essential process for the
development of a functional vascular system. The
failure of angiogenesis to occur during
development will unavoidably lead to the death of
the embryo. In adult, angiogenesis is involved in
tissue repair, female reproductive cycle and
inflammation. Angiogenesis also characterizes
several pathological conditions including cancer
and retinopathies (Carmeliet, 2003).
During cancer progression, in order for cells
within an aberrant proliferative lesion to develop
to a larger size into a tumor, cells must acquire
angiogenic ability. The ability to induce and
maintain angiogenesis is acquired in a discrete
event during tumor development through an
“angiogenic switch” from quiescent to activated
vasculature (Hanahan and Folkman, 1996). The
induction of angiogenesis is prerequisite for the
rapid clonal expansion of tumor cells associated
with the formation of macroscopic, clinically
relevant tumors.
Counterbalancing positive and negative vascular
growth signals induce or inhibit angiogenesis.
Tumors activate the angiogenic switch by
changing the balance of these growth signals. One
strategy to do that involves altered expression of
genes coding for vascular growth factors and
inhibitors. Many tumors upregulate the expression
of VEGF and FGFs and/or downregulate the
expression of endogenous angiogenesis inhibitors
including TSP-1. Altered expression or activation
of proteases also play and important part in the
angiogenic switch by controlling the
bioavailability of angiogenic growth factors and
inhibitors. A variety of proteases can release
bFGF and VEGF from the ECM, while a
component of the blood clotting system plasmin,
and autocatalyze its own degradation from a pro-
angiogenic molecule to an angiogenesis inhibitor,
angiostatin (reviewed in Hanahan and Weinberg,
2000). Comparison of the gene expression
patterns in endothelial cells from malignant versus
non-malignant tissues by serial analysis of gene
expression (SAGE) revealed that largest group of
differentially expressed genes were genes coding
for ECM proteins highlighting the role of the
ECM and the endothelial cell/mural cell basement
membrane and its functional regulation during
angiogenesis (St Croix et al., 2000). Basement
membrane does not disappear during
angiogenesis, but instead remodels constantly as
endothelial cells sprout during blood vessel
growth. In angiogenesis, the basement membrane
shows structural abnormalities consistent with the
dynamic nature of endothelial cells and pericytes
during angiogenesis (Baluk et al., 2003).
In pathological angiogenesis, the formed blood
vessels show many abnormalities at the
molecular, structural and functional level. The cell
and ECM composition is also abnormal (reviewed
in section 4.3.). Reasons for these abnormalities
are not known, but at least part of the
abnormalities in structure and function of tumor
blood vessels reflect lack of proper maturation of
blood vessels in the tumor microenvironment
(Gee et al., 2003). Given the abnormalities in
structure and function of tumor blood vessels, it
seems likely that blood vessels in normal and
tumor tissue form by different mechanisms.
Dvorak (2003) describes elegantly the formation
of angiogenic blood vessels in response to VEGF-
A in mouse tissue. First abnormal blood vessel
structures appear soon (time frame in hours) after
the initiation of VEGF-A overexpression in mouse
tissue arising from the enlargements of pre-
existing microvessels, mainly from venules. These
VEGFR-2 positive sinusoids, named “mother
vessels”, are large and hyperpermeable and have
thin walls, serpentine structure and poor pericyte
coverage. Mother vessels are formed by a multi
step process involving digestion of the blood
vessel basement membranes, detachment of
pericytes and morphological changes in
endothelial cells including spreading and thinning
of the cells to cover an expanded surface area.
Vesiculo-vacuolar organelles, cytoplasmic
vesicles and vacuoles in endothelial cells, provide
an intracellular storage for membrane that can be
mobilized rapidly to the growing plasma
membrane allowing the enlargement of
endothelial cells. Many mother vessels develop
into poorly organized vascular structures called
glomeruloid bodies. Glomeruloid bodies are first
recognized few days after VEGF-A
overexpression as focal collections of large
primitive cells in the mother vessel lining. As
glomeruloid bodies expand, the large lumens of
mother vessels start dividing into multiple small
and tortuous channels. As VEGF-A expression in
the tissue subsides, glomeruloid bodies resolve to
normal appearing capillaries through apoptosis
and reorganization of endothelial cells and
pericytes (Dvorak, 2003). The detailed
mechanisms by which different growth factors
produced by tumors or by inflammatory cells
produce the angiogenic response are likely to
differ, leading to different phenotypes of
angiogenic vasculature.
In addition to the sprouting and co-option of
neighboring pre-existing vessels, angiogenesis
during tumor growth and wound healing is also
supported by the mobilization and incorporation
of circulating endothelial progenitor cells (CEPs)
to the growing blood vessels. CEPs are highly
proliferative bone marrow-derived cells that upon
recruitment to growing blood vessels will
differentiate into endothelial cells. VEGF through
interaction with its receptors VEGFR-2 and
VEGFR-1 expressed on endothelial and
hematopoietic stem cells promotes the co-
mobilization of CEPs and hematopoietic cells
from the bone marrow and recruitment of these
cells into the sites of tissue injury and
angiogenesis. The collaboration between recruited
CEPs and hematopoietic cells facilitates the
differentiation and integration of CEPs into the
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growing vascular bed (reviewed in Rafii et al.,
2002).
3.2. Role of hypoxia in angiogenesis
Within the tissues, the architecture of the vascular
network brings the circulatory system with
oxygen and nutrients to close contact with all
cells. Local oxygen tension seems to be the
critical signal for cells to detect vascular
insufficiency. This has a profound effect on the
vasculature, which responds to hypoxia through
the induction of new blood vessel formation. The
diffusion coefficient of oxygen within tissues is
about 150-200 µm. The location of both dividing
and apoptotic tumor cells within spontaneous and
implanted murine tumor models has been shown
to reflect the oxygen diffusion in tissues; tumor
cells located less than 100 µm away from a blood
vessel are viable while more distant tumor cells
are undergoing apoptosis (Fidler et al., 2002).
Hypoxia-inducible factor-1 (HIF-1) is a
transcriptional activator that functions as the
master regulator of O2 homeostasis in tissues.
HIF-1 is a heterodimer that consists of the
hypoxic response factor HIF-1α  and the
constitutively expressed aryl hydrocarbon receptor
nuclear translocator (ARNT; HIF-1β ). In the
absence of oxygen, HIF-1 binds to hypoxia
response elements (HREs) in the gene promoter
regions, thereby activating the expression of a
variety of hypoxia-response genes. In the presence
of oxygen HIF-1α  is bound to the tumor
suppressor Von Hippel-Lindau (VHL) protein.
Subsequently, HIF-1α becomes ubiquitylated and
targeted to the proteasome for degradation. This
O2-dependent activity of HIF-1 depends on
hydroxylation of the HIF-1α  by a prolyl
hydroxylase protein and by a FIH1-protein.
Hydroxylation of a proline residue is required for
the binding of VHL protein to HIF1-α  and the
hydroxylation of an asparagine residue is required
for the binding of HIF-1α co-activators p300 and
CBP. Under hypoxic conditions, O2 becomes the
limiting factor for these hydroxylation reactions
ultimately leading to a decreased rate of HIF-1α
degradation (reviewed in Semenza, 2003b).
HIF-1-targeted genes encode proteins that
function in pathways that increase O2 delivery and
mediate adaptive responses to O2 deprivation.
These pathways include angiogenesis, glycolysis,
growth factor signaling, cell immortalization,
tissue invasion and metastasis, apoptosis and pH
regulation. To date, more than 60 putative direct
HIF-1 target genes have been identified (reviewed
in Semenza, 2003b).
Besides being regulated by the tissue O2
concentration, the major growth factor-stimulated
signal transduction pathways have a role in HIF-1
regulation by inducing the expression of HIF1α.
In contrast to hypoxia, growth factors and
cytokines stimulate HIF-1α  synthesis through
activation of the PI3K or mitogen-activated
protein kinase (MAPK) pathways. While hypoxia
increases HIF-1α levels in all cell types, growth
factor induced HIF-1α expression is dependent on
the cell type (reviewed in Semenza, 2003b). HIF-
1α was also demonstrated to act as a negative or
positive factor in astrocytoma progression
depending on the microenvironment in which the
tumor grew. This observation lead to the notion
that HIF-1α-regulated hypoxic response to the
microenvironment is highly dependent on the
local environment in which those tumors arise and
involves both growth factor (VEGF)-dependent
and -independent mechanisms (Blouw et al.,
2003).
In human cancer cells, intratumoral hypoxia,
growth factor expression and genetic alterations
affecting signal transduction pathways lead to
increased HIF-1 activity, which promotes
angiogenesis, metabolic adaptation, and other
critical aspects of tumor progression (reviewed in
Semenza, 2003b).
Development of the retinal vasculature brings us a
well-characterized example of hypoxia during the
development of vasculature. Blood vessels enter
the back of the embryonic eye at the eyecup stage
and reach the vitreal surface via the choroidal
fissure. This fissure closes around the developing
optic nerve and the blood vessels close to the
vitreal surface that supply the innermost part of
the central retina. As the retina expands during
and after the fetal period, the vessels branch and
grow radially outward toward the retinal periphery
(reviewed in Provis, 2001). The invading retinal
vasculature is associated with astrocytes.
Astrocytes lie in the avascular zone just a few
hundred micrometers ahead of the radially
spreading vessels, and are thought to stimulate
and control the direction of vessel growth by local
release of VEGF (Sandercoe et al., 1999). Low
tissue O2 concentration is the key regulator of
VEGF production in the developing retinal
vasculature Differentiated astrocytes lying just
ahead of the invading vascular endothelium are
critically sensitive to hypoxia and respond by
upregulation of VEGF which in turn stimulates
the endothelial cell proliferation at the vascular
front (Pierce et al., 1995; Stone et al., 1995). In a
similar way, Müller cells are though to regulate
development of the secondary vascular plexus in
the retina (reviewed in Provis, 2001). Once blood
vessels mature to the stage at which they are
invested with pericytes they are believed to loose
responsiveness to VEGF (Benjamin et al., 1998).
Another set of blood vessels supplies the choroid,
just external to the pigment epithelial layer. The
pigment epithelial layer itself and the entire length
of the photoreceptor cells, from their synaptic
endings in the outer plexiform layer, through their
nuclei in the outer nuclear layer, to their
specialized inner and outer segments close to the
pigment epithelium are normally avascular
(reviewed in Provis, 2001). In experimental or
clinical contexts in which retinal hypoxia induces
VEGF expression, new blood vessels will form
either on the inner neural retina in young subjects
or, in some older subjects, from the choroid across
the pigment epithelium (Schlingemann and van
Hinsbergh, 1997). In contrast, when VEGF basal
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expression drops, endothelial cells undergo
apoptosis (Alon et al., 1995) and retinal
vasculature regresses resulting in a reduced retinal
blood supply. On the other hand, hypoxic
regulation of angiogenic factors such as VEGF,
TGF-β (de Kozak et al., 1997; Ogata et al., 1997),
growth hormone (GH), insulin-like growth factor-
I (IGF-1) and its receptors (Smith et al., 1997),
placental growth factor (PlGF; Khaliq et al.,
1998) and inhibitory factors such as pigment
epithelium-derived factor (PEDF; Dawson et al.,
1999) have also been shown to regulate retinal
neovascularization in ischemic retinopathies in
patients and animal models.
3.3. Pro-angiogenic factors and their
receptors
Oncogene and hypoxia-driven expression of pro-
angiogenic factors, such as VEGF, bFGF,
Interleukin-8 (IL-8), PlGF, TGF-β and PDGF are
one of the key elements in the induction of the
“angiogenic switch” (Hanahan and Folkman,
1996).
Of the numerous growth factors contributing to
angiogenesis, members of VEGF family of
secreted glycoproteins are considered to be key
angiogenic mediators contributing to both
physiological and pathological angiogenesis. The
importance of VEGF for blood vessel formation is
demonstrated by the fact that mice with only a
single allele of normal VEGF are embryologically
lethal (Carmeliet et al., 1996; Ferrara et al., 1996),
as are the mice deficient with VEGFR-1, -2 and
–3 (Fong et al., 1995; Shalaby et al., 1995;
Dumont et al., 1998). VEGF was first isolated
from tumor cells as a factor inducing vascular
permeability (Senger et al., 1983), and
subsequently it has been shown to induce
migration, proliferation and survival of
endothelial cells and angiogenesis (Ferrara, 1999).
The VEGF family includes VEGF-A, VEGF-B,
VEGF-C, VEGF-D, the viral VEGF homologue
VEGF-E and PlGF. Four different isoforms of
VEGF have been identified in human; VEGF121,
VEGF165, VEGF189 and VEGF206 arising from
alternative splicing of VEGF mRNA. The longer
forms of VEGF are matrix bound through their
heparin-binding domains, while the shorter forms
(VEGF121 and some of VEGF165) are freely
diffusible. The longer forms can be released from
the ECM by plasmin cleavage, thus increasing
local VEGF concentration during tissue growth
and remodeling involving proteolysis (reviewed in
Veikkola and Alitalo, 1999). Even after the
embryonic development, VEGF-A continues
playing a crucial role in the formation of new
blood vessels; withdrawal of VEGF-A leads to
endothelial cell apoptosis and the inhibition of
new blood vessel formation resulting in blood
vessel regression (Gerber et al., 1999). After the
newly formed blood vessels have recruited a
pericyte coverage, they are no longer dependent
on VEGF-A for their survival (Benjamin et al.,
1998). Whereas VEGF-A is involved in vascular
permeability and angiogenesis, VEGF-B is
studied for its role in the regulation of ECM
degeneration, cell adhesion and migration and
VEGF-C and VEGF-D are studied intensively for
their role in angiogenesis and lymphangiogenesis
in cancer (reviewed in Veikkola and Alitalo,
1999). PlGF-1 induces increased vascular
permeability, proliferation, chemotaxis and
angiogenesis and may act synergistically with
VEGF-A in pathological angiogenesis (Carmeliet
et al., 2001). Interestingly, if PlGF-1 is produced
by the same cells that produce VEGF they form
functionally inactive heterodimers that fail to
activate VEGFR-2 and VEGFR-2 signaling
pathways. High levels of PlGF-1 expression by
VEGF-producing tumors force VEGF to dimerize
with PlGF-1 resulting in inhibition of
angiogenesis and tumor growth (Eriksson et al.,
2002).
Three VEGF receptor tyrosine kinases have been
described; VEGFR-1, -2 and –3. VEGFR-1 binds
VEGF-A, VEGF-B and PlGF, VEGFR-2 binds
VEGF-A, VEGF-C, VEGF-D and VEGF-E, and
VEGFR-3 binds VEGF-C and VEGF-D. NRP-1
binds PlGF-2 and a specific isoform of VEGF-A;
VEGF165 enhancing the binding of VEGF-A to
VEGFR-2 (reviewed in Veikkola and Alitalo,
1999). VEGFR-2 is considered to be the receptor
mediating functional VEGF signaling in
endothelial cells and there is recent evidence that
VEGFR-1 might be predominantly expressed in
pericytes in adult human tissues (Witmer et al.,
2002) mediating the VEGF receptor tyrosine
kinase signaling in these cells. VEGFR-3 was
initially been reported in lymphatic endothelia and
some high endothelial cell venules in adult tissues
(Kukk et al., 1996), but some studies also describe
the expression of VEGFR-3 in quiescent blood
vessel endothelium adjacent to epithelium
suggesting that VEGFR-3 and its ligands are
involved in paracrine communication between
endothelial and epithelial cells (Witmer et al.,
2002). Overexpression of VEGF-C, a VEGFR-3
ligand, results in lymphatic vessel hyperplasia in
mice (Jeltsch et al., 1997). A critical role for
VEGFR-3 signaling in lymphangiogenesis was
established in studies with patients with familiar
lymphoedema (Karkkainen et al., 2000), and the
critical role for VEGF-C as the paracrine factor
required for the lymphangiogenesis was
demonstrated recently (Karkkainen et al., 2004).
VEGFR-3 has been also found to be involved in
angiogenesis in various tumors as well as in
wound healing (Paavonen et al., 2000; Saaristo et
al., 2000).
Hypoxia-driven up-regulation of VEGF is the
major determinant in the well-characterized model
of hypoxia-induced retinal neovascularization
(Alon et al., 1995; Pierce et al., 1995; Stone et al.,
1995; Okamoto et al., 1997). Over-expression of
VEGF in the retina is sufficient to cause
intraretinal and subretinal neovascularization
(Okamoto et al., 1997), whereas inhibition of
VEGF expression or activity inhibits retinal
neovascularization (Aiello et al., 1995). VEGF is
produced by glial cells of the neural retina, such
as specialized astrocytes, including Müller cells
among other cell types (Alon et al., 1995; Pierce
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et al., 1995; Stone et al., 1995). VEGF expression
in the retina decreases within 6 hours of exposure
to 75% oxygen and remains decreased for the
duration of the hyperoxia. In contrast, an increase
in retinal VEGF expression is observed between 6
and 12 hours after the return to room air, and such
expression remains elevated during development
of the neovascularization. Therefore, VEGF levels
appear to play a dual role in this retinopathy
model: a down-regulation of VEGF by hyperoxia
induces blood vessel regression, while subsequent
up-regulation of VEGF leads to retinal
neovascularization (Alon et al., 1995; Pierce et
al., 1996).
The FGFs represent one of the largest families of
growth and differentiation factors for cells from
mesodermal and neuroectodermal origin. FGF
was first purified as a heparin-binding tumor-
derived protein stimulating the proliferation of
capillary endothelial cells (Shing et al., 1984).
More than 20 FGFs with different effects on
various target cells have been identified and four
FGF receptor (FGFR) types have been isolated to
date. Two prototypic members of the FGF family,
bFGF and acidic fibroblast growth factor (aFGF),
are ubiquitously expressed growth factors
inducing endothelial cell proliferation, migration
and capillary tube formation (reviewed in Risau,
1997 and Ornitz and Itoh, 2001). Fibroblast
growth factors stimulate endothelial cell growth
and recruit mesenchymal and/or inflammatory
cells, producing a variety of angiogenic factors
(Carmeliet, 2000). bFGF might not have a general
role in angiogenic responses, but it may be
necessary for blood vessel remodeling after
associated with tissue repair. aFGF and bFGF are
not secreted proteins, most FGFs remaining
cytoplasmic or binding to the ECM because of
their affinity to heparin. FGFs may be released
upon a cell injury and they might have a role in
angiogenesis following a tissue injury where
FGFs are deposited in the ECM (Healy and
Herman, 1992). In vitro FGFs demonstrate
striking synergistic effects with VEGF in the
induction of endothelial cell proliferation,
migration and capillary tube formation (Goto et
al., 1993).
T G F - β -1, -2 and -3 are structurally and
functionally closely related secreted proteins
belonging to a superfamily of multifunctional
cytokines. TGF-β  isoforms inhibit the
proliferation of most cell types, but can act as a
growth stimulator of cells from mesenchymal
origin, including endothelial cells. TGF-β family
members mediate vascular development and
regulate a vast number of cellular functions from
proliferation, migration, ECM production and
deposition to cell differentiation (reviewed in
Pepper, 1997). In tumorigenesis, TGF-β plays a
dual role in the growth inhibitory pathway
downstream of TGF-β , and in the process of
epithelial to mesenchymal transdifferentiation
(reviewed in Moustakas et al., 2002).
In vascular endothelium, TGF-βs are produced as
latent forms where TGF-β  dimer is bound to
latency-associated peptide. On activation from the
latent TGF-β  complex, TGF-β  binds to its
constitutively active serine threonine kinase type
II receptor (TβR-II) and subsequently forming
heterodimers with type I receptors, or activin
receptor-like kinases (ALKs 1-7) activating them.
ALKs then phosphorylate cytoplasmic receptor-
regulated Smads and form complexes with
common partner Smads and translocate to the
nucleus where they act as sequence specific
transcriptional activators. The specificity of TGF-
β  signaling and subsequent changes in cell
function are specified by the expression pattern of
type I and type III receptors. In addition to widely
expressed TβRII, TβRIII and ALK-5, endothelial
cells express ALK-1 type I receptor and endoglin,
type IIII receptors phosphorylating Smads 1, 5
and 8 (reviewed in van den Driesche et al., 2003).
Several ECM proteins can bind to TGF-β and
modulate its activity. For example, ECM
proteoglycan decorin binds to TGF-β inhibiting its
activity while TGF-β binding to TSP-1 leads to
increased activity (Yamaguchi et al., 1990;
Ribeiro et al., 1999).
Exogenous TGF-β  has been described to have
both stimulatory and inhibitory effects on
endothelial cells depending on in vitro or in vivo
assays used (reviewed in Pepper, 1997). Studies
done using gene knockout mice, have revealed a
clear involvement of TGF-β  family signaling
during vascular development and the maintenance
of vascular integrity. TGF-β  null mice show
defects in endothelial cell differentiation resulting
in inadequate capillary tube formation and fragile
vessels with reduced cellular adhesiveness
(Dickson et al., 1995). TGF-β receptor I and II
deficient mice also show a similar phenotype
(Oshima et al., 1996; Larsson et al., 2001). These
mice show deficiencies in vasculogenesis, in
contrast to mice deficient of endoglin, which show
no defects in vasculogenesis. Instead, endoglin
deficient mice show a failure of endothelial cell
remodeling as well as failure to properly recruit
mesenchymal cells to growing blood vessels and
induce their differentiation to pericytes and
vascular smooth muscle cells (Li et al., 1999).
From the CXC chemokine family members, IL-8
has long been recognized to function in regulation
of pathological angiogenesis, tumor growth and
metastasis. (Koch et al., 1992; Strieter et al.,
1995). IL-8 receptors CXCR1 and CXCR2, as
well as CXCR4, another receptor for an
angiogenic chemokine CXCL12, are expressed on
endothelial cell surface (Li et al., 2003; Salcedo
and Oppenheim, 2003) IL-8 has been shown to
directly induce endothelial cell proliferation,
survival and capillary tube formation. IL-8 also
upregulates endothelial cell expression of MMP-2
and MMP-9 (Li et al., 2003). Growth factors can
also influence chemokine functions on angiogenic
blood vessels. CXCL12 upregulates VEGF-A
expression and VEGF-A upregulates CXCR4
expression, thus creating an amplification loop
that is influenced by hypoxia-induced growth
factor expression (reviewed in Romagnani et al.,
2004). CXC chemokines provide a fine and
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coordinated regulation of angiogenesis and
inflammation. The coordination of angiogenesis
and inflammation is a result of the ability shared
by endothelial cells and leukocytes to respond to
chemokines. Interplay between growth factors,
cytokines and adhesion molecules regulates the
inflammatory response leading to angiogenesis,
tissue repair and generation of new tissue
(reviewed in Romagnani et al., 2004).
3.4. Endogenous angiogenesis inhibitors
There are two classes of angiogenesis inhibitors,
direct and indirect. Direct angiogenesis inhibitors
prevent endothelial cells from responding to
various endothelial cell mitogens or motogens by
proliferation, migration or escape from apoptosis.
Direct endogenous inhibitors of angiogenesis
include angiostatin, endostatin, tumstatin,
thrombospondins, vasostatin and PEDF discussed
briefly below. Indirect anti-angiogenic factors
target proteins that are expressed on tumor cells or
their receptors in endothelial cells that are
normally activated in angiogenesis (reviewed in
Kerbel and Folkman, 2002).
Angiostatin is a 38 kDa internal protein fragment
of plasminogen. It contains the first kringle
domain of plasminogen and it is produced by the
degradation of plasminogen by several MMPs
such as MMP-2, MMP-7, MMP-9 and MMP-12.
Angiostatin has been shown to have multiple anti-
angiogenic activities in vivo and i n  v i t r o .
Angiostatin causes regression of tumors, makes
endothelial cells resistant to angiogenic stimuli,
and induces dormancy of metastasis defined by a
balance of proliferating and apoptotic tumor cells
(O'Reilly et al., 1996; O'Reilly et al., 1994,
reviewed in O'Reilly, 2002). Additionally,
angiostatin induces apoptosis of endothelial cells
(Claesson-Welsh et al., 1998). Angiostatin has
been shown to bind ATP synthase, angiomotin
and annexin II on endothelial cells (reviewed in
Kerbel and Folkman, 2002).
Two angiogenesis inhibitors derive from
precursors of collagen molecules. Endostatin is a
20 kDa proteolytic fragment of carboxy-terminal
collagen XVIII and tumstatin is a fragment of type
IV collagen. Endostatin is an endogenous and
specific inhibitor of endothelial cell proliferation,
migration, invasion, capillary tube formation and
angiogenesis (O'Reilly et al., 1997). Several
proteases have been described to cleave collagen
XVIII producing endostatin, cathepsin L being the
most potent one. Other proteases include
cathepsin B, elastase and several MMPs (Felbor et
al. , 2000; Ferreras et al., 2000). The first
identified mechanisms for endostatin effects on
endothelial survival were inhibition of the two
anti-apoptotic proteins Bcl-2 and Bcl-XL
(Dhanabal et al., 1999). Inhibitory action by
endostatin has been proposed to involve binding
to α5β1 integrin leading to the inhibition of focal
adhesion kinase/c-Raf/MEK1/2/p38/ERK1
mitogen-activated protein kinase pathway
(Sudhakar et al., 2003). More recently, endostatin
was shown to downregulate many signaling
pathways associated with pro-angiogenic activity
on microvascular endothelial cell, and upregulate
many anti-angiogenic genes. For instance,
signaling pathways associated with TSP-1
regulation have been shown to be tied to
endostatin. Endostatin upregulates TSP-1 while
suppressing Id—1, a downregulator of TSP-1
(Abdollahi et al., 2004).
Tumstatin, a 28 kDa fragment of type IV collagen
binds to αvβ3 integrin, inhibits the proliferation of
endothelial cells in vitro and angiogenesis and
tumor growth in vivo selectively stimulating
apoptosis of endothelial cells (Maeshima et al.,
2000a; Maeshima et al., 2000b). Tumstatin has
been shown to function as an endothelial cell
specific inhibitor of cap-dependent protein
synthesis. Through interaction with αvβ3 integrin,
tumstatin inhibits the activation of focal adhesion
kinase, PI3K, protein kinase B and mTOR, the
mammalian target of rapamycin, and prevents the
dissociation of eIF4E, eukaryotic initiation factor
4E protein from 4E-binding protein 1 (Maeshima
et al., 2002).
Thrombospondin is an ECM molecule and it is
also an inhibitor of endothelial cell adhesion,
motility, proliferation and angiogenesis in vivo
(Good et al., 1990). It is a protein consisting of
three identical disulfide-linked 180kDa chains and
exists in two isoforms: TSP-1 and TSP-2. CD36 is
the cellular receptor for TSP-1 on microvascular
endothelial cells and it is necessary for the anti-
angiogenic activity of TSP-1. A histidine-rich
glycoprotein that is present in high concentration
in the plasma binds to TSP-1 interfering with the
interaction of TSP-1 with CD36 thus opposing the
anti-angiogenic effect of TSP-1 (Dawson et al.,
1997). TSP-2 is highly expressed in developing
vessels. Disruption of the thrombospondin 2 gene
(Thbs2) in mice results in a complex phenotype
characterized mainly by abnormalities in
fibroblasts, connective tissues, and blood vessels.
Disruption of Thbs2 is characterized by increased
angiogenesis during foreign body reaction
(Kyriakides et al., 1999). TSP-2 has been shown
to exert a strong anti-angiogenic effect on
squamous cell carcinomas in mice by significantly
reducing the density and size of intratumoral
vessels. Combined expression of TSP-1 and TSP-
2 completely suppress squamous cell carcinoma
development, suggesting that a combination of
these angiogenesis inhibitors may provide better
therapeutic efficiency than TSP-1 or TSP-2 alone
(Streit et al., 1999). TSP-1 has been demonstrated
to be one of the key regulators of the angiogenic
switch in a genetically defined tumor model. In
this model, cooperative activity of the oncogenes,
ras and myc, Ras inducing the sequential
activation of PI3K, Rho, and ROCK, leading to
activation of Myc, leads directly to angiogenesis
and tumor formation by repressing TSP-1
expression (Watnick et al., 2003).
Vasostatin is a molecule composed of 180 amino
acid from the N-terminal domain of the human
calreticulin. It is a potent and selective inhibitor of
endothelial cell proliferation, and it has anti-
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angiogenic activity in vivo (Pike et al., 1998).
Vasostatin was shown to selectively affect tumor
angiogenesis, but not physiological angiogenesis
during wound healing (Lange-Asschenfeldt et al.,
2001).
Some chemokines have anti-angiogenic activity.
CXCL4 and CXCL10 inhibit angiogenesis by
interfering with the binding of bFGF or VEGF165
to their receptors or by several receptor-dependent
mechanisms (reviewed in Romagnani et al., 2004)
Pigment-epithelium-derived factor (PEDF) that is
expressed in the retina, is a potent inhibitor of
angiogenesis and is one of the key regulators in
maintaining vitreous and cornea of the eye
avascular. PEDF was shown to inhibit
neovascularization of the cornea in a rat model in
vivo, as well as endothelial cell proliferation and
migration in vitro (Dawson et al., 1999). Unlike
other angiogenesis inhibitors, PEDF is directly
regulated by hypoxia at the translational or post-
translational level, hypoxia decreasing PEDF
levels and hyperoxia increasing them (Dawson et
al., 1999). The anti-angiogenic activity of PEDF
is not limited to the retinal microenvironment.
Overexpression of PEDF in melanoma cells was
demonstrated to inhibit tumor growth by two
different mechanisms; by inhibition of tumor
angiogenesis and by induction of Fas ligand-
dependent apoptosis in tumor cells (Abe et al.,
2004).
Interferon (IFN)-α  and IFN-β  are indirect
endogenous inhibitors of angiogenesis (Kerbel
and Folkman, 2002). IFN-α  and IFN-β
downregulates the tumor cell expression of bFGF
by a mechanism independent of their
antiproliferative effects (Singh et al., 1995), thus
leading to diminished angiogenic signals for
endothelial cells.
3.5. Role of proteases and peptidases in
blood vessel formation
Degradation of ECM proteins is essential for
blood vessel formation and remodeling during
development, growth, and tissue repair. On the
other hand, excessive degradation of the ECM has
an important role in many pathological conditions
including rheumatoid arthritis and cancer
(reviewed in Egeblad and Werb, 2002, and
Murphy et al., 2002). Proteolytic enzymes are
classif ied as ei ther  exopeptidases or
endopeptidases based on whether they cleave
terminal or internal peptide bonds, respectively.
3.5.1. Matrix metalloproteinases
MMPs are a large family of metallo-
endopeptidases that degrade the protein
components of the ECM and basement membrane.
MMPs play important roles in wound healing,
angiogenesis, embryogenesis and in pathological
processes such as tumor invasion and metastasis,
basically in every process involving tissue
remodeling. Historically MMPs have been divided
into four groups; collagenases, gelatinases,
stromeolysins and matrilysins, based on their
ECM substrate specificity. Nowadays they are
divided into different structural groups from
which five are secreted and three membrane-type
MMPs (MT-MMPs). MT-MMPs are covalently
linked to the cell membrane, but even the secreted
MMPs can be associated with the cell membrane
by binding to cell surface molecules such as
integrins, CD44 or cell surface-associated heparan
sulphate proteoglycans, collagen type IV and
EMMPRIN co-localizing their proteolytic activity
to site of cell-ECM contact (reviewed in Egeblad
and Werb, 2002, and Stamenkovic, 2003).
MMP activity is controlled by the activation of
their transcription, proteolytic activation of the
zymogen form (all MMPs are produced as
zymogens; they contain a pro-peptide whose
cleavage is required for MMP activation) and by
the inhibitory activity of a variety of endogenous
MMP inhibitors (reviewed in Egeblad and Werb,
2002, and Stamenkovic, 2003). Most MMPs can
be activated by the proteolytic activity of other
MMPs and a variety of serine proteases. α2-
macroglobulin is the major MMP inhibitor in
tissue fluids leading to the clearance of MMP-α2-
macroglobulin complex by scavenger receptors
(Sottrup-Jensen and Birkedal-Hansen, 1989).
Other MMP-inhibitors include TIMPs which bind
reversibly to MMPs blocking enzyme activity
(Gomez et al., 1997). TSP-1 binds to proMMP-2
and -9 blocking their activation while TSP-2
mediates MMP-2 clearance by scavenger receptor
(Bein and Simons, 2000; Rodriguez-Manzaneque
et al., 2001). The only cell surface MMP inhibitor
known is RECK, which has been shown to inhibit
MMP-2, MMP-9 and MT1-MMP (Oh et al.,
2001).
Degradation of ECM substrates does more than
create space for growing and migrating cells.
Since cells have receptors, like integrins, for
structural ECM components, degradation of ECM
components affects cell signaling trough these
receptors. Cleavage of laminin-5 and type IV
collagen results in exposure of pro-migratory
cryptic sites. Cleavage of insulin-like growth
factor-binding protein and perlecan releases
insulin-like growth factor. MMP-2 and MMP-9,
when localized on the cell membrane, can cleave
the latent form of TGF-β leading to its activation
(Yu and Stamenkovic, 2000). Another example is
the cleavage of SPARC, a matricellular protein of
the ECM, by MMP-3. Produced peptides can
regulate endothelial cell proliferation and/or
migration and angiogenesis (Sage et al., 2003). In
addition to the proteolytic degradation of ECM
molecules, recent data has extended the substrate
specificity of MMPs to include enzyme inhibitors,
cell-bound precursors of cytokines and active
cytokines, cell adhesion molecules and growth
factor receptors. MMPs participate in releasing
cell-bound growth factor receptor precursor
forms, including TGF-α . Some growth factor
receptors are also substrates for MMPs. Different
MMPs cleave FGFR-1, ERBB2, ERBB4 and
hepatocyte growth factor receptor c-MET
resulting in formation of soluble decoy-receptors.
Cleavage of cell adhesion molecules E-cadherin,
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CD44 and the αv-integrin enhances tumor cell
invasion and migration (reviewed in Egeblad and
Werb, 2002, and Stamenkovic, 2003).
MMPs are upregulated in majority of human
cancers, and their expression is often associated
with poor survival. In addition to the role MMPs
play in the formation of the tumor vasculature,
they can promote cancer progression by
increasing the growth rate, invasion, migration
and metastasis potential of tumor cells (reviewed
in Egeblad and Werb, 2002).
3.5.2. Aminopeptidases
Aminopeptidases are a large group of enzymes
widely encountered in nature. They are involved
in a number of biological processes such as
maturation, regulation and degradation of proteins
and polypeptides. The expression and enzymatic
activity of some of the aminopeptidases have been
shown to play a role in the angiogenesis and
tumor growth. These aminopeptidases include
methionine aminopeptidase-2 (MetAP-2),
aminopeptidase N (APN) and aminopeptidase A
(APA).
Methionine aminopeptidases (MetAP-1 and
M e t A P - 2 )  a r e  m o n o m e r i c  c o b a l t
metallopeptidases that remove the initial N-
terminal methionine residues from polypeptides.
MetAP-2 is a ubiquitous cytosolic housekeeping
enzyme. It was found to be a target of a potent
angiogenesis inhibitor fumagillin analogue TNP-
470, which binds covalently to MetAP-2
inhibiting its enzymatic activity (Ingber et al.,
1990; Sin et al., 1997). Since the inhibition of the
MetAP-2 inhibits the proliferation of endothelial
cells in vitro and in vivo mediating the anti-
angiogenic effect of TNP-470, there has to be a
level of targeting the effect of the drug to the
proliferating endothelial cells. This level of
targeting comes most likely from the specific
MetAP-2 substrates that do exist in the
proliferating endothelial cells. MetAP-2 is
responsible for removing the methionine from
specific proteins in endothelial cells and inhibition
of this process affects a wide range of post-
translational modifications controlling protein
activation, translocation and turnover (reviewed in
Bradshaw and Yi, 2002).
Cloning of CD13 revealed that this protein is
identical to APN (Look et al., 1989). CD13/APN
(E.C. 3.4.11.2) is a highly conserved 150 kDa
transmembrane glycoprotein, which is
incorporated into the cell membrane through its
N-terminal hydrophobic segment (Look et al.,
1989; Xu et al., 1997). The large, extracellular
carboxy- terminal domain contains a pentapeptide
(HEXXH-motif, HELAH in CD13/APN)
characteristic of many zinc-dependent
metalloproteases (Look et al., 1989). APN has
zinc metallopeptidase activity hydrolyzing
unsubstituted, N-terminal amino acids with
neutral side chains (Ala>Phe>Leu>Gly) from
oligopeptide substrates (Lalu et al., 1986; Roques
et al., 1993).
CD13/APN was originally thought to be a marker
restricted to subsets of normal and malignant
myeloid lineage cells (Drexler, 1987; Favaloro et
al., 1988; Amoscato et al., 1989; Ashmun and
Look, 1990; Makrynikola et al., 1995). It is now
known to be expressed in many different cell
types (Look et al., 1989), including vascular
endothelium, smooth muscle cells (Palmieri et al.,
1985) and pericytes (Kunz et al., 1994; Alliot et
al., 1999), antigen presenting cells (mainly B
cells, macrophages, dendritic cells, and veiled
cells; (Hansen et al., 1993) and keratinocytes
(Gabrilovac et al., 2004), as well as in established
tumor cell lines (Amoscato et al., 1990) and in
many tumor tissues, including pancreatic
carcinoma (Ikeda et al., 2003), prostate cancer
(Ishii et al., 2001), mesenchymal tumors
(Mechtersheimer and Moller, 1990), melanomas
(Menrad et al., 1993) and clear cell renal
carcinomas (Nanus et al., 1998). The CD13/APN
gene has two different promoters. The proximal
promoter directs CD13/APN transcriptional
regulation in kidney, intestine, and liver epithelial
cells, whereas the distal promoter controls
CD13/APN  expression in myeloid cells and
fibroblasts. The transcripts from both promoters
encode the same CD13/APN protein as they differ
only in their 5’ untranslated regions (Shapiro et
al., 1991).
Many natural substrates have been discovered for
APN; vasoactive peptides lysyl-bradykinin and
angiotensin III (AngIII), neuropeptide hormones
leu/met-enkephalin, neurokinin A, and
somatostatin, and some cytokines and
immunomodulatory peptides, like tuftsin and IL-8
(reviewed in Riemann et al., 1999). In synaptic
membranes CD13/APN metabolizes enkephalins
and endorphins (Matsas et al., 1984; Konkoy et
al., 1996) and in the intestinal brush border, it
degrades regulatory peptides and scavenges amino
acids (Turner et al., 1987; Rawlings and Barrett,
1993); in lymphocytes, its activity is associated
with mitotic activation, antigen processing
(Mouritsen et al., 1992; Falk et al., 1994), cell
adhesion, and migration (Koch et al., 1991;
Menrad et al., 1993; Saiki et al., 1993).
CD13/APN has also been implicated in tumor
invasion (Saiki et al., 1993; Fujii et al., 1995; Ishii
et al., 2001), signal transduction in myeloid cells
(Lohn et al., 1997; Santos et al., 2000), cell cycle
control and differentiation (Riemann et al., 1997;
Lohn et al., 2002). CD13/APN has also been
suggested to have a role as a scavenger of short,
nonspecific peptides in the circulation (Janas et
al. , 2002). Lymphocytic expression of CD13
represents a potentially increased cellular ability
to inactivate inflammatory mediators.
Furthermore, CD13/APN could be involved in
adhesion, in lymphocytic migration, or in the
antigen processing of peptides bound in the
groove of MHC class II molecules (Makrynikola
et al., 1995; Riemann et al., 1997), and as a
receptor for corona viruses (Delmas et al., 1992;
Yeager et al., 1992). Several factors have been
shown to induce the expression of CD13/APN. A
direct cell-cell contact of lymphocytes with
CD13/APN expressing adherent cells, such as
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fibroblast-like synoviocytes, human umbilical
vein endothelial cells (HUVECs), epithelial cells
and macrophages, induces CD13/APN expression
on lymphocytes (Riemann et al., 1997). IL-4
stimulation increases CD13/APN activity in
human monocytes, macrophages, and endothelial
cells (van Hal et al., 1994) as do some other T-cell
derived cytokines, such as interferon-γ and IL-13
(Riemann et al., 1995). Studies using monoclonal
antibodies indicate that CD13/APN undergoes
regulatory intramolecular alterations that result in
exposure of cryptic sites and regulation of enzyme
activity (Xu et al., 1997). The presence of certain
epitopes has also been related to prognosis of
acute myeloid leukemia (Favaloro et al., 1988;
Makrynikola et al., 1995; Xu et al., 1997).
Cell-surface CD13/APN enzymatic activity can be
blocked by bestatin and o-phenatroline (Rawlings
and Barrett, 1993; Saiki et al., 1993; Taylor,
1993). Studies involving these inhibitors have
contributed to our understanding of the enzyme
function. For example, bestatin has been shown to
possess immunomodulatory effects (Bruley-
Rosset et al., 1979; van Hal et al., 1994). It has
also been reported that administration of high
doses of bestatin suppresses experimental or
spontaneous metastasis and inhibits tumor cell
invasion, apparently by inhibiting the degradation
of the ECM, particularly collage type IV (Yoneda
et al., 1992; Saiki et al., 1993; Fujii et al., 1995).
However, specific targets for CD13/APN in the
context of tumor progression remain unknown.
APA (glutamyl-aminopeptidase, EC 3.4.11.7) is a
homodimeric type II membrane-spanning cell
surface protein consisting of a short N-terminal
cytoplasmic domain, a single transmembrane
domain and a large extracellular domain
containing the active site (including the HEXXH-
motif, HELVH in APA; Wang et al., 1996) with
zinc metallopeptidase activity that hydrolyzes N-
terminal glutamyl or aspartyl residues from
oligopeptide substrates (Danielsen et al., 1980;
Lalu et al., 1986; Yamada et al., 1988). APA
shares significant sequence homology with
CD13/APN (Malfroy et al., 1989; Wu et al., 1990;
Nanus et al., 1993).
The murine BP-1 antigen/APA was originally
identified as a cell surface glycoprotein expressed
by pre-B and immature B cells (Cooper et al.,
1986), and it was shown to be identical to 6C3
antigen on leukemic pre-B cells (Wu et al., 1989).
Human APA was first cloned be a human kidney
differentiation antigen gp160 (Nanus et al., 1993)
or 140-160 kDa type II membrane bound
metallopeptidase identical to the mouse B cell
differentiation antigen (Li et al., 1993a). The
restricted expression of APA during B cell
differentiation (Cooper et al., 1986), and its
elevated expression in response to IL-7 (Wang et
al . , 1996) suggest a role for APA in the
developing immune system, but studies with APA
deficient mice suggests, that besides mice
developing normally, they also exhibit normal B
and T cell development (Lin et al., 1998). APA
has also been suggested to have a role in the
central nervous system in degrading
cholecystokinin-8 peptide (Migaud et al., 1996).
The only well understood role for APA is the
conversion of AngII to AngIII in the renin-
angiotensin system (Jackson, 2001). AngII, a key
element in the renin-angiotensin system regulating
blood pressure is in addition to cholecystokinin-8
(Migaud et al., 1996) the only natural substrate
characterized for APA to date (Nagatsu et al.,
1970). APA as an enzyme responsible for the
formation of AngIII represents a potential
therapeutic target for antihypertensive agents,
since AngIII is the major effector peptide of the
renin angiotensin system at least in the brain,
exerting tonic stimulatory control over blood
pressure (Reaux et al., 1999). These findings were
supported by studies in APA deficient mice that
were found to have elevated baseline blood
pressure. Furthermore, exogenous AngII lead to
an enhanced hypertensive response in these mice
indicating a physiological role for APA in
lowering blood pressure (Mitsui et al., 2003).
APA is expressed in placental trophoblasts and it
appears to have an important role in the
maintenance of homeostasis during pregnancy by
regulating trophoblast function via degradation of
AngII (Hariyama et al., 2000; Mizutani et al.,
1981) acting as a barrier to AngII between mother
and the fetus.
APA has been shown to have a widespread tissue
distribution including the small intestine intestinal
brush border, bile canaliculi in liver, proximal
renal tubules and renal glomeruli, pulmonary
alveolar walls and blood vessels of many organs
in murine tissues using both enzyme
histochemistry (Lojda and Gossrau, 1980) and
immunohistochemistry (Li et al., 1993b). The
blood vessel staining has been interpreted as
endothelial cell reactivity, but at least in rat and
mouse brain blood vessels, the APA expression
has been demonstrated to be solely on pericytes
(Healy and Wilk, 1993; Alliot et al., 1999),
suggesting that pericytes might be the source of
microvascular APA in other organs as well. APA
is also known to be expressed in variety of tumor
cell types including neoplastic cervical epithelial
cells (Fujimura et al., 2000), neoplastic
trophoblasts in choriocarcinomas (Ino et al., 2000)
and clear cell renal carcinomas (Nanus et al.,
1998).
Activated pericytes have been described to show a
marked expression of APA in angiogenic
vasculature. Microvessels of human tumors and
granulation tissue show marked expression of
APA recognized by the monoclonal antibody
RC38 (Oosterwijk et al., 1986), whereas the
expression of APA on blood vessels of normal
organs is weak or absent. APA expression in the
tumor vasculature was shown to be restricted to
the activated pericytes and their processes
(Schlingemann et al., 1996). Interestingly, these
studies were done by using the RC38 antibody,
that recognize a subspecies of APA (most likely
underglycosylated; Oosterwijk et al., 1986)
indicating that different cryptic epitopes of APA
or different forms of the enzyme can be exposed
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in a specific site depending on the tissue
microenvironment (Schlingemann et al., 1996).
4. Blood vessel heterogeneity
The organ-, tissue- and vessel-specific differences
in the vasculature associated with functional
differences in normal blood vessels, and
environmental differences of blood vessels in
diseased tissues contribute to the concept of the
heterogeneity of the vasculature.
Endothelial cells covering the inner surfaces of
blood vessels are heterogeneous both in structure
and at the level of expression patterns of cell
surface molecules. Endothelial cells vary in size
and shape, thickness, in the orientation of the
nucleus, in the presence of microvilli and
plasmalemmal vesicles. Endothelial cells can also
have a variety of different kinds of cell junctions,
contributing to the differential barrier functions at
different sites of endothelium. Heterogeneity of
endothelial cells at the expression patter level is
reflected by the differences in the cell surface
glycoprotein and lectin binding patterns and
mRNA and protein expression (reviewed in Aird,
2003). All these structural and molecular
differences are the primary determinants of the
differences in blood vessel function.
4.1. Heterogeneity of the normal
vasculature
4.1.1 Structural diversity of the normal
vasculature
Electron microscopic studies in the 50s examining
blood vessels in different organs lead to a
structural classification of capillaries into three
general categories; continuous, discontinuous and
fenestrated capillaries (Bennett et al., 1959).
Capillaries in skeletal muscle, heart, lung and
brain have a continuous endothelium while
capillaries in the liver, spleen and bone marrow
have a discontinuous endothelium that allows cell
trafficking between intracellular gaps. Capillaries
in many endocrine and exocrine glands, choroid
plexus, intestinal villi and gall bladder have
endothelial fenestrations covered by diaphragms
while capillaries of renal glomeruli have
endothelial fenestrations without the covering
diaphragm. (Simionescu and Simionescu, 1984).
Blood vessels of the brain and the retina are
examples of extremely specialized continuous
endothelium. Endothelial cells in the brain and the
retina are distinguishable from endothelial cell of
non-central nervous system origin by their
“barrier” status; blood-brain barrier in the brain
and blood-retinal barrier in the retinal vasculature.
In addition to endothelial cells and pericytes,
astrocytes and microglia are important structural
components of the retinal and brain blood vessels
contributing to the perivascular glia limitans
separating the circulation from the central nervous
system parenchyma (reviewed in Provis, 2001).
The mature phenotype of quiescent organ
vasculature in most organs is characterized by an
extensive coverage with pericytes that appear to
play a role in maintaining the quiescent phenotype
of the endothelium (Morikawa et al., 2002).
4.1.2. Molecular diversity of the normal
vasculature
Endothelial cells express receptors on their
surface for a variety of ligands such as proteins,
hormones, metabolites and lipid-transporting
particles. They also express a wide array of cell-
cell junction proteins and adhesion proteins for
cell-cell and cell-ECM interactions. Genetic
predisposition and the influence of the
microenvironment are the main determinants of
the molecular heterogeneity between endothelial
cells. Organ-specific phenotypes are either
predetermined before the endothelial cell
precursors migrate from the mesoderm to a
specific vascular bed or local cues from the
vascular bed microenvironment determine the
phenotype of the endothelial cell.
First isolated differentially expressed molecules
on vascular endothelium were involved in the
homing of leukocytes to particular organs. High
endothelial venules are specialized postcapillary
venules in lymphoid tissues that support high
levels of lymphocyte extravasation from the blood
(Bevilacqua, 1993). High endothelial venules
differ from the vascular postcapillary venules in
their structural and molecular composition, but
they also show tissue specific differences. For
example mucosal addressin cell adhesion
molecule-1 is selectively expressed on
endothelium of high endothelial venules in gut
and gut-associated lymphoid tissue. By interaction
with its integrin ligand, α 4β7, lymphocytes
presumed to be involved in mucosal immunity are
selectively recruited to these intestinal sites
(Briskin et al., 1997).
Tumor cells can also show preferential adhesion
to the endothelium of specific organs paralleling
their metastatic propensities (McCarthy et al.,
1991).
It has been established, that differences between
arteries and veins are in part genetically
determined. Arterial and venous endothelial cells
are molecularly distinct from the earliest steps of
angiogenesis during embryogenesis. Even before
the onset of circulation, endothelial cells destined
to line the arteries express ephrin-B2 and
endothelial cells fated to line the veins express
Eph-B4, a receptor for ephrinB2 (Wang et al.,
1998) thus helping to define the arterial-venous
identity. The normal sprouting and branching of
the developing vasculature involves signaling
preventing the arteries and veins from fusing
together. Notch-Gridlock signaling pathway
induces the expression of arterial genes and
suppression of venous-specific genes controlling
the assembly of first embryonic arteries (Lawson
et al., 2001; Zhong et al., 2001). Also
microvascular and macrovascular endothelial cells
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from the same organ differ in their lymphocyte
adhesion receptor expression patterns, their ability
to synthesize prostaglandins and to form capillary-
like structures (Ades et al., 1992). Ang-1 and Tie1
in combination are critical in establishing vascular
polarity during angiogenesis as a part of a distinct
genetic program for the establishment of the right-
hand side and left-hand side vascular networks
well before the network asymmetry becomes
morphologically apparent (Loughna and Sato,
2001). Also the decision to form a vein or artery is
made early on during embryogenesis, before the
start of the circulation (Wang et al., 1998).
Whereas endothelial linage is genetically
predetermined, expression of a set of vascular bed
specific genes can be regulated at a transcriptional
level after interaction with local signaling
pathways (Aird et al., 1997).
vWF is differentially expressed and regulated in
endothelial cells present in different tissues and
within the same vascular bed. It is expressed
predominantly in the endothelial cells of veins
(Yamamoto et al., 1998). Tissue factor inhibitor
pathway is a marker of microvascular
endothelium (Osterud et al., 1995), while
thrombomodulin is expressed in the vasculature of
all organs except the brain (Ishii et al., 1986).
Section 5.2.1. will review the studies done to map
the molecular diversity of the endothelium using
in vivo phage display technology.
While endothelial cell heterogeneity has been long
recognized, the exact molecular mechanisms
underlining this heterogeneity remain largely
unknown. The molecular diversity of endothelial
cells may arise from factors inherent in the cells
or signals in the cell microenvironment (Stevens
et al., 2001).
Differential glycosylation of endothelial cell
surface proteins and proteoglycans may also
contribute to the molecular heterogeneity of the
vasculature. Immunohistochemical studies of
functionally active glycan-decorated L-selectin
ligands (sialyl Lewis X) or sulfated extended core
1 lactosamine has revealed upregulation of sialyl
Lewis X or sulfo sialyl Lewis X glycans on
endothelial cell surface in inflamed tissues
(ulcerative colitis, psoriasis, thyroiditis,
myocarditis and vasculitis). In contrast, non-
inflamed endothelium does not express sialyl
Lewis X or sulfo sialyl Lewis X epitopes.
Furthermore, the expression pattern of sialyl
Lewis X or sulfo sialyl Lewis X epitopes is
different between all the analyzed organs
suggesting an existence of a glycosylation-based
“zip code” of the vasculature (Renkonen et al.,
2002).
Caveolae has also surfaced as an interesting new
target in the heterogeneity of the vasculature.
Caveolae are specialized distinct plasma
membrane microdomains and the associated
noncoated plasmalemmal vesicles (Palade, 1953)
on several cell types, including the cells of the
continuous microvascular endothelium. Many
proteins have been found enriched in caveolae,
including cell surface receptors such as platelet-
derived growth factor receptors, epithelial growth
factor receptors, basic fibroblast growth factor
receptor and endothelin receptors (reviewed in
Zajchowski and Robbins, 2002). Even though the
molecular differences of caveolae between
endothelial cells derived from different tissues
remain unknown, recent data suggests that
caveolae can contain tissue-specific cell surface
molecules. A lung endothelial cell specific
antibody targeting the caveolae has been
generated using an antibody- and subfractionation
strategy. Upon intravenous administration, this
anti-lung caveolae –antibody localized to the
microvascular endothelium of rat lungs. In
addition, targeting caveolae increased
trasendothelial transport of the anti-caveolae
antibody (McIntosh et al., 2002).
It is becoming evident that endothelial cells in
lymphatic vessels are also heterogeneous, both in
structure and in protein expression patterns.
Endothelial cells of the lymphatic vessels and
blood vessels from the same organ show a distinct
expression of large number of lineage-specific
genes (Hirakawa et al., 2003). Only a small
percentage of the profiled genes show differential
expression between the endothelial cells derived
from blood vessels or lymphatic vessels
corroborating the close relationship of the blood
vascular and lymphatic vascular system
(Hirakawa et al., 2003). Tumor lymphatic vessels
have also been suggested to carry specific markers
that are undetectable in normal lymphatic vessels
(Laakkonen et al., 2002).
4.1.3. Species specific differences
It is possible to use information about protein
expression patterns, peptide ligands and their
receptors on mouse blood vessels for the
development of vascular targeted therapies to treat
human diseases. Extrapolation of the results from
mouse experiments to human biology, however,
requires that the molecules of interest be
expressed and regulated similarly in both species.
It has recently become apparent that data derived
from mouse models are often not easily translated
into clinical applications, and results with some
mouse data derived anti-cancer drugs have been
disappointing (Coussens et al., 2002).
Data from the Human Genome Project indicate
that the higher complexity of the human species
relative to other mammalian species derives from
expression patterns of proteins at different tissue
sites, levels or times rather than from a greater
number of genes (Lander et al., 2001; Venter et
al., 2001). Several examples of cross-species
variation of gene expression patterns within the
vascular network have recently surfaced. For
example, the prostate-specific membrane antigen
(PSMA) shows notably different expression
pattern in human and mice. PSMA in human is
expressed in prostate; in mouse on the other hand,
the expression of PSMA is limited to the brain
and kidney (Bacich et al., 2001). Additionally,
PSMA is an endothelial cell marker of human
tumor blood vessels (Chang et al., 1999), whereas
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mouse tumor blood vessels do not have a
detectable endothelial expression of PSMA
(W.D.W. Heston, personal communication).
Another example of cross-species variation is the
TEM7  gene, which is highly and selectively
expressed in the endothelium of human colorectal
adenomas (St Croix et al., 2000). In Mouse,
mTEM7 is expressed in Purkinje cells of the
cerebellum, while the tumor blood vessels show
no mTEM7 expression (Carson-Walter et al.,
2001). There are also species specific differences
in the induction of protein expression by
cytokines. For example, tumor necrosis factor-α
(TNF-α) and oncostatin M function cooperatively
to induce vascular expression of P- and E-selectin
in mice but diverge significantly in their effects on
expression of P- and E-selectin in humans or
nonhuman primates (Yao et al., 1999). Species-
specific differences in protein expression and
ligand–receptor accessibility should caution us
about translating vascular targeting data obtained
in animal models directly to human studies.
4. 2. Heterogeneity of the angiogenic
vasculature
The rules of the normal blood vessel formation do
not seem to apply to tumor blood vessel
formation. There is a tremendous amount of
functional and structural irregularity and
molecular heterogeneity in tumor/angiogenic
blood vessels when compared to normal/quiescent
blood vessels. The same general ideas that apply
to the heterogeneity of the normal, quiescent,
vasculature, can be applied to angiogenic blood
vessels as well. The angiogenic blood vessels are
heterogeneous, both on a structural and on a
molecular level; certain abnormalities can develop
in some tumor blood vessels and not in others.
4.2.1. Structural diversity of the angiogenic
vasculature
Tumor blood vessels have an abnormal
morphology. They are irregular in diameter and
branching pattern and they do not exhibit the
defined structural features of arterioles, capillaries
or venules (Less et al., 1991; reviewed in
McDonald and Foss, 2000). Tumor blood vessels
are not lined with a normal monolayer of
endothelial cells, instead the vessel lining is
composed of endothelial cells that are
disorganized, loosely and irregularly connected,
branched, overlapping and sprouting. Many tumor
blood vessels also have abluminal endothelial
sprouts that penetrate deep into the perivascular
tumor tissue. Since endothelial cells do not form a
normal monolayer, they do not perform the
normal barrier function of the endothelium
(Hashizume et al., 2000; McDonald and Foss,
2000).
Proliferating cancer cells can also cause structural
changes in tumor blood vessels causing intratumor
blood vessels, especially ones without supportive
stromal structures, to collapse (Padera et al. ,
2004).
Figure 3. Scanning-electron microscopic images of the
luminal surface of blood vessels in normal mouse
mammary gland and in mammary carcinoma. In a normal
mammary-gland venule (upper panel), endothelial cells
form a monolayer on the luminal surface. The cells are
relatively uniform in size and shape, flat and tightly
apposed to one another. In a tumor blood vessel,
endothelial cells on the luminal surface are severely
deformed, separated by wide intercellular spaces,
overlap one another and have cellular projections.
Adapted with permission, from Hashizume et al., 2000.
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Most of the studied tumor blood vessels in
spontaneous and implanted murine tumor models
are covered with pericytes. However, pericytes
surrounding the endothelial cells display severe
morphological abnormalities. These pericytes are
abnormally loosely associated with the endothelial
cells with wide spaces separating the two types of
cells. They extend cytoplasmic extensions deep
into the tumor tissue, unlike in normal blood
vessels. The pericyte sleeves surrounding the
tumor blood vessels are also significantly longer
that the endothelial cell sprouts themselves. The
abnormal interactions of pericytes with
endothelial cells within tumor blood vessels may
alter the influence pericytes have on endothelial
cell morphology and function, and may contribute
to the leakiness of tumor blood vessels (Morikawa
et al., 2002).
Confocal microscopic studies have revealed that
despite the basement membrane covering the
surface of more than 99.9% of the blood vessels in
tumors, it exhibits conspicuous structural
abnormalities including broad extensions away
from the vessel wall and loose associations with
endothelial cells and pericytes (Baluk et al.,
2003).
The influence of tumor microenvironment in
tumor development is increasingly appreciated
(Liotta and Kohn, 2001). Rather than being
renegades, tumor cells recruit vasculature and
stroma through the production and secretion of
growth factors and cytokines (Brown et al., 1999).
The locally activated microenvironment (both
cellular and the extracellular elements) in turn
modifies the proliferative and invasive behavior of
tumor cells (Vaccariello et al., 1999). As
developing neoplasias activate angiogenesis and
recruit neovasculature from the surrounding
microvascular bed, the tissue microenvironment
likely influences the morphology and physiology
of the developing tumor vasculature. Comparing
the permeability of the vessels in transplanted
tumors as a function of tumor type and host tissue
site, organ specific differences in tumor blood
vessels are starting to emerge (Hobbs et al.,
1998). Expression and activity of general
angiogenic factors, such as VEGF and Ang-1
varies in different tissues. Tumors that have
highly permeable blood vessels lack Ang-1, where
as tumors with “tight”, low-permeability blood
vessels overexpress Ang-1 and/or down-regulate
VEGF expression (Jain and Munn, 2000).
By characterizing endothelial cell proliferation in
six different human tumor types, Eberhard and
colleagues (Eberhard et al., 2000) found
angiogenesis to be present in all of the tumors
with a characteristic and significant differences
between the tumor types. Notably, even in the
most angiogenic tumors, angiogenesis was up to
20-fold less intense than in the physiological
angiogenesis (cyclic bovine ovarian corpus
luteum). Also the degree of pericyte recruitment
to neovasculature in different of tumors as well as
within a given tumor type have been shown to
vary significantly probably indicating the
differences in functionality/maturity of the tumor
vascular bed (Eberhard et al., 2000).
4.2.2. Molecular diversity of the angiogenic
vasculature
Angiogenic vasculature expresses markers that are
either expressed at much lower levels or not at all
in non-proliferating endothelial cells (St Croix et
al., 2000, and reviewed in Ruoslahti, 2002 and
Trepel et al., 2002). Markers of angiogenic blood
vessels include receptors for vascular growth
factors, such as specific subtypes of VEGF and
bFGF receptors (Plate et al., 1993; Brekken et al.,
1998; Valtola et al., 1999), αv-integrins (Brooks et
al., 1994a; Brooks et al., 1994b), proteoglycans
(Schrappe et al., 1991; Burg et al., 1999) and
proteinases (Koivunen et al., 1999). Several
ephrin receptors are also overexpressed in tumors
especially during the more invasive stages of
tumor progression (reviewed in Dodelet and
Pasquale, 2000). Ephrin-A1 ligand and its
receptor EphA2 are expressed throughout tumor
vasculature in a mouse model of human breast
carcinoma and human tumor sections and may
play a role in tumor angiogenesis (Ogawa et al.,
2000). Ephrin A1 is also overexpressed in
embryonic vasculature but is absent in mature
quiescent vasculature supporting its role in
neovascularization (McBride and Ruiz, 1998). In
vivo phage display studies have revealed a variety
of stage-specific molecular changes in tumor
vasculature during carcinogenic progression of
squamous cell carcinoma (Hoffman et al., 2003)
and islet cell carcinoma of the pancreas (Joyce et
al., 2003). The nature of the local regulatory
signals are mostly unknown, although the
specialized stroma are thought to be a major
source.
Majority of the described angiogenic factors, like
VEGF and angiopoietins, stimulate growth of
endothelial cells in general, regardless of their
tissue of origin. Endocrine-gland-derived vascular
endothelial growth factor (EG-VEGF; structurally
unrelated to VEGF) was identified as an
endothelial cell mitogen specific for endocrine
gland-derived capillary endothelial cells. It was
also able to induce angiogenesis in vivo in
endocrine tissue (LeCouter et al., 2001). Mouse
EG-VEGF also has a role in the regulation of the
phenotype and growth properties of endothelial
cells in distinct capillary bed; unlike the human
EG-VEGF, mouse EG-VEGF is specific for liver
and kidney-derived endothelial cells (LeCouter et
al., 2003). Two receptors for EG-VEGF have
been characterized in both human and mouse,
their expression patterns are commensurate to the
functional effects of EG-VEGF in both human
and mouse endothelial cells (Lin et al., 2002;
LeCouter et al., 2003). Based on studies with
CXCR4 and CXCL12 (CXCR4 ligand) deficient
mice, this chemokine-chemokine receptor pair has
also been suggested to act as an organ-specific
angiogenesis modulator (reviewed in Romagnani
et al., 2004).
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4.3. Angiomics (functional genomics of
angiogenesis)
As a result of the exploration of gene expression
patterns in cancer, numerous genetic alterations
associated with cancer have been found. All
tumors contain genetic alterations that range from
subtle changes in DNA sequence to visible
cytogenetic changes like chromosome losses and
rearrangements. Moreover, abnormally high
genetic instability can be found in many tumors
(Cahill et al., 1999).
Much less is known about gene expression
patterns in tumor endothelia. A new area of
genomics, angiomics, is now exploring this aspect
of angiogenesis. By using methods like SAGE,
cDNA microarrays and oligonucleotide-based
microchips for analyzing differential gene
expression in angiogenic vessels, angiomics will
give us valuable insights into the gene expression
patterns of proliferating endothelial cells in the
context of the tumor microenvironment. By
studying the gene expression patterns of
endothelial cells derived from normal and
malignant human colorectal tissues, almost 50
differentially expressed gene transcripts were
found. Many of them encode ECM proteins, but
most of them are still unknown. Angiomics
studies have confirmed four basic hypotheses
about angiogenesis. First, normal and tumor
endothelia are highly related and share many
endothelial cell-specific markers. Second, the
endothelium derived from tumors is qualitatively
different from that derived from normal tissues of
the same type and is also different from primary
endothelial cultures. Third, differently expressed
genes are characteristically expressed in tumors
from several different tissue types, demonstrating
that tumor endothelium, in general, is different
from the endothelium in surrounding normal
tissues. Fourth, most of the genes expressed
differentially in tumor endothelium are also
expressed during angiogenesis of corpus luteum
and wound healing. Tumors may recruit
vasculature by means of the same signals
elaborated during other physiological or
pathological processes (St Croix et al., 2000).
5. Phage display technology
Phage display technology allows presentation of
large peptide and protein libraries on the surface
of filamentous phage permitting the selection of
peptides and proteins, including antibodies, with
high affinity and specificity to almost any target.
This technology has had a major influence on the
work and discoveries done in the fields of
immunology, cell biology, drug discovery and
pharmacology. The power of phage display lies in
the ability to propagate selected peptide/protein
ligands through multiple rounds of selection and
the direct link of the phenotype of the
antigen/receptor binding ligand to the genotype of
the phage particle presenting the ligand.
Phage display technology was first introduced by
George Smith as an expression vector, “fusion
phage”, capable of presenting a foreign amino
acid sequence accessible to binding an antibody
(Smith, 1985). Since then, large number of phage
displayed peptide and protein libraries has been
constructed (Bass et al., 1990; McCafferty et al.,
1990; Barbas et al., 1991; Smith, 1991; Smith and
Scott, 1993; reviewed in Hoogenboom, 2002 and
Szardenings, 2003), leading to various techniques
for screening such libraries. Peptide display
technology has since then being applied to a wide
range of protein interaction studies with purified/
recombinant proteins, cells and intact tissues in
situ as well as in vivo. A vast body of work has
been done using phage displayed antibody
libraries for diagnostic and therapeutic
applications. Since our work mainly focuses on
using phage displayed peptide libraries, I will
refer the reader to reviews on phage displayed
antibody libraries (Rader and Barbas, 1997;
Azzazy and Highsmith, 2002; Hoogenboom,
2002).
5.1. Phage display random peptide
libraries
Random peptide libraries consist of large random
collection of peptides, displayed as recombinant
proteins on the surface of a filamentous
bacteriophage. Random peptide libraries usually
contain up to 109 individual phage clones. A
comprehensive review of filamentous phage
biology has been covered by Barbas et al. (Barbas
et al., 2001) and will be described here only
briefly.
Filamentous phage particles, known as Ff, include
strains M13, f1 and ft. Fd phage particles consist
of a long cylindrical protein capsid, 930 nm in
length and 6.5 nm in diameter, enclosing a
circular, single-stranded DNA genome of about
6400 nucleotides, consisting of 11 genes. The
mass of the particle is approximately 16.3 MDa,
of which 87% is contributed by protein. The
length of the cylinder consists of approximately
2700 molecules of the major coat protein pVIII
(encoded by the gene VIII) and the other end of
the filamentous phage particle contains about five
copies of the pIII and pVI proteins (encoded by
gene III and gene VI) accounting for about 10-16
nm of the phage length and the other end contains
about five copies of the pVII and pIX proteins
(encoded by gene VII and gene IX). The pIII
protein appears to have two functional domains:
an exposed N-terminal domain that binds the F
pilus, but is not required for phage particle
assembly, and a C-terminal domain that is buried
in the particle and is an integral part of the capsid
structure. In the phage particle, the C-terminal
portion of pVIII is inside the phage particle, close
to the DNA, while the N-terminal part is exposed
to the surroundings.
Fd particles are able to infect a variety of Gram-
negative bacteria, including E. coli, using pili (F
pilus in E. coli) as receptors. Fd does not produce
a lytic infection in E. coli, instead it induces a
state in which the infected bacteria produce and
secrete phage particles without undergoing a lysis.
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Infection is initiated by the attachment of phage
pIII protein to the f pilus of E. coli. Only the
circular single-stranded DNA enters the bacterium
where it is converted by the host DNA replication
machinery into the double-stranded plasmid-like
replicative form. The replicative form undergoes a
rolling circle replication to make single-stranded
DNA and also serves as a template for the
expression of pIII and pVIII proteins. Phage
progeny are assembled by packaging the single-
stranded DNA genome into protein coats and
extruded through the bacterial membrane to the
medium (Russel, 1991).
Most of the currently used phage display vectors
use the N-terminus of pIII protein or pVIII protein
to display the foreign peptide or protein (Smith
and Scott, 1993). The pIII libraries display 3-5
copies of each individual peptide (Scott and
Smith, 1990), whereas pVIII libraries can display
up to 2700 copies of small (up to six amino acids)
peptides (Greenwood et al., 1991). The pIII and
pVIII proteins can display peptides of various
length and cysteine residues can be introduced to
the fusion peptide to create conformational
constraints by the formation of “loops” between
disulfide bridged cysteine residues. Furthermore,
the exogenous peptides are well exposed,
facilitating the insert-target interactions. Fairly
large peptide inserts (up to 38 amino acids; Kay et
al ., 1993) can be introduced into the amino
terminus of pIII protein without the loss of phage
infectivity or particle assembly. Random peptides
are encoded by synthetic oligonucleotides with
each amino acid being encoded by the degenarate
codon NNK (N= A, C, G or T; K= G or T). In our
laboratory, we use peptide libraries where the
random peptides are recombined to the amino
terminus of the pIII protein using and fd-based
vector, fUSE5 (Scott and Smith, 1990). These
random peptide libraries are likely to yield higher
affinity binding peptides, since only 3-5 copies of
the fusion peptide are displayed on a given phage
particle and the multivalency of the peptide is not
as likely to influence the binding of the peptide to
its target.
5.2. Screening phage display libraries
Phage display of random peptide libraries is a
powerful method for obtaining small peptide
ligands for virtually any protein of interest. A high
proportion of isolated peptide ligands interact with
the natural binding site of the target protein acting
as antagonists or agonists of the natural protein
functions (Hyde-DeRuyscher et al., 2000,
reviewed in Kay and Hamilton, 2001). This might
be because of the hydrophilic nature of the surface
of the proteins, which has a role in preventing
non-functional interactions with other molecules.
However, the binding sites of molecules will
generally allow water molecules to be displaced
by the binding of specific ligands (Ringe and
Mattos, 1999). Peptide ligands isolated from
phage display libraries tend to react with the
protein binding sites only because they are small,
and will not have sufficient binding energy to
displace water from the non-binding surfaces of
the target protein. Besides proteins, peptides
affecting biologically significant protein-DNA
interactions (Cheng et al., 1996), peptides binding
to carbohydrates (Peletskaya et al., 1996;
Matsubara et al., 1999; Noda et al., 2001), carbon
nanotubes (Wang et al., 2003) and small chemical
compounds like taxol (Rodi et al., 1999) have
been isolated from phage display random peptide
libraries. Recently, Cardó-Vila et al. introduced
an approach based on phage display technology to
identify molecules that specifically interact with
the cytoplasmic domain of the β5 integrin and
revealed a functional link between the α vβ5
integrin, annexin V, and programmed cell death
(Cardo-Vila et al., 2003).
In general, the affinity selection of ligands from a
phage display random peptide libraries involves 7
fundamental steps: i) preparation of a primary
library or amplification of an existing library, ii)
exposure of the phage particles to a target
(immobilized protein/cell surface protein/vascular
endothelium) for which specific ligands are
planned to be identified, iii) removal of non-
specific binders (washing/perfusion), iv) recovery
of the target bound phage by elution or direct
bacterial infection and amplification of the
recovered phage, v) repetition of the steps i-iv,
usually three to six rounds, until an enriched
population of binders are obtained, and finally, vi)
sequencing the peptide inserts of the enriched
phage clones (Figure 4; see section 5.2.1. for a
more detailed description of screening phage
libraries in vivo). Enriched peptide inserts are then
analyzed, and desired peptides can then be
synthesized as recombinant or synthetic peptides
for further analysis of the ligand-target
interaction.
It is a common observation that the binding motif
of a targeting peptide is a tripeptide motif
appearing several times in different sequence
contexts. Three amino acid residues seem to
provide the minimal framework for structural
formation and protein–protein interaction
(Vendruscolo et al., 2001). Examples of such
biochemical recognition units and binding of
ligand motifs to their receptors include RGD,
LDV and LLG to integrins (Koivunen et al., 2001;
Ruoslahti, 1996), and GFE to membrane
dipeptidase (Rajotte et al., 1998; Rajotte and
Ruoslahti, 1999).
5.2.1. In vivo selection of phage display
libraries
In vivo selection of phage display random peptide
libraries allows for the selection of specific
peptide ligands that bind to different vascular
beds. Vascular targeting exploits molecular
differences that exists in blood vessels of different
organs and tissues, as well as differences between
normal blood vessels and angiogenic blood
vessels, for example in tumors (Pasqualini and
Ruoslahti, 1996; Pasqualini et al., 1997; Arap et
al., 1998; Rajotte et al., 1998). In the in vivo
procedure, phage capable of homing to certain
organs or tumors following an intravenous
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injection are selected from the libraries; the ability
of individual peptides to target a tissue can also be
analyzed by this method (Pasqualini and
Ruoslahti, 1996; Arap et al., 1998; Rajotte et al.,
1998).
Figure 4. Schematic illustration of the selection of the phage displayed random peptide libraries for the identification of
specifically binding pepdies to known and unknown targets. In vitro selection of peptides binding to purified receptors and
cells as well as in vivo selection of peptides binding to specific vascular beds are illustrated.
In general, 109 to 1010 transforming units of phage
displayed random peptide library are injected
intravenously into a deeply anesthetized mouse
via the tail vein, and phage are allowed to
circulate within the mouse. Depending on the time
the phage library is allowed to circulate, the
selection of the peptides can be biased towards a
recovery of peptides that either bind to the blood
vessels (short circulation time, 5-10 minutes,
before phage recovery), or peptides that will get
internalized by endothelial cells of the normal
blood vessels or endothelial, periendothelial or
tumor cells in the tumor vasculature (circulation
time 24 hours or longer). Mouse is then perfused
through a catheter inserted in the left ventricle and
bled through a small incision in the right atrial
chamber or ascending vena cava. After perfusion,
the desired organs are isolated, and phage are
recovered from the tissue by infecting E. coli
bacteria with the tissue homogenate, and phage
are amplified. Selective binding of the phage pool
is quantified by calculating the number of
recovered phage titers from the organs of interest.
The amplified phage is purified and used for
subsequent rounds of panning; repeated injection
of phage, vascular perfusion, tissue removal and
isolation and amplification of phage, until a
population of phage that bind selectively to the
vasculature of the target organ is obtained.
Generally, three rounds of in vivo selection are
sufficient to select for specific organ- and tumor-
homing phage, but additional rounds can be done.
After the desired enrichment of the phage pool to
a certain organ has been obtained, 50-100 phage
clones from the last two rounds of selection are
sequenced. Peptide sequences are compared with
each other to identify enriched peptides or peptide
motifs. The selectivity of identified candidate
clones is then validated by individually comparing
their homing to other organs and also to the
homing of an insertless phage clone (Pasqualini
and Ruoslahti, 1996; Pasqualini et al., 2001).
Since 1996 when Pasqualini and Ruoslahti
described the methodology for selecting phage
capable of homing to different vascular beds by
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screening of phage display random peptide
libraries in vivo (Pasqualini and Ruoslahti, 1996),
numerous murine tissue-specific endothelial cell
markers have been identified this way by our
laboratory and others (reviewed in Trepel et al.,
2002; George et al., 2003). These include peptide
ligands targeting brain and kidney (Pasqualini and
Ruoslahti, 1996), lung, skin, pancreas, intestine,
uterus, adrenal gland and retina (Rajotte et al.,
1998), muscle (Samoylova and Smith, 1999),
prostate (Arap et al., 2002), normal and malignant
breast tissue (Essler and Ruoslahti, 2002), lymph
nodes (Trepel et al., 2001), placenta (Kolonin et
al., 2002) and white adipose tissue (Kolonin et al.
2004). In vivo phage display approach has also
revealed a vascular address system that allows
tissue-specific targeting of angiogenesis-related
molecules in tumor blood vessels (Pasqualini et
al., 1997; Arap et al., 1998; Burg et al., 1999;
Koivunen et al., 1999; Hoffman et al., 2003;
Joyce et al., 2003) as well as in tumor lymphatic
vessels (Laakkonen et al., 2002). In addition, it
has been possible to identify unique molecular
signatures by in vivo phage display that are
specifically expressed at different stages of tumor
progression from a highly proliferative and
angiogenic dysplastic lesion to invasive phase in
transgenic mouse models (Hoffman et al., 2003;
Joyce et al., 2003). By using transgenic mouse
models for multistage tumorigenesis involving the
pancreatic islets of Langerhans, Joyce et al.
identified peptides that discriminate between the
vasculature of the premalignant angiogenic islets
and fully developed tumors (Joyce et al., 2003).
Similar study has also been done with transgenic
model of squamous cell carcinoma further
confirming the findings of a tumor stage-specific
vascular signature (Hoffman et al., 2003). Peptide
ligands homing to atherosclerotic regions of blood
vessel walls have been identified by using in vivo
phage display in mice deficient in low-density
lipoprotein (Houston et al., 2001). As a strategy to
isolate peptide ligands to receptors in human
synovium vasculature, Lee et al. have used in vivo
phage display in conjunction with mice
transplanted with human synovium tissue (Lee et
al., 2002). Since the blood vessels from human
synovium grafts have been shown to form
functional anastomosis with murine subdermal
vessels and supporting the adhesion and
extravasation of human leukocytes into the grafts
(Wahid et al., 2000), they were able to isolate
peptide ligands targeting human vasculature
supporting human tissue without actually using
human patients (Lee et al., 2002).
Integration of the isolation of ligands from the in
vivo screenings to proteomic strategies to identify
the receptors for these ligands has produced an
array of tissue specific vascular receptors.
Complementary approaches have been used to
identify receptors for tissue homing peptides.
Membrane dipeptidase on lung endothelium was
identified as the receptor for GFE-peptide (Rajotte
and Ruoslahti, 1999), aminopeptidase P on both
normal and malignant breast tissue as the receptor
for CPGPEGAGC-peptide (Essler and Ruoslahti,
2002), FcRn/β2-microglobulin as a target for the
TPKTSVT-peptide in placenta (Kolonin et al.,
2002) and prohibitin as the receptor for
CKGGRAKDC-peptide in the white adipose
tissue (Kolonin et al., 2004).
Besides offering a way of identifying endothelial
cell surface markers accessible to the circulation
and providing novel tools for selective vascular
targeting, in vivo phage display studies further our
understanding of organ and tumor endothelium
specificity and define the role that endothelial cell
markers play in angiogenesis. Some of these
vascular markers are vascular proteases that not
only serve as receptors for circulating ligands but
also modulate angiogenesis (Koivunen et al.,
1999).
Tumor targeting peptide ligands have also been
used for delivery of cytotoxic chemotherapy
(Arap et al., 1998), proapoptotic peptides (Arap et
al., 2002, Ellerby et al. 1999), cytokines (Curnis
et al., 2000) and liposomes (Pastorino et al., 2003)
to receptors in the angiogenic vasculature showing
marked therapeutic efficacy in tumor-bearing
mouse models. Tumor targeting peptide ligands
can also deliver imaging agents to tumor
vasculature (Hong and Clayman, 2000). There are
many problems with potential therapy
applications associated with the use of small
peptides, including the delivery, stability and
large-scale synthesis (Latham, 1999); however,
they can be an excellent starting point for rational
design of drug candidates. Peptidomimetics can
be designed maintaining the overall structure and
biological properties of the peptide, while
increasing the stability of the peptidomimetic
compounds (Kieber-Emmons et al., 1997; Ripka
and Rich, 1998).
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Aims of the study
The specific aims of this study were
1) To identify the receptor for the tumor homing NGR-peptide (Arap et al., 1998) and to study
the functional role of this receptor (CD13/ aminopeptidase N) in angiogenesis.
2) To study the role of aminopeptidase A (APA) in angiogenesis and identify APA ligands
that can be used for targeted therapy.
3) To examine whether reducing the metabolic rate of the retina by abrogating photoreceptor
cells will functionally affect angiogenesis in the retina.
4) To develop new methodology for the identification of functional molecular targets on blood
vessels.
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Materials and methods
Detailed descriptions of the materials and methods are found in the original publications.
Materials Original publication
Animals I, II, III, IV
Antibodies I, II, III, V, VI
Cell lines I, II, III, V
cDNA probes III, IV
Chemical enzyme inhibitors II, III
Patients IV, VI
Phage libraries I, V, VI
Plasmids I, II, III
Purified proteins, growth factors and receptors I, II, III, V, VI
Synthetic peptides I, II, V, VI
Methods Original publication
BRASIL optimization V
CAM assay I, II
Chemotaxic assay I
Chloramphenicol acetyl transferase assay III
Cell proliferation assay I, III
Cytotoxicity assay in vitro II
CoCl2 (hypoxia) treatment of cells III
Enzyme activity assay for APA I
Enzyme activity assay for CD13/APN II
Gelfoam in vivo assay of angiogenesis I
Immunocapture of proteins I, II
Immuno-electron microscopy I
Immunofluorescence staining of tissues I
Immunohistochemical staining of tissues I, II, IV, VI
In situ enzyme histochemistry I
In situ hybridization IV
Mouse model of retinal neovascularization I, II, III, IV
Northern blot analysis III, IV
Phage binding assay in vitro I, II, V, VI
Phage binding assay on cells, conventional I, II, V
Phage binding assay on cells, BRASIL V
Phage homing assay in vivo I, II
Phage binding assay on tissue section VI
Reverse transcriptase-PCR III
Protein cell surface expression assay III
Screening phage library on cells, conventional I
Screening phage library on cells, BRASIL V
Screening phage library in vivo VI
Secreted alkaline phosphatase activity assay III
Reporter gene assays III
Three-dimensional cell culture I, III
Transfection of cDNA I, II, III
Tumor models in mice I, II, III
Tumor therapy experiments in mice I, II
Statistical analysis I, II, IV, V, VI
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Results
1. CD13/APN and APA as functional
targets in angiogenic blood vessels (I-III)
1.1. CD13/APN and APA expression in
angiogenic vasculature (I, II)
Pasqualini et al. previously identified the RGD-
binding peptide motif, WN/DDGWL (Pasqualini
et al., 1995). This motif resembles a site in certain
integrin ß subunits that participates in binding
RGD-containing integrin ligands. This motif is
also present in the extracellular domain of
CD13/APN and some other aminopeptidases.
Given the similarity of the RGD and NGR motifs,
we hypothesized that the receptor for the NGR
phage in tumor vasculature (Arap et al., 1998)
might be an aminopeptidase.
We studied the expression of CD13/APN in
endothelial cells to determine whether its
expression is consistent with its role as the
homing receptor in tumors for the NGR phage.
Immunohistochemical staining showed strong
mouse CD13/APN expression in the vasculature
of tumors formed by the MDA-MB-435 human
breast carcinoma cells in nude mice (II, Fig. 3A).
An antibody specific for human CD13/APN did
not stain these tumors (II, Fig. 3B), which agrees
with the lack of CD13/APN expression by these
cells in vitro. The blood vessels in all normal
mouse tissues examined were negative for
CD13/APN (II, Fig. 3C and 3D show liver and
spleen, respectively).
APN immunostaining was also found in blood
vessels, including capillaries, of various tumors
from patients. Fig. 4A (II) shows vascular
CD13/APN staining in a human breast carcinoma.
The vasculature in human malignant gliomas and
lymph node metastases from multiple tumor types
was also positive for CD13/APN. In contrast, the
blood vessels in various normal human tissues
were essentially negative for CD13/APN. Faint
staining was sometimes seen in endothelial cells
of arteries but not in capillaries; Fig. 4B (II)
shows such staining for normal breast tissue.
Blood vessels in corpus luteum expressed
CD13/APN (II, Fig. 4C). Consistent with the fact
that blood vessels in this tissue undergo
angiogenesis (Klauber et al., 1997), this finding
suggests that the expression of CD13/APN in
blood vessels is related to angiogenesis.
Confocal immunofluorescence microscopy
showed that endothelial cells and periendothelial
layers of the vessels (presumably pericytes)
expressed CD13/APN in tumors (II, Fig. 4D). The
periendothelial CD13/APN staining co-localized
with staining for APA, a marker of pericytes and
smooth muscle cells (Schlingemann et al., 1996)
in blood vessels. In the described tissue
localization studies, two different antibodies, one
against human CD13/APN (WM15) and the other
against mouse CD13/APN (R3-63), were used.
Both showed similar localization of CD13/APN in
human and mouse tissues.
The extensive proliferation of blood vessels in
malignant gliomas suggests an early role of
angiogenesis in brain tumors (Wesseling et al.,
1995). To investigate the expression of APA in
brain tumor vasculature, we compared the
localizat ion of  APA expression by
immunostaining to the localization of APA
activity by enzyme histochemistry in a panel of
primary and metastatic human brain tumors and in
the incidental normal tissue adjacent to the
tumors. APA enzyme activity in tissue sections
co-localized with APA expression as detected by
an RC38 antibody. The staining pattern was
consistent with APA localization to perivascular
cells in the tumor microvasculature (I, Fig. 5A and
5B, glioblastoma multiforme; 5C and 5D,
squamous cell carcinoma of the lung metastatic to
the brain). Staining and enzymatic activity were
apparent in sites of glomerular vascular
proliferation in malignant gliomas and metastatic
carcinomas. In contrast, APA expression and
activity were barely detectable in capillaries in
normal brain parenchyma. By double-staining
with RC38 and with a PAL-E antibody, a general
endothelial marker (Schlingemann et al., 1985),
APA expression in colon adenocarcinoma
metastatic to the brain appears to be restricted to
perivascular cells (I, Fig. 5E). We also showed by
immunostaining that blood vessels in human non-
malignant granulation tissue express APA (I, Fig.
5F). Finally, we localized APA staining to
perivascular cells by immuno-electron microscopy
(I, Fig. 5G).
These results show that CD13/APN and APA are
present in tumor blood vessels of various tumors
from patients.  Furthermore, APA present in the
blood vessels during the progression of malignant
tumors is enzymatically active and therefore may
contribute to the angiogenic process associated
with human brain tumors.
1.2. CD13/APN and APA binding peptides
derived from phage display random
peptide libraries (I, II)
We tested the binding of NGR phage to
immunocaptured CD13/APN. Two different NGR
phage bound specifically to immunocaptured
CD13/APN, whereas the tumor-homing RGD-4C
phage and another RGD phage showed no binding
(II, Fig. 1A). The specificity of the binding was
further examined by inhibiting the CD13/APN
binding of one of the NGR phage with soluble
peptides. Addition of the soluble, cyclic CNGRC
peptide blocked the binding of NGR phage to
CD13/APN while two other cyclic control
peptides had no effect (II, Fig. 1B).
NGR phage also bound to Molt-4 T-cell leukemia
and MDA-MB-435 breast carcinoma cells
transfected with CD13/APN cDNA (Ashmun and
Look, 1990), but not cells transfected with empty
vector or with CD20 cDNA (II, Fig. 1C). The
binding of NGR phage to the cells was blocked by
the CNGRC peptide in a dose-dependent manner,
but not by a control peptide of a similar general
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structure (CARAC). Furthermore, a conjugate of
the CNGRC peptide and the cytotoxic drug
doxorubicin was selectively toxic to CD13/APN-
expressing cells. When CD13/APN-transfected
and control MDA-MB-435 cells were exposed to
the conjugate for only 20 minutes, a significant
fraction of the CD13/APN-expressing cells were
killed, while CD13/APN-negative cells were
essentially unaffected (II, Fig. 2). Free
doxorubicin and doxorubicin coupled to the
CARAC control peptide showed no significant
toxicity upon incubation of these cells for the
same period of time. The doxorubicin-RGD-4C
conjugate was toxic to cells, regardless of their
CD13/APN expression. This outcome is in
agreement with the expression of the αvß3 integrin
by the MDA-MB-435 cells (Arap et al., 1998).
The selective toxicity of the CNGRC conjugate
was lost when the incubation with the drug was
prolonged; upon prolonged exposure, all
doxorubicin compounds were found to be highly
toxic to both types of cells. These results provide
further evidence for the binding of NGR to
CD13/APN at cell surfaces.
To identify peptides capable of binding to APA,
we screened APA-transfected cells with a phage
display library (Smith and Scott, 1993). We stably
transfected SK-RC-49 renal carcinoma cells with
a vector expressing full-length APA cDNA. We
verified that APA was functional in transfected
cells by an enzyme activity assay specific for
APA. An increase in phage binding to SK-RC-
49/APA cells relative to SK-RC-49 cells was
observed in the third round of selection (I, Fig.
2A). DNA sequencing revealed an enrichment of
the sequence CYNLCIRECESIC-GADGA-
CWTWCADGCSRSC containing tandem repeats
of the general library sequence CX3CX3CX3C on
each side of the pIII peptide linker GADGA
sequence. 50% of randomly selected phage clones
displayed such tandem repeat after the second
round and 100% displayed it after the third round
(I, Table 1).
Phage displaying enriched peptide motifs were
tested individually for APA binding. Phage
displaying the inserts CPKVCPRECESNC,
CYNLCIRECESICGADGACWTWCADGCSRS
C or CLGQCASICVNDC preferentially bound to
SK-RC-49/APA cells relative to SK-RC-49 cells;
insertless control phage (fd-tet) showed no
binding preference (I, Fig. 2B). We synthesized
peptides containing APA-binding motifs
(consensus sequence CPRECESIC; I, Table 1).
Specificity of the binding of phage displaying
C P K V C P R E C E S N C  o r
CYNLCIRECESICGADGACWTWCADGCSRS
C peptides to SK-RC-49/APA cells was
demonstrated by inhibition of phage binding by
the synthetic peptide; several negative control
peptides had no inhibitory effect. Binding of
CLGQCASICVNDC phage to SK-RC-49/APA
cells was not affected by the synthetic peptide
suggesting that the SIC sequence in the consensus
motif is not critical for binding. We also evaluated
whether the selected peptides would bind to the
isolated APA protein. We immunocaptured APA
from SK-RC-49/APA lysate with the RC38
antibody and showed, that it remained
enzymatically active (I, Fig. 2C). We used phage
d i s p l a y i n g  C P K V C P R E C E S N C ,
C L G Q C A S I C V N D C ,  o r
CYNLCIRECESICGADGACWTWCADGCSRS
C in binding assays to the immunocaptured APA.
We found up to 12-fold enrichment of phage
binding to APA compared to immunocaptured cell
lysates from the SK-RC-49 cells; control
insertless phage (fd-tet) showed no binding
preference (I, Fig. 2D).
We also wanted to evaluate whether the synthetic
CPRECESIC peptide had any effect on APA
enzyme activity. We incubated APA-transfected
cells with the APA-specific substrate α-glutamyl-
p-nitroanilide with increasing concentrations of
APA-binding or control peptides. The APA-
binding peptide inhibited APA enzyme activity
while the control peptide had no effect (I, Fig.
3A). We calculated the IC50 of the peptide for
APA enzyme inhibition to be ~800 µM. The
inhibition was specific to APA since the peptide
did not affect the enzymatic activity of the closely
related protein CD13/APN.
These data support the specific binding of the
CNGRC peptide to CD13/APN and peptides with
the consensus motif CPRECESIC to APA.
1.3 CD13/APN and APA as targets for
systemic delivery of therapeutics to
angiogenic vasculature (I, II)
To assess the possibility of using CD13/APN and
APA as vascular targets for systemic delivery of
therapeutics to tumors, we evaluated the ability of
APA and CD13/APN binding phage to home to
tumor blood vessels in vivo.
109 TU/mouse of CD13/APN binding CNGRC -
phage were administered intravenously to nude
mice bearing human breast carcinoma MDA-MB-
435-derived xenografts. Phage homing was
quantified by recovery from tissue homogenates
by bacterial infection. CNGRC phage was
enriched in tumors compared to a control
insertless phage (fd-tet) In addition, the in vivo
homing of the CNGRC phage to tumors was
blocked by co-injection of a rat anti-mouse
CD13/APN antibody R3-63 (II, Fig. 1D) capable
of inhibiting the enzymatic activity of CD13/APN
(Hansen et al., 1993). In contrast, tumor homing
of the RGD-4C phage was not affected by R3-63,
and normal rat IgG had no effect on the homing of
either phage. (II, Fig. 1D).
Similarly, 109 TU/mouse of the APA binding
CPKVCPRECESNC phage were administered
intravenously to nude mice bearing human breast
carcinoma MDA-MB-435-derived xenografts.
Phage homing was quantified by recovery from
tissue homogenates by bacterial infection.
CPKVCPRECESNC phage was enriched in
tumors compared to control organs; in contrast,
control insertless phage (fd-tet) showed no
enrichment in tumors (I, Fig. 6A). Homing of
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CPKVCPRECESNC phage to tumor vasculature
w a s  s u b s e q u e n t l y  c o n f i r m e d  b y
immunohistochemical staining of phage on tissue
sections. Strong phage staining was observed in
tumor blood vessels, but not in normal brain blood
v e s s e l s ,  o f  m i c e  t h a t  r e c e i v e d
CPKVCPRECESNC phage; in contrast, control
phage without insert did not home to tumor blood
vessels (I, Fig. 6B).
These results show that CD13/APN and APA-
binding phage target tumor blood vessels in vivo.
Thus both CD13/APN and APA expressed in the
angiogenic vasculature can serve as targets for
systemic delivery of therapeutics.
1.4. Inhibition of angiogenesis and tumor
growth by genetic elimination or
biochemical inhibition of CD13/APN and
APA (I, II)
To test the functional role of the CD13/APN and
APA enzymatic activities in angiogenesis, we
studied the effects of CD13/APN and APA
inhibitors in the chick embryo chorioallantoic
membrane (CAM) assay. In this simplified in vivo
model of angiogenesis, neovascularization is
stimulated with VEGF of bFGF adsorbed on to a
gelatin sponge placed on the CAM (Ribatti et al.,
1997).
Immunostaining of the CAM showed that the anti-
mouse CD13/APN antibody R3-63 recognizes
CAM (chicken) vasculature, making it possible to
test its effect on bFGF-induced angiogenesis in
the CAM. CAMs were stimulated on embryonic
day (E) 8 with sponges containing bFGF only,
bFGF plus anti-APN R3-63, bFGF plus normal rat
IgG, bFGF plus bestatin, bFGF plus actinonin, or
bFGF plus leupeptin. CAMs were examined on
E12 and neovascularization was quantified by
counting the number of emerging capillaries. R3-
63 significantly suppressed vessel growth in the
CAM assay, as did CD13/APN inhibitor bestatin
and actinonin, another chemical CD13/APN
inhibitor (II, Fig. 5B). Normal rat IgG or
leupeptin, which does not inhibit CD13/APN
activity, had no effect (II, Fig. 5B). Similarly,
CAMs were stimulated with sponges containing
VEGF only, VEGF plus CPRECESIC, or VEGF
plus control peptides. CAMs were examined and
neovascularization was quantified (I, Fig. 4B).
Significant induction of neovascularization was
found when a sponge with VEGF was placed on
the CAM compared to a sponge with no growth
factors. CPRECESIC peptide (1 mM) inhibited
VEGF-induced CAM neovascularization by 40%.
Equimolar concentrations of a negative control
peptide or lower CPRECESIC peptide
concentrations (0.1 mM and 0.3 mM) did not
affect the number or branching of the growing
blood vessels.
These data show that inhibiting the enzymatic
activity of either CD13/APN or APA inhibits
blood vessel formation in a standard model of
angiogenesis.
We used the mouse model of O2-induced
retinopathy (Smith et al., 1994) to test the effect
of biochemical CD13/APN inhibition on
angiogenesis. Mice were exposed to 75% O2 from
P7 to P12, and then returned to room air and
treated with intravenous injection of vehicle
alone, anti-mouse CD13/APN R3-63 and 2M-7
antibodies or normal rat IgG (250 µg/mouse), or
bestatin, (200 µg/mouse). Angiogenesis was
quantified by counting endothelial cell nuclei
protruding into the vitreous space on P17. The
number of retinal neovessels in mice treated with
vehicle alone was set at 100%. Both anti-mouse
CD13/APN antibodies  and bestatin reduced the
neovascularization significantly, whereas rat IgG
had no effect (II, Fig. 5A).
To evaluate whether CD13/APN inhibitors
(chemical CD13/APN inhibitor bestatin or anti-
APN blocking antibodies) suppress tumor growth
in vivo, we used MDA-MB-435 derived breast
carcinoma xenografts. We chose this model
because CD13/APN expression is undetectable in
MDA-MB-435 cells, but strongly induced in the
tumor blood vessels associated with MDA-MB-
435 -derived tumors (II, Fig. 3A) and accessible
upon systemic delivery as shown by the CNGRC-
phage homing to the tumor vasculature (Arap et
al., 1998; II, Fig. 1D). Tumor-bearing mice
received vehicle, bestatin (250 µg/mouse), a
mixture of R3-63 and 2M-7 antibodies, or normal
rat IgG (125 µg/mouse) given intraperitoneally
once a week for 3 weeks and tumors were
monitored for three weeks. Anti-mouse
CD13/APN antibodies and bestatin inhibited
significantly the growth of tumors, whereas
normal rat IgG had no effect (II, Fig. 5C).
To evaluate whether APA inhibitory ligands
(APA-binding peptides or anti-APA blocking
antibodies) suppress tumor growth in vivo, we
used EF43-fgf4-derived tumors, an established
mouse mammary carcinoma model (Deroanne et
al., 1997; Hajitou et al., 2001). We chose this
model because APA expression is undetectable in
EF43-fgf4 cells but strongly induced in the tumor
blood vessels associated with EF43-fgf4-derived
tumors (I, Fig. 7 A) and homing of APA-binding
phage to tumor vasculature was experimentally
validated. Tumor-bearing mice received vehicle,
CPRECESIC or control peptides (250 µg/mouse)
and tumors were monitored (I, Fig. 7B). We
observed differences in tumor growth as early as 5
days after treatment initiation and when the
experiment was terminated at the end of two
weeks, CPRECESIC-treated mice had
significantly smaller tumors relative to tumor-
bearing control mice that received control peptide;
tumors in mice treated by control peptide behaved
similarly to those tumors in mice receiving
vehicle alone indicating that the control peptide
had no measurable effect. However, because the
APA-inhibitory peptides may require a relatively
high molar range (~250 nanomoles/mouse/dose)
to be effective, we also evaluated the effects of
anti-APA antibodies on tumor growth. We used
an established regimen of two anti-APA
monoclonal antibodies (ASD-37/41) with
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synergistic APA inhibitory properties (Assmann
et al., 1992; Mentzel et al., 1999) on the same
animal model. Tumor-bearing mice received
vehicle, ASD-37/41, or isotype control IgG (200
µg/mouse) and tumors were monitored (I, Fig.
7C). Again, we noticed clear differences in tumor
growth. By the end of two weeks when the
experiment was terminated, ASD-37/41-treated
mice had significantly smaller tumor volumes
relative to tumor-bearing control mice that
received isotype negative control IgG; tumors in
mice treated with control IgG behaved similarly to
those tumors in mice receiving vehicle only
indicating that control IgG had no detectable
effect on tumor growth. Finally, to analyze post-
treatment effects of APA-inhibitory antibodies in
tumors and their angiogenic blood vessels, we
examined tissue sections of all groups by CD31-
immunostaining (I, Fig. 7D). In contrast to the
recognized (Deroanne et al., 1997; Hajitou et al.,
2001) extensive blood vessel network typically
observed in EF43-fgf4-derived tumors, ASD-
37/41-treated tumors exhibited a mixture of viable
tissue (towards the outer rim of the tumors) and
neighbouring regions of disrupted vascular
structure along with large areas of widespread cell
death and destruction of the tumor architecture;
inhibitory peptides had similar but less
pronounced effect on treated tumors (I, Fig. 7D).
Taken together, these results indicate that
CD13/APN and APA-inhibitory ligands and
antibodies can specifically target angiogenic
vasculature and suppress tumor growth in vivo.
We have also evaluated the angiogenic response
of APA -/- mice in two in vivo models of
angiogenesis. First, we used a mouse model of O2-
induced retinopathy (Smith et al., 1994). APA
wild type (APA +/+), APA heterozygotes
(APA+/-) and APA-null (APA -/-) mice were
exposed to 75% O2 from P7 to P12, and then
returned to room air. Retinas were analyzed at
P17, when neovascularization had supervened on
the vitreal surface. Angiogenesis was quantified
by counting endothelial cell nuclei protruding into
the vitreous space (Smith et al., 1994). Induction
of retinal angiogenesis was seen in wild type mice
on P17 (I, Fig. 1A), but significantly fewer
endothelial cell nuclei were found in retinas from
APA -/- mice (I, Fig. 1B). An intermediate
decrease in retinal angiogenesis was observed in
the APA +/- mice suggesting dose-dependence (I,
Fig. 1C). No endothelial cell nuclei protruding
into the vitreous space were found in mice
exposed only to room air regardless of their
genotype or time of analysis.
As a second model, we adopted a quantitative in
vivo  angiogenesis assay utilizing implanted
gelfoam sponges saturated with angiogenic
growth factors VEGF, bFGF and TGF-α
(McCarty et al., 2002). To compare angiogenesis
induction from subcutaneous tissue, sponges were
implanted into the flanks of wild type (APA +/+)
or APA-null mice (APA -/-). After two weeks, the
sponges were harvested and stained with anti-
CD31 antibodies to detect the endothelial cells of
newly formed blood vessels permeating the
sponge. Strong induction of CD31-positive
capillary structure formation was observed in the
growth factor-absorbed sponges implanted into
wild type mice (I, Fig. 1D) whereas the number of
CD31-positive capillary structures was much
smaller in APA -/- mice and the only limited
capillary formation observed was observed at the
outer surface of the sponge (I, Fig. 1E).
These results suggest a deficient angiogenic
response in APA -/- mice to relative hypoxia or to
angiogenic growth factors as compared with their
otherwise isogenic APA +/+ counterparts.
1.5. CD13/APN activation by angiogenic
signals (III)
To investigate the mechanisms of CD13/APN
induction in tumor vasculature, the regulation of
CD13/APN by factors contributing to angiogenic
progression were studied.
First, we characterized CD13/APN endothelial cell
transcripts by Northern blot analysis. CD13/APN
cell-surface expression is regulated by two
independent, mutually exclusive, promoters
separated by an 8-kb intron (Shapiro et al., 1991;
III, Fig. 1A). Analysis of CD13/APN transcripts in
primary HUVECs or the Kaposi sarcoma-derived
KS1767 cell line by Northern blot demonstrated
that the endothelial cells express the shorter 3.4-
kb transcript (III, Fig. 1B). These data suggest that
CD13/APN  transcription in endothelial cells
initiates from the proximal liver/intestinal
epithelial promoter and that the KS1767 cell line
faithfully recapitulates CD13/APN transcription
initiation in primary cells. Further analysis by S1
nuclease, RT-PCR, and immunoprecipitation
confirmed that the CD13/APN  transcript in
KS1767 cells initiates from the proximal start site,
is identical in sequence to that expressed in
hepatic epithelial cells, and encodes a protein that
is indistinguishable in size and abundance from
that expressed in hepatocytes and myeloid cells.
In order to delineate the promoter region
regulating endothelial cell expression, we fused
approximately 1-kb of upstream sequences
flanking the transcriptional start site of either the
distal (myeloid) or proximal (epithelial) promoter
(III, Fig. 1A) upstream of the CAT or luciferase
reporter genes and transiently transfected these
constructs into HUVECs or KS1767 cells (III,
Fig. 2A and B, respectively). Significant reporter
gene activity was observed in those cells
containing sequences from the proximal, but not
the distal, promoter, indicating that the
information required for CD13/APN expression in
both primary endothelial cells and cell lines is
contained within this 1-kb fragment.
To investigate whether hypoxia induces
CD13/APN expression, we evaluated the response
of endogenous CD13/APN  mRNA and the
proximal promoter constructs to either hypoxic
culture conditions or cobalt chloride treatment.
RT-PCR analysis indicated that the expression of
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CD13/APN increases in vivo in mouse retinas
undergoing hypoxia-induced neovascularization
when compared with untreated controls (III, Fig.
3A). In addition, treatment of KS1767 cells with
cobalt chloride or in environmental hypoxia
induced a time-dependent expression of
endogenous CD13/APN mRNA and protein (III,
Fig. 3B and C) and transfected C D 1 3 / A P N
reporter gene levels (III, Fig. 3D). Therefore,
hypoxia increases CD13/APN  expression in a
manner analogous to the hypoxic transcriptional
up-regulation observed with other angiogenic
regulators (Folkman and D'Amore, 1996;
Hanahan and Folkman, 1996; Hanahan, 1997).
To address the possibility that the hypoxic
induction of CD13/APN is indirectly mediated by
hypoxia-induced growth factor up-regulation in
vascular endothelium, we cultured primary
HUVECs in low or high concentrations of serum
(which contains functional concentrations of
many angiogenic factors) or with the individual
angiogenic growth factors, bFGF, VEGF, TNF, or
IGF-1 (III, Fig. 4A). CD13/APN expression was
significantly induced upon serum stimulation (4-
fold) and increased between 1.5- to 2.5-fold on
culture with each of the individual angiogenic
factors (bFGF > VEGF = TNF > IGF-1).
Similarly, treatment of HUVECs with these same
angiogenic factors up-regulated levels of the 3.4-
kb CD13/APN transcript to varying degrees (III,
Fig. 4B), implying that transcription from the
proximal promoter is induced by certain
angiogenic growth factors. Therefore, the
expression of CD13/APN is activated in primary
endothelial cells by growth factors that are
produced in the tumor microenvironment.
To confirm that our in vitro model faithfully
reflects the induction of CD13/APN in primary
vascular endothelium, we assessed whether
CD13/APN expression in the KS1767 cell line
was also serum regulated. Flow cytometric
analysis of KS1767 cells cultured in the presence
of 10% serum for 24 hours demonstrated a 10-fold
increase in CD13/APN cell surface expression
when compared with cells exposed to low-serum
concentrations (III, Fig. 5A). Similarly, Northern
analysis of KS1767 cells showed a dose-
dependent 3- to 4-fold increase in CD13/APN
message levels in response to increasing levels of
serum (and consequently, angiogenic factors, III,
Fig. 5B), as well as a time-dependent response to
the individual factors bFGF and VEGF (Fig. 5C),
comparable with that of primary vascular
endothelium (III, Fig. 4B). Therefore, these data
confirmed the validity of the KS1767 cell line as
an in vitro model for the study of CD13/APN
regulation in endothelial cells.
To confirm, that the proximal promoter controls
expression of CD13/APN during angiogenesis, we
examined whether a reporter plasmids containing
this promoter is also be upregulated in response to
serum and growth factor stimulation. KS1767
cells were transiently transfected with a proximal
promoter-driven luciferase reporter plasmid and
cultured in medium containing 1% serum and
either bFGF, VEGF, or IGF-1 (III, Fig. 6A). The
bFGF-treated cells consistently showed a 2.5-fold
increase in promoter activity, whereas the addition
of VEGF or TNF resulted in a more modest, 1.5-
fold increases over controls. Simultaneous
addition of bFGF and VEGF produced a less than
additive effect, perhaps suggesting a functional
overlap between the stimulatory effects of the
individual factors. Importantly, minimal induction
was observed with those conditions containing
IGF-1, demonstrating that the response is specific
for certain angiogenic growth factors. To confirm
these observations, neutralizing antibodies for
human bFGF, human VEGF, or both factors were
added to cultures of KS1767 cells transiently
transfected with the proximal promoter constructs
in 10% serum; this resulted in a progressive
inhibition of CD13 promoter activity (III, Fig.
6B). Together, these results indicate that the
proximal promoter regulates C D 1 3 / A P N
transcription in response to angiogenic growth
factors, and is therefore likely to control
CD13/APN expression during angiogenesis.
1.6. CD13/APN and APA as regulators of
endothe l ia l  ce l l  funct ion  and
morphogenesis (I, III)
We studied the regulation of CD13/APN
expression on endothelial cells differentiating into
capillary-like structures characteristic of
angiogenesis on Matrigel to determine whether
our promoter data obtained in KS1767 cells
accurately reflect transcriptional regulation during
angiogenesis. To ensure that the Matrigel-model
recapitulated the pattern of selective expression of
CD13/APN in tumor endothelium (II, Fig. 4A and
D), we analyzed the RNA from matrix-stimulated
or matrix-unstimulated EOMA cells (Obeso et al.,
1990). EOMA cells express very low levels of
CD13/APN (III, Fig. 1) and, in this respect,
correspond to resting endothelial cells. RT-PCR
analysis indicated that the low endogenous
CD13/APN  mRNA levels in EOMA cells are
increased 3-to 4-fold on angiogenic stimulation,
similar to the levels of the angiogenic regulator β3
integrin, whereas control β-actin levels remain
unchanged (III, Fig. 7A).
To confirm that the proximal C D 1 3 / A P N
promoter controls its expression during
angiogenesis, we stably transfected reporter
plasmids containing this promoter upstream of the
GFP reporter gene into EOMA cells. Stably
transfected cell pools in cultured under
unstimulated conditions formed a cobblestone
monolayer characteristic of endothelial cells and
were negative for CD13-driven GFP expression
throughout the culture period, arguing against
inhibition of expression via cell-cell contact (III,
Fig. 7B). In contrast, upon angiogenic stimulation
on the Matrigel, the CD13-GFP-containing
transfectants formed extensive capillary networks
that were highly fluorescent, confirming that the
factors regulating this promoter are responsible
for the induction of CD13/APN gene expression
during tube formation.
36
We injected the GFP-containing EOMA cell lines
subcutaneously into immuno-compromised mice
to form tumor xenografts in order to establish that
the proximal promoter responds to angiogenic
signals during tumor progression in vivo. Tumors
were harvested, mechanically disrupted to form
single-cell suspensions, and assayed for GFP
expression by flow cytometric analysis. Tumors
derived from the CMV-GFP- and CD13-GFP-
containing EOMA lines contained 23% to 30%
GFP-positive cells compared with background
levels found in the null-GFP-derived tumors (III,
Fig. 7C). The relatively low percentage of GFP-
positive cells in the xenografts reflects a
prominent host-derived stromal component of
these tumors. Therefore, transcription from the
CD13/APN proximal promoter plasmid faithfully
reflects the up-regulation of the endogenous
CD13/APN gene that occurs during endothelial
cell capillary tube formation in vitro and tumor
growth in vivo.
Because CD13/APN transcription is induced in
endothelial cells undergoing capillary tube
formation, it is possible that its functional role is
at the level of control of endothelial
morphogenesis. To address this possibility, we
cultured primary HUVECs on Matrigel in the
presence of the CD13/APN inhibitors, bestatin or
amastatin, or with anti-APN blocking antibody
(MY7). Each of the inhibitors was extremely
effective at abrogating the ability of the cells to
organize a capillary network; under control
conditions with vehicle alone, a nonspecific
protease inhibitor (trypsin inhibitor) or isotype-
matched control antibodies (UPC10) formed
characteristic, organized networks (III, Fig. 8A).
In contrast, treatment of HUVECs with MY7 or
bestatin had no effect on proliferation rates as
measured by metabolic activity (III, Figure 8B),
implying that in contrast to APA, CD13/APN
does not play a role in endothelial cell
proliferation during angiogenesis.
Because of the enzymatic inhibitory activity of
APA-binding peptides and the reduced tumor
growth in mice treated with APA inhibitors, we
reasoned that the APA inhibitory peptide might
affect endothelial cell function. We correlated the
effect of APA inhibition by the CPRECESIC
peptide on the migration and proliferation of
endothelial cells. For this study, we used human
dermal microvascular endothelial cells (HMEC)
in which the APA expression was verified by
immunostaining with RC38 and the APA activity
by its specific enzyme assay. CPRECESIC
peptide suppressed the migration of HMECs in
the Boyden chamber assay (I, Fig. 3B).
Suppression of cell migration was dose-dependent
and commensurate with inhibition of APA
enzymatic activity. Up to 60% suppression in cell
migration was observed at 1 mM of peptide but
significant inhibition was detected at
concentrations as low as 100 µM (I, Fig. 3B).
Similarly, proliferation of HMECs was suppressed
by CPRECESIC (~40% at 1 mM) in a dose-
dependent manner (I, Fig. 3C). Inhibition of cell
proliferation was also observed at 0.3 mM but
lower peptide concentrations had no significant
effect. A negative control peptide affected neither
cell migration nor proliferation.
To determine whether inhibition of APA enzyme
activity with CPRECESIC peptide would affect
endothelial cell morphogenesis and capillary tube
formation, we tested the ability of HMECs to
differentiate into the capillary-like structures
characteristic of angiogenesis in the presence of
CPRECESIC on a gel of reconstituted basement
membrane matrix (Matrigel). The formation of
cord/tube-like structures was progressively
impaired by increasing concentrations of
CPRECESIC peptide, relative to the network
formation in controls without peptide  (I, Fig. 4A,
upper left panel) or with an unrelated control
peptide (Fig. 4A, upper right panel). The number
and length of capillary-like branching structures
was reduced at 0.3 mM CPRECESIC peptide (I,
Fig. 4A, lower left panel), whereas cell
interconnections and the capillary network
organization were severely lost at a peptide
concentration of 1mM (I, Fig. 4A, lower right
panel).
2. An anti-angiogenic state in the retinas of
mice and humans with photoreceptor cell
degeneration (IV)
2.1. Absence of angiogenesis and the
failure of up-regulation of VEGF in mice
with inherited retinal degeneration (IV)
To test our hypothesis whether O2 consumption by
rod cells is a major driving force in ischemic
retinal neovascularization, we designed
experiments to test the angiogenic response of the
Pdebrd1 mutant retinas in response to ischemia by
using the mouse models of O2-induced
retinopathy (Smith et al., 1994) and retinal
degeneration (Sidman and Green, 1965)
simultaneously. Pdebrd1 mice have a classic
autosomal recessive inherited degenerative
disease of photoreceptor cells known as retinal
degeneration. This disease is caused by a
nonsense mutation in the β  subunit of the rod
photoreceptor cell-specific phosphodiesterase
(Sidman and Greene, 1965; Bowes et al., 1990;
Pittler and Baehr, 1991; Lem et al., 1992). Light
absorption by rhodopsin activates transducin, a G-
protein, which in turn promotes cGMP hydrolysis
by the specific phosphodiesterase, leading to
hyperpolarization of rod photoreceptor cells (Roof
and Makino, 2000). The retinal development in
Pdebrd1 / Pdebrd1 mice proceeds normally until
P11. At that time development of photoreceptor
cell outer segments arrests and the rod cell nuclei,
inner segments and outer segments begin to
degenerate. Photoreceptor cell degeneration then
proceeds rapidly, and exceeds 80% by P15, and
90% by P21 (Farber, 1995). By P25-30 only one
sparsely populated row of photoreceptor cell
nuclei remains and the outer segments have
disappeared. By the beginning of the fourth
postnatal week, most surviving photoreceptor
cells are cone cells (Carter-Dawson et al., 1978).
Apoptosis of the photoreceptor cell is the final
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pathogenic event common to all animal models of
retinal degeneration (Chang et al., 1993; Portera-
Cailliau et al., 1994). Combination of the O2-
induced retinopathy and retinal degeneration
produced the surprising finding that the reactive
retinal neovascularization characteristic of normal
young mice exposed to high O2 levels, and
observed in wild-type (wt) and heterozygous
animals, failed to occur in Pdebrd1 homozygotes.
Neovascularization was quantified by counting
vascular endothelial cell nuclei protruding into the
vitreous space from at least six sections of 8-36
eyes in five independent experiments (IV, Table
1). Extensive induction of retinal neo-
vascularization was seen in C57BL/6 +/+ wt mice
on P17 after 75% oxygen treatment from P7 to
P12 (IV, Fig.1B) and in heterozygous +/ Pdebrd1
mice. Virtually no endothelial cell nuclei were
seen in the Pdebrd1/Pdebrd1 retinas on P17 after
exposure to 75% oxygen from P7 to P12 (IV, Fig.
1D). At this time only a few layers of nuclei
remained in the photoreceptor cell layer. Also, no
endothelial cell nuclei were seen on or after P21,
ruling out the possibility of delayed retinal
neovascularization. No endothelial cell nuclei
were seen on P17 in either wt or Pdebrd1/Pdebrd1
mice exposed only to room air (IV, Figs. 1A and
C). Staining for von Willebrandt Factor confirmed
that the cells protruding into the vitreous of wt
mice treated with 75% oxygen were indeed
endothelial cells (IV, Fig. 1E and G) and that such
cells were almost completely confined to the
neural retina in Pdebrd1/Pdebrd1 homozygotes (IV,
Fig. 1G and H).
VEGF has been suggested to be one of the key
angiogenic factors in oxygen-induced retinal
neovascularization (Alon et al., 1995; Pierce et
al., 1995; Stone et al., 1995; Okamoto et al.,
1997; Duh and Aiello, 1999). We hypothesized
that differences in VEGF expression could play a
role in the lack of neovascularization in the retinas
of Pdebrd1/ Pdebrd1 mice and therefore examined
VEGF-expression in retinal tissue by Northern
blot analysis (IV, Fig. 2). Total RNAs from wt
and Pdebrd1/ Pdebrd1 mouse retinas were analyzed
on P12 after exposing mice for 5 days to either
75% O2 or to room air. A decline in VEGF
expression was seen during exposure to
hyperoxia. This decrease was followed by a 150%
increase in the VEGF expression in wt mouse
retinas observed 12 hours after the return to room
air after 75% O2 exposure, compared to that seen
following exposure to room air only. In Pdebrd1/
Pdebrd1 mice retinal VEGF expression remained
low and unchanged even after exposure to 75% O2
for 5 days, comparable to retinas of similar
(otherwise isogenic) mice exposed only to room
air. To determine whether the inhibition of
neovascularization was a consequence of an
altered spatial expression pattern of VEGF rather
than an overall alteration in VEGF expression
levels in the Pdebrd1/ Pdebrd1 mouse retina, we
analyzed VEGF-expression in the retina by in situ
hybridization. Tissue sections from wt and
Pdebrd1/ Pdebrd1 mouse eyes were evaluatedonP12,
12 hours after of exposure to either 75% O2 or
room air for 5 days. Slightly higher VEGF mRNA
levels were seen in the inner nuclear layer and in
the inner plexiform layer of wt mouse retinas on
P12, after 12 hours in room air following 75% O2
exposure. These expression patterns are consistent
with previous studies (Pierce et al., 1995), but a
comparable increase in VEGF expression was not
seen in any region in Pdebrd1/Pdebrd1 mouse
retinas after 75% O2 exposure.
2.2. Regression of established proliferative
retinopathy in patient at the onset of
clinically detectable retinal degeneration
(IV)
As a clinical counterpart to the mouse experiment
in which an exogenous stimulus of pathological
formation of new retinal blood vessels fails in the
presence of advanced photoreceptor cell
degeneration, we presented a clinical case in
which proliferative retinopathy regressed
spontaneously in a diabetic patient with
concurrent retinitis pigmentosa.
On fundus examination of a 36-year-old female,
diagnosed with type I diabetes mellitus for the
past 34 years, we observed in both eyes inactive
fibroglial membranes projecting into the vitreous
from the optic discs (IV, Fig. 3). This pattern was
c o n s i s t e n t  w i t h  r e g r e s s e d  r e t i n a l
neovascularization, often observed in cases of
patients with proliferative diabetic retinopathy
after successful laser treatment (Roof and Makino,
2000). However, this patient had never received
laser treatment. In the periphery and midperiphery
of the fundus, attenuated vasculature and atrophic
retina with granular and bone spicule pigmentary
changes were observed, consistent with a
diagnosis of retinitis pigmentosa (IV, Fig. 3) and
confirmed by a virtually flat electroretinogram
(i.e., less than 10 µV). In non-diabetics with
retinitis pigmentosa, spontaneous regression of
optic disc neovascularization caused by an
unknown mechanism can also occur (Hayakawa et
al., 1993). This example and other sporadic
clinical case reports (Butner, 1984; Uliss et al.,
1986; Hayakawa et al., 1993) suggest that in the
clinical setting of rod photoreceptor cell
degeneration, proliferative retinopathies may fail
to develop or regress early.
3. Development of new strategies in phage
display –technology for the study of
endothelial cells in vitro and in vivo (V, VI)
3.1. Probing target cell surfaces by
biopanning and rapid analysis of selective
interactive ligands (BRASIL; V)
We devised a method termed biopanning and
rapid analysis of selective interactive ligands
(BRASIL) from an assay described to measure
receptor binding of specific yet low-affinity
ligands (Hatzfeld et al., 1982; Ouaissi et al., 1984;
Levesque et al., 1985; Giordano et al., 1994).
We set out to study cell binding by using BRASIL
to test an established ligand-receptor pair.
Experiments were designed using RGD-4C phage
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(displaying the motif ACDCRGDCFCG, termed
RGD-4C peptide), which is a specific ligand for
αv integrins (Pasqualini et al., 1997). We reasoned
that cell-surface–bound phage could be
specifically carried through an organic phase and
recovered by infection of the host bacteria. αv
integrin-expressing Kaposi's sarcoma cells were
detached, incubated on ice with RGD-4C phage or
control insertless phage (fd-tet), and the mixture
was separated by differential centrifugation
through the organic phase. Phage recovery
correlated directly with increasing phage input
and the recovery ratio (phage output from organic
lower layer/phage input from aqueous upper
layer), and decreased with host bacteria saturation
(V, Fig. 1A). Under non-saturating conditions, the
ratio of specific (RGD-4C) phage to control (fd-
tet) phage (termed 'enrichment') ranged from 100
to 500. We also showed that the binding of RGD-
4C phage to KS1767 cells is specific since such
cell-phage binding was inhibited by the cognate
synthetic RGD-4C peptide in a dose-dependent
manner; while negative control peptides GRGESP
(V, Fig. 1B) or CARAC at the same molar
concentrations had no inhibitory effect. No phage
were present at the bottom of the tube or in the
organic phase in the absence of KS1767 cells.
Next, we compared BRASIL with conventional
cell-panning strategies that require washing steps.
The number of RGD-4C phage recovered by
BRASIL was significantly higher than using a
conventional phage-cell binding strategy
involving washing (V, Fig. 1C). Conversely,
significantly lower background with the negative
control phage was observed (V, Fig. 1C). Given
the significant increase in recovery of specific
phage and the substantial decrease in background,
the overall accuracy (cell-specific phage recovery)
improved consistently by more than one order of
magnitude when BRASIL was used relative to
conventional cell-panning methods.
Next, we tested whether BRASIL could also be
used to screen phage display random peptide
libraries on cells. We designed a two-step panning
strategy to isolate phage that bind to angiogenic
(VEGF-stimulated) endothelial cells. First, to
decrease non-specific binding, we pre-cleared the
phage library on starved endothelial cells (before
panning on the same cell line stimulated with
recombinant VEGF165; starved HUVECs were
incubated with the phage library and centrifuged
through the organic phase (V, Fig. 2A). Second,
the unbound phage pool left in the aqueous phase
was transferred to a fresh tube and incubated with
VEGF-stimulated HUVECs. After centrifugation
through the organic phase, phage bound to the
VEGF-stimulated HUVEC pellet were recovered
by bacterial infection, amplified and subjected to
two more rounds of selection (V, Fig. 2A).
To asses the efficiency of the selection method,
we compared 21 random phage clones for binding
to starved and VEGF-stimulated HUVECs.
Fourteen out of 21 clones (67%) had a greater
than 150% enhancement in the ratio of cell
binding upon VEGF stimulation normalized to
control insertless phage. Sequence alignment
analysis of 34 clones randomly chosen from the
selected phage revealed that 24 clones (70%) of
the phage recovered by BRASIL had peptide
motifs that could be mapped to sequences present
in VEGF family members (V, Table 1).
3.2.Validation of a chimeric ligand mimic
of VEGFR-1 and neuropilin-1 (V)
We chose the CPQPRPLC phage and
CNIRRQGC phage (a representative phage out of
three different clones displaying the motif
IRRE/Q) for in vitro phage binding assay on
VEGFR-1. The receptor was immobilized on a
microtiter well-plate and incubated with
CPQPRPLC phage, CNIRRQGC phage or fd-tet
as a negative control. Both CPQPRPLC and
CNIRRQGC phage bound to VEGFR-1 (V, Fig.
2B). The CPQPRPLC phage bound best with an
average of over 1,000-fold enrichment observed
over each of the controls used: CPQPRPLC phage
binding to VEGFR-1 over bovine serum albumin
and CPQPRPLC phage over fd-tet phage binding
to VEGFR-1 (V, Fig. 2B).
The CPQPRPLC sequence matched motifs found
within the VEGF-B isoforms (V, Fig. 2C). VEGF-
B has two mRNA splice variants generated by the
use of different, but overlapping, reading frames
of exon 6 (isoforms 167 and 186), which diverge
in sequence in their C termini (Olofsson et al.,
1999). The pentapeptide motif PRPLC is found in
the recombinant human VEGF-B167 C-terminal
region encoded by exon 6B, starting at the second
residue after the boundary between exons 5 and
6B. PRPLC is a NRP-1 binding domain (Makinen
et al., 1999). On the other hand, the tetrapeptide
motif PQPR—which overlaps with PRPLC and
also with the phage-displayed CPQPRPLC
peptide—is found in the C terminal of
recombinant human VEGF-B186, and encoded by
exon 6A. PQPR is embedded within a 12-residue
known NRP-1 binding site (Makinen et al., 1999).
The motif IRRE/Q also showed homology to
VEGF family members (V, Table 1) but it was not
studied further here.
We evaluated the binding of phage displaying the
peptide CPQPRPLC to a panel of VEGF receptors
(V, Fig. 3A). In a manner consistent with the
receptor recognition profile of VEGF-B (Olofsson
et al., 1999), CPQPRPLC bound to VEGFR-1 and
to NRP-1, but not to VEGFR-2 or to neuropilin-2.
CPQPRPLC phage binding to VEGFR-1 and to
NRP-1 was inhibited by pre-incubation with
VEGF165 (V, Fig. 3B) but not with PDGF-BB.
These results are consistent with the fact that
VEGF165 and VEGF-B isoforms compete for
binding to VEGFR-1 (Olofsson et al., 1999) and
suggest that CPQPRPLC and VEGF165 might
recognize closely related or overlapping binding
sites. Finally, binding of CPQPRPLC phage to the
immobilized VEGFR-1 and NRP-1 was specific
because it could be inhibited by the corresponding
synthetic peptides in a concentration-dependent
manner (V, Fig. 3C and D).
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These data show that CPQPRPLC is a chimeric
VEGF-B-family mimic, and that this peptide
interacts specifically with VEGFR-1 and NRP-1.
3.3. Probing human blood vessels with a
phage display random peptide library in
vivo (VI)
We reasoned that in vivo selection of phage-
display random peptide libraries in humans would
advance the identification of human vascular
targeting probes and facilitate development of
targeted delivery of therapeutic and imaging
agents to the vasculature. We took the initial step
toward developing an in vivo  phage
display–based, ligand–receptor map of human
blood vessels.
A large-scale preparation of a phage random
peptide library displaying the insert CX7C was
constructed to create the highest possible insert
diversity. The diversity of the library was
determined to be 2x108 and its final titer was
approximately 1x1012 TU per ml. A 48-year-old
m a l e  p a t i e n t  w i t h  W a l d e n s t r ö m
macroglobulinemia, who after massive
intracranial bleeding remained comatose with
progressive and irreversible loss of brainstem
function until the patient met the formal criteria
for brain-based determination of death (Wijdicks,
2001), received an intravenous infusion of 1x1014
TU of the unselected CX7C phage library. 15
minutes after phage library infusion tissue
samples were obtained from bone marrow,
prostate, liver, fat-tissue, skeletal muscle and skin,
to provide histopathological diagnosis and to
recover phage from these organs (VI, Fig. 1A).
Tissues were weighted and homogenized, and
phage were recovered by bacterial infection.
Binding of the phage pool was quantified by
calculating the number of recovered phage titers
from the recovered tissue samples. Phage
recovered from each tissue were processed for
sequencing of the peptide inserts, as well as from
the unselected library.
To analyze the distribution of inserts from the
random peptide library, we designed a high-
throughput pattern recognition software to analyze
short amino-acid residue sequences. This
automated program allowed surveillance of
peptide inserts recovered from the phage library
screening. Based on SAS (version 8; SAS
Institute) and Perl (version 5.0), the program
conducts an exhaustive amino-acid residue
sequence count and keeps track of the relative
frequencies of n  distinct tripeptide motifs
representing all possible n3 overlapping tripeptide
motifs in both directions (n<<n3). This analysis
was applied for phage recovered from each target
tissue and for the unselected CX7C random phage-
display peptide library. Counts were recorded for
all overlapping interior tripeptide motifs, subject
only to reflection and single-voting restrictions.
No peptide was allowed to contribute more than
once for a single tripeptide motif (or a reversed
tripeptide motif). Tripeptide motifs in both
directions are chemically nonsymmetrical and not
necessarily equivalent. However, because we
often recover forward and reverse tripeptides
recognizing the same receptor by in vivo phage
display, we chose to take this redundancy into
account, with the understanding that this is not a
general feature that is applicable to every
ligand–receptor pair interaction. Each peptide
contributed five tripeptide motifs. Tripeptide
motif counts were conditioned on the total number
for all motifs being held fixed within a tissue. The
significance of association of a given allocation of
counts was assessed by the one-tailed Fisher's
exact test. Results were considered statistically
significant at P  < 0.05. In summary, to test for
randomness of distribution, we compared the
relative frequencies of a particular tripeptide motif
from each target to those of the motifs from the
unselected library; such an approach is
intrinsically a large-scale contingency table
association test.
To determine the distribution of the peptide
inserts homing to specific sites after intravenous
administration, we compared the relative
frequencies of every tripeptide motif from each
target tissue to those from the unselected library.
We analyzed 4,716 phage inserts recovered from
the five tissues and from the unselected library.
Tripeptide motifs were chosen for the phage insert
analysis because three amino-acid residues seem
to provide the minimal framework for structural
formation and protein–protein interaction
(Vendruscolo et al., 2001). Each phage insert
analyzed contained seven amino-acid residues and
contributed five potential tripeptide motifs; thus,
counting both peptide orientations, a total of
47,160 tripeptide motifs were surveyed.
Comparisons of the motif frequencies in a given
organ relative to those frequencies in the
unselected library showed a nonrandom nature of
the peptide distribution (VI, Table 1); such a bias
is particularly noteworthy given that only a single
round of in vivo screening was performed. Of the
tripeptide motifs selected from tissues, some were
preferentially recovered in a single site whereas
others were recovered from multiple sites. These
data are consistent with some peptides homing in
a tissue-specific manner and others targeting
several tissues. We next adapted the ClustalW
software from the European Molecular Biology
Laboratory to analyze the original cyclic phage
peptide inserts of seven amino-acid residues
containing the tripeptide motifs. This analysis
revealed four to six amino-acid residue motifs that
were shared among multiple peptides isolated
from a given organ (VI, Fig. 2). We searched for
each of these motifs in online databases
(http://www.ncbi.nlm.nih.gov/BLAST through the
National Center for Biotechnology Information)
and found that some appeared within known
human proteins. As our motifs are likely to
represent sequences present in circulating ligands
(either secreted proteins or surface receptors
expressed on circulating cells) that home to
vascular receptors, we compiled a panel of
candidate human proteins potentially mimicked
by selected peptide motifs (VI, Table 2).
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3.4.Validation of a candidate ligand-
receptor pair in prostate vasculature (VI)
We isolated from the prostate a potential
mimetope of interleukin 11 (IL-11), which has
been previously shown to interact with receptors
within endothelium and prostate epithelium
(Mahboubi et al., 2000; Campbell et al., 2001).
Because of the availability of the IL-11 receptor
(IL-11R) and well-characterized interaction
between the candidate ligand (IL-11) and its
receptor, we chose the motif RRAGGS, a peptide
mimic of IL-11 (VI, Table 2), for validation. We
show by phage overlay on human tissue sections
that a prostate-homing phage displaying an IL-11
peptide mimic specifically bound to the
endothelium and to the epithelium of normal
prostate (VI, Fig. 3A), but not to control organs,
such as skin (VI, Fig. 3B). In contrast, a phage
selected from the skin (displaying the motif
HGGVG), did not bind to prostate tissue (VI, Fig.
3C); however, this phage specifically recognized
blood vessels in the skin (VI, Fig. 3D). Moreover,
the immunostaining pattern obtained with an
antibody against human IL-11R on normal
prostate tissue (VI, Fig. 3E) is indistinguishable
from that of the CGRRAGGSC-displaying phage
overlay (VI, Fig. 3A); a control antibody showed
no staining in prostate tissue (VI, Fig. 3F). These
findings were recapitulated in multiple tissue
sections obtained from several different patients.
Finally, by using a ligand–receptor binding assay
in vitro, we demonstrate the interaction of the
CGRRAGGSC phage with immobilized IL-11R at
the protein–protein level. Recombinant IL-11Rα,
VEGFR-1, and leptin receptor (OB-R;
homologous to a co-receptor of IL-11Rα) were
immobilized on microtiter wells and incubated
with the CGRRAGGSC phage, an unrelated
phage clone (displaying the peptide
CRVDFSKGC) or insertless phage (fd-tet). The
CGRRAGGSC phage bound to the IL-11Rα in
contrast to the control receptors and control phage
(VI, Fig. 4A). Such binding was specific because
it was inhibited by the native IL-11 ligand, but not
a negative control IL-1, in a concentration-
dependent manner (VI, Fig. 4B).
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Discussion
1 Novel role for CD13/APN and APA as
regulators of angiogenesis and vascular
receptors for circulating ligands (I-III)
Several approaches indicate that the vascular
endothelium of angiogenic blood vessels express
surface markers that are accessible from the
circulation in tumors but are undetectable,
inactive, or inaccessible in normal blood vessels.
Such cell markers include growth factor receptors,
cell adhesion molecules and proteoglycans
(Brooks et al., 1994a; Pasqualini et al., 1997;
Arap et al., 1998; Brekken et al., 1998; Burg et
al., 1999). Membrane-associated proteases such as
gelatinases have also been found to be molecular
targets in tumor blood vessels (Koivunen et al.,
1999). In the work presented here, we described
the identification of two membrane-associated
aminopeptidases, CD13/APN and APA, as
functional markers of angiogenic blood vessels.
NGR-peptide was previously isolated as a peptide
motif homing to tumor vasculature (Arap et al.,
1998). We showed that tumor-homing NGR
peptides bind to CD13/APN. We also showed that
CD13/APN is a new marker for angiogenic
vasculature, and that it is functionally important in
angiogenesis. Soon after discovering the
functional role CD13/APN had in angiogenesis,
we hypothesized that APA, a closely related
membrane aminopeptidase, could also have a
functional role in this process. We predicted that
genetic elimination of APA or biochemical
inhibition of its enzymatic activity would lead to
insights into mechanisms of abnormal blood
vessel formation. We also reasoned that
identification of a specific APA ligand might
yield a desirable targeting tool, given the high
expression of this protease in the newly formed
blood vessels of human tumors (Schlingemann et
al., 1996).
The phage binding assays and in vivo homing
experiments in human tumor xenografts in mice
showed that NGR peptides bind selectively to
CD13/APN. Phage displaying NGR-peptides
interacted with immunocaptured CD13/APN and
CD13/APN-transfected cells in culture. This
binding is specific; in each case, the binding was
inhibited by the cognate soluble peptide.
Furthermore, anti-APN antibody inhibited in vivo
homing of NGR phage to human tumor xenografts
in mice, strongly suggesting that CD13/APN is
the receptor for NGR peptides in the tumor
vasculature.
The expression pattern of CD13/APN agrees with
its proposed role as the receptor for the NGR
peptides in tumor vasculature; CD13/APN is
specifically expressed in endothelial and
periendothelial cells in angiogenesis. Various
types of tumors in two species, analyzed with two
monoclonal anti-APN antibodies and with an
NGR phage overlay, consistently revealed
CD13/APN expression in tumor vasculature. The
vascular CD13/APN expression was independent
of whether the tumor cells expressed CD13/APN.
We also found strong CD13/APN expression in
the blood vessels of corpus luteum and have
shown in other work that retinal neovasculature
expresses CD13/APN. In each case, in tumors, in
the corpus luteum, and during retinal
neovascularization, the vasculature is undergoing
angiogenesis (Smith et al., 1994; Folkman, 1995;
Hanahan and Folkman, 1996; Klauber et al.,
1997). Thus, CD13/APN expression correlates
with angiogenesis. We did not find CD13/APN
expression in the vasculature of any normal
human tissues, including the blood vessels in the
brain. However, others have found CD13/APN in
the pericytes associated with the blood-brain
barrier (Kunz et al., 1994). Although we are
uncertain as to the cause, this discrepancy may
relate to expression levels, which appear to be far
higher in angiogenesis than in resting blood
vessels. Importantly, both studies found the
endothelial cells in the brain to lack CD13/APN.
We showed that CD13/APN is not only a
previously unrecognized marker of angiogenic
endothelial cells but is also functionally important
in angiogenesis since CD13/APN inhibitors, such
as inhibitory antibodies R3-63 and 2M-7, and
chemical inhibitors bestatin and actinonin, were
found to suppress angiogenesis. In accordance
with earlier studies (Fujii et al., 1995; Saiki et al.,
1993) the CD13/APN inhibitors also suppressed
tumor growth. Our results suggest that inhibition
of angiogenesis is likely to be a factor in the anti-
tumor activity of these compounds. The role of
CD13/APN in angiogenesis may be to facilitate
endothelial cell invasion of tissue, which is an
essential component of angiogenesis (Bussolino et
al., 1997; Zetter, 1998). Experiments with tumor
cells have shown that CD13/APN expression can
increase cell invasiveness (Fujii et al., 1995).
Because compounds that are enzymatic inhibitors
of CD13/APN inhibit angiogenesis, this putative
invasion-promoting effect would appear to be
related to the enzymatic activity of CD13/APN.
Another possibility is that CD13/APN could
modulate the activity of growth factors or
cytokines. Such activities are common among
aminopeptidases, including CD13/APN (Ward et
al., 1990; Taylor, 1993; van Hal et al., 1994;
Lendeckel et al., 1999).
The expression of CD13/APN in angiogenesis
may depend on growth factors and cytokines;
TNF-α and bFGF have previously been shown to
up-regulate CD13/APN expression in cells
(Riemann et al., 1995; van Hal et al., 1994).
Consistent with the role of CD13/APN as an
angiogenic regulator in vascular endothelial cells,
we showed that hypoxia markedly induces
endogenous CD13/APN mRNA and reporter gene
transcription levels in endothelial cells. During the
initial stages of angiogenesis, signals generated by
hypoxic stimuli alter the expression of many
genes contributing to angiogenic differentiation,
including those encoding glycolytic enzymes,
glucose transporters, and angiogenic and
hematopoietic growth factors (Semenza, 1999).
Expression of these genes can be affected either
42
positively or negatively through transcriptional
and posttranscriptional mechanisms (Semenza and
Wang, 1992; Ikeda et al., 1995; Schmedtje et al.,
1997; Discher et al., 1998; Kroll et al., 1999). The
elevation of CD13/APN expression could be a
direct response to hypoxia-activated DNA-binding
transcription factors, such as HIF-1 or hypoxia-
associated factor, or a secondary consequence of
hypoxia-induced autocrine growth factor
production. Examination of the sequence of the
CD13/APN proximal promoter failed to reveal a
consensus HIF-1 (Wang and Semenza, 1993) or
EP-17 (Gupta et al., 2000) binding site; however,
numerous other consensus sites for transcription
factors important for angiogenesis are present.
Identification of the specific transcription factors
regulating CD13/APN gene expression in
response to angiogenic stimuli will be important
for elucidating the molecular mechanisms
controlling its angiogenic activation.
We also tested a panel of cytokines whose
expression has been shown to be up-regulated by
hypoxia. Of those specific cytokines tested,
CD13/APN mRNA, protein, and promoter activity
levels were increased most strikingly in response
to bFGF and VEGF. These factors are co-
expressed in a variety of cancers and functionally
complement each other during angiogenesis
(Hanahan and Folkman, 1996; Koolwijk et al.,
1996). Thus, it is reasonable to assume that they
would play a similar role in the angiogenic
induction of CD13/APN . The regulation of
specific genes by bFGF and VEGF has been
shown to initiate signaling cascades involving
several different intermediates including Ras,
phospholipase C, p125FAK, and PI3K (reviewed
in Tallquist et al., 1999). Finally, functional
antagonists of CD13/APN interfere with tube
formation but not proliferation of primary
vascular endothelial cells, suggesting that
CD13/APN functions in the control of endothelial
cell morphogenesis. These studies clearly
establish the CD13/APN aminopeptidase as an
important regulator of endothelial morphogenesis
during angiogenesis. Indeed, following the studies
described in this thesis, Bhagwat et al. showed
that CD13/APN is a transcriptional target of
Ras/MAPK and PI3K pathways, two Ras-
mediated signaling pathways that have been
implicated to play a role during the angiogenic
switch. Furthermore, under conditions where
CD13/APN up-regulation is prevented by
inhibiting the Ras/MAPK and PI3K pathways,
exogenous expression of CD13/APN can rescue
the angiogenic progression in an in vivo model of
angiogenesis (Bhagwat et al., 2003).
Our first insights to the functional role for APA in
angiogenesis derived from the in vivo studies with
APA knockout mice. Knockout APA -/- mice
develop normally (Lin et al., 1998), but our study
shows a severely impaired angiogenic response in
oxygen-induced retinopathy in a mouse model of
retinopathy of prematurity (Smith et al., 1994) as
well as in an in vivo model of angiogenesis where
angiogenic growth factors are used to induce new
blood vessel formation into a subcutaneous
gelfoam plug (McCarty et al., 2002). The fact that
APA -/- mice develop normally with no gross
phenotypic abnormalities suggests that while APA
may participate in embryonic angiogenesis, it is
not an essential participant. The molecular events
associated with de novo formation of blood
vessels during early development may be
redundant or compensated by other proteases. Our
data indicate a functional role for APA in the
pathological formation of new blood vessels from
a preformed vascular bed. These data strengthen
the candidacy of APA as a specific vascular target
to inhibit abnormal angiogenesis associated with
tumor formation and retinal neovascularization.
In order to obtain molecular probes for studying
the role of APA activity in angiogenesis as well as
ligands to target tumor blood vessels in vivo, we
screened a combinatorial peptide library for APA
binding peptides. We selected APA-binding phage
d i s p l a y i n g  t h e  s e q u e n c e s
CYNLCIRECESICGADGACWTWCADGCSRS
C and CPKVCPRECESNC that bound to APA.
Their binding to APA was specifically inhibited
by the synthetic peptide with a consensus APA
binding motif CPRECESIC. Binding of one of the
isolated phage (CLGQCASICVNDC) to APA was
not inhibited by CPRECESIC peptide, possibly
due to the short sequence shared with the other
isolated peptides leading to a low-affinity
interaction suggesting, that the sequence
CPRECES alone is sufficient to promote
inhibition. In addition to binding APA in vitro, the
CPKVCPRECESNC phage also homed to the
vasculature of human tumor xenografts and
murine tumors in vivo indicating that APA
binding peptides can be used as ligands to target
APA in tumor vasculature for the purpose of
systemic delivery of therapeutics. Since a search
of human sequence databases for sequences
homologous to the selected peptides did not yield
matches consistent with potential endogenous
APA-ligands, the biological substrate responsible
for APA inhibition by the consensus motif
CPRECESIC may remain unknown until three-
dimensional structure of the interaction of ligand
peptides and the APA active site has been solved.
In vitro and in vivo angiogenesis assays were
performed to further define the functional basis
for the role of APA in blood vessel formation.
Because our evaluation of APA enzyme activity
in freshly isolated endothelial cells led to the
observation of high enzyme activity in HMECs
and in some tumor-derived endothelial cells, we
used HMECs in our in vitro angiogenesis assays.
We found that the synthetic CPRECESIC peptide
inhibited VEGF-induced migration and
proliferation of HMECs. CPRECESIC peptide
also inhibits cord/ tube formation of
microvascular endothelial cells in a Matrigel assay
and angiogenesis in VEGF-stimulated CAMs.
In addition to mouse models, we evaluated
whether abnormal angiogenesis associated with
certain human diseases is related to the expression
of APA in the vasculature. We examined the
expression and activity of APA in malignant
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gliomas and metastatic carcinomas to the brain
and showed that APA is not only present in
angiogenic blood vessels of human malignant
gliomas but also that the protein overexpressed in
the perivascular cells is enzymatically active. In
contrast, the presence of the enzyme and its
corresponding proteolytic activity were
undetectable in the blood vessels and adjacent
normal brain. Pericytes, which were once seen
merely as the contractile microvessel equivalent
of smooth muscle cells surrounding larger blood
vessels, also play an active role in
neovascularization and maturation, remodeling
and maintenance of the vascular system
(Schlingemann et al., 1990; Schlingemann et al.,
1991; Allt and Lawrenson, 2001; Morikawa et al.,
2002). Similarly to endothelial cells, perivascular
cells also exhibit molecular, functional and
structural heterogeneity (Morikawa et al., 2002),
of which overexpression of APA, as well as
CD13/APN, in tumor blood vessels are good
examples. APA may play a significant role in
several functions of perivascular cells, such as
secretion of growth factors, modulation of the
ECM and regulation of vascular permeability.
Overexpression of APA in activated blood vessels
has been associated with perivascular cells in
human tumors here and elsewhere (Schlingemann
et al., 1996) but the exact cellular location of
active APA in the vascular endothelium of blood
vessels during tumorigenesis is still not entirely
clear. A further level of complexity arises because
tumor cells per se express APA in several human
cancers (Finstad et al., 1985; Nanus et al., 1998;
Fujimura et al., 2000; Ino et al., 2000) making it
difficult to differentiate the origin of APA
enzymatic activity. In the study presented here,
we showed that APA expression and activity are
strongly increased in tumor blood vessels during
late stages of human malignant glioma
progression. We have also observed, that
endothelial cells derived from mature
macrovessels like human umbilical vein
endothelial cells, express little or no APA, while
HMECs, extracted from small, immature blood
vessels show much higher APA expression. One
might speculate that this process mimics an
angiogenic switch (Hanahan and Folkman, 1996)
in which endothelial cells are recruited to form
new capillaries for extensive tumor growth. Once
tumor blood vessels mature to the stage at which
they are covered with perivascular cells, APA
expression is reduced in the endothelial cells. In
turn, activated perivascular cells covering more
mature tumor blood vessels express high levels of
APA.
Given that the selected APA-binding phage home
to tumor vasculature, and the consensus motif
deduced from APA-binding peptides specifically
inhibit APA enzymatic activity, we evaluated
whether APA-binding peptides can be used as
targeted inhibitory carriers. Although APA is also
expressed in many cell types in normal tissues (Li
et al., 1993b; Schlingemann et al., 1996; Alliot et
al. , 1999), our results showed that APA is
exposed, active, and available for binding to
circulating ligands from the luminal side of the
vascular endothelium because APA-binding phage
selectively targets tumor vasculature in human
breast carcinoma-derived tumor xenografts. After
documenting the expression of the target in the
tumor vasculature, in a mouse model of mammary
carcinoma (Deroanne et al., 1997; Hajitou et al.,
2001), we successfully targeted this tumor with
the APA-binding phage and chose this model for
therapy experiments. We showed that APA-
inhibitory ligands--such as the described APA-
binding peptides or anti-APA monoclonal
antibodies (Assmann et al., 1992) --specifically
target angiogenic vasculature and suppress tumor
growth in vivo in this experimental system. The
IC50 of the ASD-37 monoclonal antibody for the
APA enzyme activity was found to be ~60 nM.
The apparently superior inhibitory ability of anti-
APA monoclonal antibodies is commensurate
with and one likely explanation for the more
evident histopathological findings observed after
treatment with such antibodies relative to our
APA-binding peptides. Considering these
promising pre-clinical results, and the fact that
antibody-related toxicity occurred only when mice
received over 20-fold the doses required to
produce the anti-tumor activity in the present
study (Assmann et al., 1992; Mentzel et al.,
1999), anti-APA inhibitory antibodies should be
at least considered as candidates for drug
development and, possibly, translation into
clinical applications.
How CD13/APN and APA facilitate angiogenesis
is still not known. The function of CD13/APN
appears to depend on the availability of its
substrates, thus the location the enzyme; its
location on the cell surface mandates that its
functional activity is dictated by substrates that
are available in the immediate intercellular space.
CD13/APN has been implicated in the catabolism
of neuroactive peptides (Matsas et al., 1984;
Konkoy et al., 1996; Noble and Roques, 1997),
amino acid scavenging and degradation of
regulatory peptides (Turner et al., 1987; Rawlings
and Barrett, 1993), cell adhesion alterations
(Menrad et al., 1993), tumor invasion and
metastasis (Saiki et al., 1993; Fujii et al., 1995;),
as well as antigen processing and presentation
(Mouritsen et al., 1992; Falk et al., 1994).
Because the switch from the quiescent to
angiogenic endothelial phenotype involves an
alteration in the relative levels of angiogenic
inhibitors and activators (Hanahan and Folkman,
1996), it is intriguing to postulate a role for
CD13/APN in the processing of small regulatory
molecules required to initiate, maintain, or
suppress the angiogenic program in tumor vessel
endothelium. CD13/APN is also present in human
plasma as a soluble form. Soluble CD13/APN
activity is elevated in cancer patient plasma and
effusions and this activity has a strong correlation
with the tumor load suggesting that the soluble
plasma CD13/APN is, at least, partly originating
from tumor/ tumor endothelium (van Hensbergen
et al., 2002). Interestingly, CD13/APN has
recently been suggested as a prognostic marker
for pancreatic carcinoma patients and the
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C D 1 3 / A P N  gene expression in pancreatic
carcinoma tumors was associated with an increase
of the intratumor microvessel density (Ikeda et al.,
2003). An intriguing feature of CD13/APN is that
its expression and enzymatic activity can be
physiologically regulated. Its activity and
substrate specificity depend on conformational
changes induced by various stimuli, including
proliferative signals. Studies using monoclonal
antibodies indicate that CD13/APN undergoes
regulatory intramolecular alterations that result in
exposure of cryptic sites and regulation of enzyme
activity (Xu et al., 1997). The immunoreactivity
patterns obtained with cultured cells and tissue
sections from kidney, breast, and prostate
carcinomas suggest that different CD13/APN
forms are expressed in myeloid cells, epithelia,
and tumor-associated blood vessels (Curnis et al.,
2002). Association with proteins or factors present
only in the tumor microenvironment might cause
differential reactivity or accessibility to different
CD13/APN ligands, such as the tumor vasculature
targeting NGR-peptide ligand.
Even less is known about the natural substrates
and function of APA. It also appears to be a
molecule that has different functions, according to
the organ and time period examined. A broad
spectrum of tissues expresses APA (Li et al.,
1993b), but its only well understood role is in the
conversion of AngII to AngIII in the renin-
angiotensin system (Jackson, 2001). In vivo,
AngII remains the best-characterized substrate for
APA.
Interestingly, angiogenesis regulators that belong
to the renin-angiotensin system are degraded by
APA and CD13/APN, suggesting a synergistic
role of these enzymes in the generation of pro-
angiogenic molecules such as AngIII and AngIV
(Stroth and Unger, 1999). In the renin-angiotensin
system, renin converts angiotensinogen to AngI
and ACE converts AngI into AngII, which seems
to be the major effector in blood pressure and
homeostasis control. APA further converts AngII
into AngIII (Jackson, 2001). While angiotensins
are usually investigated in relation to mechanisms
of arterial hypertension, several studies suggest a
role for angiotensins in blood vessel formation
(Andrade et al., 1996; le Noble et al., 1996;
Munzenmaier and Greene, 1996; Walsh et al.,
1997; Monton et al., 1998;Nadal et al., 2002).
Furthermore, inhibition of ACE suppresses
angiogenesis (Volpert et al., 1996; Yoshiji et al.,
2001). However, involvement of ACE in vessel
formation is not so simple, since physiological
angiogenesis seems to be improved by the use of
ACE inhibitors (Takeshita et al., 2001; Emanueli
et al., 2002). In another study AngII was
suggested to play a role as a humoral regulator of
peripheral angiogenesis involving two receptor
subtypes with opposing actions. AngII exhibited
an anti-angiogenic effect through the AT1
receptor and pro-angiogenic effect through the
AT2 receptor (Walther et al., 2003). The
established involvement of angiotensins in
angiogenesis referenced above and the
overexpression of APA and CD13/APN in
angiogenic blood vessels suggest a mechanism for
these peptidases in neovascularization.
As predicted by our hypothesis that APA is a
functional target for molecular agents that can
inhibit angiogenesis, we observed a decreased
neovascularization in APA -/- mice following
induction of angiogenesis by hypoxia and by
growth factors and reduced tumor growth in mice
treated with APA inhibitors. We have also
demonstrated that CD13/APN has a functional
role in angiogenesis. Our data are consistent with
those showing a stimulatory effect of angiotensins
on endothelial cell migration (Kifor and Dzau,
1987) and proliferation (Monton et al., 1998).
Also, angiotensin receptors are expressed in the
CAM, suggesting that angiotensins might play a
role in angiogenesis and capillary branching (le
Noble et al., 1996). Our results, however, could
also reflect a more general effect of APA and
CD13/APN on angiogenic mechanisms such as a
role in degradation of ECM by processing other
unknown substrates (Sang, 1998). Sequential
degradation of ECM proteins or other angiogenic
proteins may generate bioactive peptides that are
able to regulate angiogenesis either positively or
negatively. Natural and synthetic inhibitors of
other metalloproteases inhibit not only in vivo
angiogenesis (Sang, 1998; Koivunen et al., 1999;
Egeblad and Werb, 2002) but also migration and
proliferation of microvascular cells in vitro
(Murphy et al., 1993; Zempo et al., 1996).
Furthermore, knockout mice in which other
metalloproteases have been eliminated (such as
MMP-2 or -9) show a defect in angiogenesis
(reviewed in Egeblad and Werb, 2002).
Due to their specific expression and accessibility
on tumor blood vessels APA and CD13/APN in
the cell membranes of activated endothelial cells
or perivascular cells can be systemically targeted,
making them suitable candidate receptor for
targeted imaging or therapy. Openings between
defective endothelial cells of tumor blood vessels
(Hashizume et al., 2000) enable access to the
perivascular cell layer of the vasculature; other
cell surface receptors of activated perivascular
cells (such as the proteoglycan NG2) have been
targeted by in vivo phage display (Burg et al.,
1999). Combinatorial strategies targeting both the
endothelial and perivascular cell compartments
are likely to provide improved efficacy for
antiangiogenic therapies in multiple stages of
tumorigenesis (Bergers et al., 2003). Following
the identification of the CD13/APN peptide ligand
homing to angiogenic vasculature, it has been
successfully used to target an array of therapies to
tumor vasculature including cytotoxic drugs (Arap
et al., 1998), pro-apoptotic peptides (Ellerby et
al., 1999), cytokines (Curnis et al., 2000) and
liposomes (Pastorino et al., 2003) showing
marked therapeutic efficacy in tumor-bearing
mouse models.
In summary, our results have revealed new roles
for APA and CD13/ APN as functional targets in
angiogenic vasculature that may contribute to an
important regulatory pro-angiogenic pathway.
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These peptidases are expressed in both the
endothelial and periendothelial cell compartment
of angiogenic blood vessels and are therefore
accessible to circulating ligands and may therefore
be used to target therapies to angiogenic
vasculature. Their enzyme activities regulate the
angiogenesis process, since either genetic or
biochemical ablation of the activity of these
enzymes significantly reduces the formation of
new blood vessels in several pathological states,
such as cancer and retinopathies. The APA and
CD13/APN ligand motifs described here may
therefore serve as a peptidomimetic drug leads
against angiogenic mechanisms. Taken together,
the studies described in here showed that APA
and CD13/APN are specific vascular targets to be
critically evaluated in translational clinical trials
against pathologic angiogenesis.
2. Absence of retinal angiogenesis under
reduced metabolic stress (VI)
Angiogenesis is a hallmark of eye diseases
ranging from retinopathy of prematurity in
oxygen-treated neonates to diabetic retinopathy in
adults to age-related macular degeneration in the
elderly. We asked what local factors might
account for the reason why the retina is especially
or uniquely damaged by pathological
neovascularization in diabetic retinopathy and
retinopathy of prematurity. A feature
distinguishing the retina from other parts of the
central nervous system and from other organs is
the presence of large numbers of specialized
photoreceptor cells—140 mill ion rod
photoreceptor cells and 6 million cone
photoreceptor cells. We hypothesized that these
retinal diseases may be based on the unusual
signaling properties of photoreceptor cells (Pugh
et al., 1999; Ebrey and Koutalos, 2001; Hurley,
2002; Hammes et al., 2003) and on the continual
proximal growth and distal shedding of their outer
segments throughout life (Young and Bok, 1969).
These hypotheses lead to strong predictions about
epidemiology and treatment, some of which are
currently being tested.
Diabetes mellitus is the main cause of a
devastating number of new cases of adult
blindness and nearly all people with type 1
diabetes show some symptoms of diabetic
retinopathy, usually after about 20 years of living
with diabetes. Among the many features of this
disease, diabetic retinopathy stands out, with its
dramatic formation of new blood vessels in the
retina, a pathological feature considered to be a
hallmark of ischemic retinopathies in general. In
the most advanced form of diabetic retinopathy,
proliferative diabetic retinopathy, new blood
vessels grow uncontrollably on the retinal inner
surface, causing hemorrhages and even retinal
detachment. Surgical and laser photo-coagulation
treatments are only partially effective and may
further damage the retinal tissue. Even though
well-maintained metabolic control in diabetic
patients may decrease the risk of proliferative
diabetic retinopathy, new ways for its prevention
and treatment are clearly needed. In the retina but
not elsewhere, clinical and experimental diabetes
cause loss of pericytes, and swelling and damage
to capillary endothelial cells that result in the
microaneurysms, capillary dropout, leakage,
cellular damage and new blood vessel growth that
characterize diabetic retinopathy (Kern and
Engerman, 1996; Witmer et al., 2003). This
microvasculopathy indicates that local factors
unique to retina provoke diabetic retinopathy --an
unexpected inference about a tissue often
considered “an approachable part of the brain”
(Dowling, 1987).
A major difference between retina and other
central nervous system regions is the
photoreceptors. Their signal transduction
mechanism is unusually energy-demanding; rods,
under conditions of dark adaptation, produce more
heat and consume more oxygen than any other
cell type. This explains why dark adaptation is
disturbed, in a variety of pathological conditions,
before other visual functions fail, ranging from
polycythaemia vera to partial carotid occlusion
(Havelius et al., 2000). In normal persons, the
sensitivity of rod vision begins to drop when there
is a slight reduction of inspired oxygen, equivalent
to ascending to 3,000 feet or 1 kilometer
(McFarland and Evans, 1939). Thus, the loss of
dark adaptation in diabetics with stage 0
retinopathy is understandable, and the much
greater loss of rod function during more advanced
stages of diabetic retinopathy is well attested.
Recordings with oxygen microelectrodes in
normal eyes show a precipitous drop in pO2 as the
microelectrode passes inward from the level of the
choroidal blood vessels to a minimum in the
vicinity of the photoreceptor cell bodies and
synapses (Linsenmeier, 1986). In dark-adapted
eyes this minimum pO2 tension is zero, but during
an even brief flash of light it reaches 30 mm Hg.
Unlike other brain cells, rods function in ultra-low
oxygen environments but their intense activity in
darkness reduces the pO2 of the avascular inner
retina.
Arden proposed the intriguing hypothesis that the
high oxygen consumption of dark-adapted rod
cells is the driving force of inner retinal hypoxia,
with subsequent VEGF production leading to
retinal neovascularization in ischemic
retinopathies (Arden, 2001). Hyperglycemia, but
especially hypoxia, increases the production of
VEGF (Shweiki et al., 1992; Semenza, 2003a).
Mild reductions in oxygen delivery in diabetes
mellitus are due to many causes and may be
important particularly in the retina where the
safety margin is so low (Arden, 2001). Arden’s
hypothesis was indirectly supported by the
observation that diabetic retinopathy rarely occurs
in retinitis pigmentosa patients (Pruett, 1983;
Butner, 1984; Uliss et al., 1986; Hayakawa et al.,
1993; Arden, 2001). Anecdotal reports also
describe diabetic individuals with absence of
diabetic retinopathy in eyes with large retinal
scars, although the fellow eye is typically affected
(Arden, 2001). In adults with the mitochondrial
disorder MIDD 3243, diabetes is characteristic,
and diabetic retinopathy commonly occurs unless
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retinal degeneration develops (Smith et al.,
1999b). Perhaps the best evidence of the
importance of hypoxia is the successful treatment
of diabetic retinopathy by pan-retinal
photocoagulation (Arden, 2001), which may work
simply by destroying enough rods to increase
retinal pO2 (Stefansson et al., 1986). Our findings
show for the first time that degeneration of rod
cells leads to a total lack of reactive retinal
neovascularization, accompanied by a failure in
the expected VEGF up-regulation. Taken
together, these observations from Pdebrd1/ Pdebrd1
mice and a human patient afflicted with both
diabetes mellitus and retinitis pigmentosa provide
direct experimental and mechanistic evidence in
support of Arden’s hypothesis (Arden, 2001) and
suggest that VEGF is a primary link between rod
cell numbers and retinal neovascularization.
Indeed, it is tempting to speculate that reducing
the metabolic rate of rod cells at critical time
windows may improve the incidence of
retinopathy of prematurity or perhaps slow the
progression of diabetic retinopathy in adults.
Despite advances in pediatric care, retinopathy of
prematurity remains a serious clinical problem.
Premature infants are customarily maintained in
intensive care units, which are well illuminated,
though ordinary care units typically maintain
reduced illumination. Extrapolating from the
observations of Pdebrd1/ Pdebrd1 mice, this is not a
correct arrangement. When neonates are in a high-
oxygen environment, they should be exposed to as
little light as possible. Red light (wavelength >660
nm) is scarcely absorbed by rods; general and
local illumination with light emitting diodes
should suffice for all necessary manipulations.
When the neonate is returned to a normal air
environment, the room should be brightly lit, so
that the oxygen demand of the still-immature eye
is minimized. It is conceivable that increased
exposure of premature neonates to light may
reduce O2 consumption by rod photoreceptor cells
and retinal hypoxia, ultimately improving their
retinopathy. Paradoxically, such reasoning
challenges the current recommendation to
decrease ambient light exposure in that setting,
which has actually failed to prevent retinopathy of
prematurity (Reynolds et al., 1998).
It is noted that VEGF is not the only angiogenic
mediator whose production in the eye is affected
by changes in pO2 (Ogata et al., 1997; Smith et
al., 1997; Khaliq et al., 1998; Yoshida et al.,
1998; Dawson et al., 1999; Carmeliet et al., 2001;
Ogata et al., 2002). Moreover, VEGF inhibitors
and blockers can only partially halt angiogenesis
in the retinopathy of prematurity model (Aiello et
al., 1995) and not all of patients with diabetic
retinopathy show a rise in VEGF (Aiello et al.,
1994). Thus, the total absence of retinal
neovascularization in homozygous Pdebrd1/
Pdebr d 1  mice argues that the degeneration of
photoreceptor cells may have further effects on
angiogenesis that are not VEGF-mediated. Our
data do not rule out a possible role for other
angiogenic factors known to be regulated by
hypoxia, such as TGF-β  (Ogata et al., 1997),
insulin-like growth factor-1 (Smith et al., 1999a),
PlGF (Khaliq et al., 1998) and IL-8 (Yoshida et
al., 1998), and more studies are needed to clarify
these multiple interactions in the retina.
Growth factors and inhibitors may be involved in
coordinating neural and vascular components of
the retina by functioning simultaneously as
photoreceptor cell survival factors and endothelial
cell regulators. bFGF is elevated in P d e brd1/
Pdebrd1 mice several days before photoreceptor
cell death (Gao and Hollyfield, 1995) and intra-
vitreous injection of bFGF delays the onset of
photoreceptor cell degeneration in selected animal
models (Faktorovich et al., 1990). PEDF, which is
encoded by a gene closely linked to the Pdeb
locus (Tombran-Tink et al., 1994), is a survival
factor for photoreceptor cells (Cayouette et al.,
1999) and has been proposed also to play an anti-
angiogenic role in the retina (Dawson et al.,
1999). Given that PEDF concentration is highest
in the matrix surrounding the photoreceptor cell
layer (Becerra, 1997; Dawson et al., 1999) that
undergoes apoptosis in Pdebrd1/ Pdebrd1 mice
(Chang et al., 1993; Portera-Cailliau et al., 1994),
one might expect that a loss of PEDF would be
correlated with an increase rather than a decrease
in retinal angiogenesis. In our system, preliminary
data based on immunostaining failed to show a
correlation between PEDF and neovascularization
and suggest that PEDF does not play a major role
in the phenomenon described here. However, it is
possible that PEDF or other angiogenesis
inhibitors are released during the photoreceptor
cell apoptotic process, which may contribute to
the lack of retinal neovascularization. Roles for
additional factors are suggested by the dramatic
but unexplained variations in timing of retinal
capillary growth into the pigment epithelial cell
layer among mutant mice that share a similarity in
timing of photoreceptor cell degeneration
(Nishikawa and LaVail, 1998). Finally, the
neurotransmitter dopamine has been recently
shown to inhibit VEGF-induced angiogenesis
(Basu et al., 2001). However, dopamine synthesis
and utilization are known to be suppressed at least
in some mouse models of retinal degeneration
(Nir et al., 2000).
In summary, we have shown that ischemia-
induced neovascularization of the retina is
abolished in a mouse strain with inherited
photoreceptor cell degeneration. We also
documented that regression of established reactive
retinal neovascularization caused by diabetes
mellitus could occur in a subset of adult patients
also afflicted with retinitis pigmentosa. This
striking, previously unreported failure to mount a
reactive retinal neovascularization response to
potent exogenous stimuli was associated with an
absence of the expected VEGF up-regulation in
the retina. Our findings support the hypothesis
that O2 consumption by rod cells is a major
dr iv ing  force  in  i schemic  re t ina l
neovascularization and controls VEGF
production, although additional trophic agents and
cytokines are likely also to be involved in this
complex biological phenomenon. Further
characterization of this anti-angiogenic state in the
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retina may lead to therapeutic approaches against
debilitating eye diseases such as ischemic
retinopathies and late complications of retinitis
pigmentosa.
3. Potential of probing blood vessels by
phage display technology (V, VI)
Identification of the endothelial cell surface
receptor fingerprint is required for the
development of vascular-targeted therapies.
Several features in the biology of cell surface
receptors point to the rationality of receptor ligand
identification for intact receptor molecules
embedded in cell membranes instead of isolated
receptors. As opposed to purified receptors,
membrane-bound proteins are more likely to
preserve their active conformation, which are
often lost once proteins are removed from their
natural environment on the cell membrane. In
addition, many cell surface receptors are active as
homodimers or heterodimers whose formation
may require the cell membrane environment;
these interactions further contribute to the ligand
specificities of some receptors. Combinatorial
approaches for probing the molecular
heterogeneity of cell surfaces allow the
identification of cell membrane ligands in an
unbiased functional assay and without any
predetermined notions of the cell surface receptor
repertoire; thus, unknown receptors can be
targeted. Nonetheless, the great complexity of cell
surface molecules still presents a challenge for the
isolation of highly specific ligands for a given cell
population.
We have developed a new approach for the
isolation of cell surface-binding peptides from
phage libraries. To circumvent some of the
practical difficulties in probing the cell surface,
i.e. the recovery of non-specific clones and the
loss of cells and subsequent specific phage clones,
we developed the BRASIL method for probing
the cell surface with phage display libraries.
BRASIL method is based on differential
centrifugation in which cells of interest incubated
with a phage library in an aqueous upper phase
are centrifuged through an organic phase
separating the unbound phage from the specific
phage-cell complex. On side-by-side comparison
to current protocols, BRASIL was more sensitive
and more specific than techniques that rely on
washing or limiting dilution steps to eliminate
background during successive rounds of selection.
BRASIL method is an efficient and convenient
technique for the selection of phage that binds
specifically to a given cell surface. We have
recently performed a screening of the NCI 60-cell
panel using the BRASIL method to create a ligand
“fingerprint” for the NCI 60-cell panel
demonstrating the applicability of the BRASIL
method for high-throughput analysis (Bover et al.,
in progress). Furthermore, BRASIL method is
also more sensitive and more specific than phage
selection techniques that rely on washing of the
cells, and therefore represents a significant
improvement over conventional cell-panning
methods. The use of BRASIL method is not
limited to random peptide libraries or mammalian
cells, but can be used to screen antibody fragment
displaying phage libraries and as well as other cell
types, such as aspergillosis causing fungus
A s p e r g i l l u s  f u m i g a t u s  (J.L., unpublished
observations).
Since our long-standing interest has been in
targeting the vascular endothelium, we screened a
phage-display random peptide library on
activated, VEGF165-stimulated endothelial cells
after a library subtraction step with quiescent
endothelial cells. We subsequently isolated a
CPQPRPLC peptide ligand for VEGF-receptor.
This VEGF-receptor ligand appears to be a
chimera between overlapping binding sites on
different VEGF-B isoforms, since part of it
resembles a neuropilin-1 binding site found in
VEGF-B167 (PRPLC) and the overlapping motif
PQPR resembles a neuropilin-1-binding epitope
of VEGF-B186 (Makinen et al., 1999). Our
chimeric peptide ligand interacts specifically with
VEGF receptors in a pattern consistent with
VEGF-B-type ligands (Olofsson et al., 1999) as
confirmed by binding assays with individual
phage on a panel of purified targets. We further
examined the ability of the synthetic VEGF-
receptor ligand to block phage binding to VEGF
receptors in vitro and found that the isolated
peptide ligand is about 100-fold more efficient in
blocking phage binding to VEGFR-1 than to
neuropilin-1. Because of the observed differential
interaction of the chimeric peptide ligand with its’
receptors, it is tempting to speculate that our
chimeric motif interacts with VEGF receptors
differentially. If so, this differential binding may
be due to differences in the number of peptide-
binding sites on each receptor, or in the affinity of
the interaction at each binding site. Alternatively,
such ligand-receptor interactions may be
dependent on the conditions used for the binding
assay. Full understanding of binding mechanisms
awaits elucidation of the X-ray crystal structures
of VEGFR-1– or NRP-1–CPQPRPLC peptide
complexes. Although one cannot as yet assert that
BRASIL will be well suited for any cell-selection
application, the isolation and further elucidation
of vascular receptor-ligand interaction attests to
the belief that vascular targets can be found on
endothelial cell membranes in vitro by using the
BRASIL method.
Important application for the BRASIL method can
be foreseen in both targeting and identification of
ligand-receptor pairs in cell populations derived
from patient samples. The method may be used in
tandem with fluorescence-activated cell sorting of
leukemic cells obtained from bone marrow
aspirates from patients or even with circulating
endothelial progenitor cells from periferal blood.
Tumor- and inflammatory cells from ascites or
fine-needle aspirates of solid tumors also seem
like ideal clinical material for the identification of
novel tumor antigens with the BRASIL method.
Moreover, because multiple samples and several
selection rounds can be performed in a short
amount of time, automation for high-throughput
clinical applications is likely to follow.
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Besides probing endothelial cell surfaces in vitro,
the work presented in this thesis describes the
identification of vascular receptors and the
isolation their peptide ligands by screening blood
vessels in vivo using phage displayed random
peptide libraries. Probing cell surfaces of the
blood vessel components in vivo may yield to
selection of targeting peptides more suitable to
clinical applications since they bind to native
receptors as they are expressed in vivo.
The work done to discover addresses present only
in tumor blood vessels but not in blood vessels of
normal tissues has been focusing in the use of
animal models of human and murine cancers.
Based on the work presented in here and previous
work by others (Arap et al., 1998; Curnis et al.,
2002), we have found it possible to identify
vascular receptors in tumor-bearing mice that are
also present in human tumors, thus, validating the
use animal models to find molecular markers of
human blood vessels. However, it is not kown
whether targeted delivery will always be achieved
in humans by using mouse-derived probes.
Extrapolation of the results from mouse
experiments to human biology requires that the
molecules of interest be expressed and regulated
similarly in both species. The prominent species-
specific differences in protein expression patterns
and ligand–receptor accessibility prompt us to
carefully evaluate the information obtained from
animal studies before directly applying it to
clinical studies. Clearly, the construction of a
human vascular map will be of essence in the
successful translation of vascular targeting into
clinical practice.
The molecular diversity of receptors in human
blood vessels remains largely unexplored despite
major progress brought about by the human
genome project (Lander et al., 2001; Venter et al.,
2001). The human genome project has produced a
very useful index of genes, but our understanding
where and when given genes are expressed lags
far behind. Aside from in vivo phage display, the
use of methods such as SAGE clearly shows that
the genetic progression of malignant cells is
paralleled by epigenetic changes in nonmalignant
endothelial cells induced by angiogenesis of the
tumor vasculature (St Croix et al., 2000). Because
SAGE is based on differential expression levels of
transcripts, it fails to address functional
interactions (for example, binding) at the
protein–protein level. Potential vascular targets
may also be overlooked in high-throughput DNA
sequencing or in gene arrays since many of the
targets may be expressed in very restricted but
highly specific locations in the vascular
endothelium and in general, genetic approaches
do not take into account the anatomical and
functional context of the target molecules. In vivo
phage display technology has expanded our
knowledge of the spatial and temporal expression
of vascular markers, and allowed us to take the
first steps in elucidating the endothelium based
protein-protein interaction map in vivo, a field that
can be defined as “vascular proteomics” (see
Trepel et al., 2002). The complexity of the human
endothelium is also apparent from recent studies
showing that the profile of certain endothelial cell
receptors can vary depending on ethnic
background (Wu et al., 2001). In fact, in vivo
phage-display in humans might reveal diversity of
receptors expressed in the blood vessels even at
the level of individual patients. However, our
validation studies show that at least some
ligand–receptor pairs are detectable in multiple
unrelated subjects. Another advantage of the
method described here is that selected targeting
peptides bind to native receptors as they are
expressed in vivo. Even if a ligand–receptor
interaction is mediated through a conformational
rather than a linear epitope, it is possible to select
binders in the screening.
We started the process towards the construction of
the human molecular vascular map by screening a
phage displayed random CX7C peptide library in a
patient with Waldenström macroglobulinemia.
Recovered peptide inserts, as well as the
unselected phage library, were analyzed for the
presence of short amino-acid sequences with a
high-throughput pattern recognition software
comparing the relative frequencies of every
tripeptide motif from each target tissue to the
frequencies of the motifs from the unselected
library to test for randomness of distribution. We
chose tripeptide motifs for the peptide insert
analysis because three amino-acid residues seem
to provide the minimal framework for structural
formation and protein–protein interaction
(Vendruscolo et al., 2001). Comparisons of the
motif frequencies in a given organ relative to
those frequencies in the unselected library showed
a nonrandom nature of the peptide distribution;
such a bias is remarkable given that only a single
round of in vivo screening was performed.
Of the tripeptide motifs recovered from tissues,
some were preferentially found in a single site
whereas others were recovered from multiple
sites. This indicates that some of the recovered
peptides home in a tissue-specific manner binding
to differentially expressed endothelial cell
markers in a given tissue while others bind to
ubiquitous endothelial cell surface molecules.
Further analysis of the original phage peptide
inserts revealed four to six amino-acid residue
motifs that were shared among multiple peptides
isolated from a given organ. Each of these motifs
were searched for similarities to known proteins
in online databases, and found that some of the
enriched peptide motifs appeared within known
human proteins. Since our screening method
isolates ligands for differentially expressed
vascular receptors, our recovered peptide motifs
are likely to mimic epitopes present in circulating
ligands interacting with endothelial cell surface
molecules. These circulating ligands may be
either secreted proteins or surface receptors
present on circulating cells interacting with the
target tissue. We were able to identify a panel of
candidate human proteins potentially mimicked
by selected peptide motifs.
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For example, one of the peptide motifs identified
from the bone marrow is contained within bone
morphogenetic protein-3B, which is a growth
factor known to regulate bone development
(Daluiski et al., 2001). It is reasonable to expect
that that the isolated peptide ligand mimics this
protein. In addition to secreted ligands, motifs
were also found in several extracellular or
transmembrane proteins that may operate
selectively in the target tissue, such as sortilin in
fat (Lin et al., 1997). We have also recovered
motifs from multiple organs; one such peptide is a
candidate mimic peptide of perlecan, a protein
known to maintain vascular homeostasis (Nugent
et al., 2000). Similarly, we also identified IL-11 as
a ligand mimicked by a peptide specifically
enriched in the prostate tissue. IL-11 has been
previously shown to signal through the IL-11
receptors within endothelium and prostate
epithelium (Mahboubi et al., 2000; Campbell et
al. , 2001). This IL-11 mimicking peptide
specifically bound to the endothelium and to the
epithelium of normal prostate in phage overlay
assay with human tissue sections; on the other
hand, IL-11 mimetope failed to bind other organs,
such as skin. In contrast, a phage isolated from the
skin did not bind to prostate or other tissues;
instead, this phage specifically identified blood
vessels in the skin. Furthermore, the binding of
the IL-11 mimetope peptide to IL-11Rα  was
verified in vitro. Validation of the of the ligand-
receptor interaction has confirmed that our high-
throughput identification of circulating peptide
ligands does provide us with functional
information in vascular biology in addition to
organ homing ligands useful by themselves for
vascular targeting. Additional support for the use
of combinatorial screenings in patients for the
development of anticancer targeted therapies
comes from the studies by Zurita et al., where
IL11Rα was shown to be a potential target for
intervention in human prostate cancer (Zurita et
al., 2004). Expression of IL-11Rα is increased in
a stage-specific manner during disease
progression in primary and metastatic prostate
cancer and its associated blood vessels.
Furthermore, a peptide guided by the IL-11
mimetope (CGRRAGGSC) peptide to the IL-
11Rα linked to the well-established proapoptotic
peptide D(KLAKLAK)2 (Ellerby et al., 1999) was
specifically targeted and internalized in to prostate
cancer cells resulting in apoptosis (Zurita et al.,
2004).
Precedent exists to suggest that phage can be
safely administered to patients, as bacteriophage
were used in humans during the pre-antibiotic era
(Barrow and Soothill, 1997). Ultimately, it may
become possible to determine molecular profiles
of blood vessels in specific conditions; infusing
phage libraries systemically before resections of
lung, prostate, breast and colorectal carcinomas,
or even regionally before resection of limb
sarcomas may yield useful vascular targets.
Exploiting this experimental paradigm
systematically with the developed analytical tools
may permit the construction of a molecular map
outlining vascular diversity in each human organ,
tissue or disease. Translation of high-throughput
in vivo phage-display technology may provide a
contextual and functional link between genomics
and proteomics. Based on the therapeutic promise
of peptide- or peptidomimetic-targeting probes
(Latham, 1999), clinical applications are likely to
follow.
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